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ABSTRACT
The polymerase chain reaction (PCR) is an in vitro amplification technique
used to synthesize multiple copies of a nucleic acid sequence. The reaction is
driven by Taq polymerase which copies the template sequence directed by 2
sequence-specific oligonucleotide primers. The technique results in the
exponential increase of template sequence, permitting the detection of rare
nucleic acids. This thesis considers the application of PCR to the detection
and characterization of human immunodeficiency virus (HIV) nucleic acid and
hepatitis B virus (HBV) DNA in clinical samples.
HIV-1 can infect a subset of T lymphocytes and establish a latent infection,
resulting in very few cells in the peripheral blood harbouring viral nucleic acid.
The sensitivity offered by PCR was, therefore, essential for the detection of
HIV-1 nucleic acid in patient peripheral blood mononuclear cells (PBMCs).
Primers were selected from the po/and env sequences for the detection of
HIV-1 DNA, and amplifications of the envelope gene were used to
demonstrate sequence variability.
HIV-1 DNA was detected in all 32 patients (59 of the 61 PBMC samples
tested). Viral DNA sequences were detected in all nuclear extracts tested,
71% of cytoplasmic extracts, and in 50% of purified monocytic cells.
Primers were selected to differentiate between HIV-1 DNA structural forms.
Covalently closed circular unintegrated viral DNA (CUVD) with 1 or 2 LTR
sequences was detected by amplifying across the junction site, and linear
unintegrated viral DNA (LUVD) was detected using a ligation-mediated PCR
(L-PCR). CUVD was detected in 65% of patient samples and was associated
with disease progression (0.02>P>0.01). The detection of LUVD was negative
for all patient samples.
The hepatitis B virus replicates in hepatocytes and is released into the blood
XI
of infected individuals. The infection is conventionally diagnosed by
immunoassays detecting viral antigens and their corresponding antibodies in
sera, and the presence of viral DNA is determined by hybridization assays.
HBV DNA was detected in patient serum samples using 4 specific primers in a
nested PCR. The primers were selected to hybridize to the S-gene sequence
of HBV using the nucleotide consensus sequence for 5 HBsAg subtypes
(adrcg, adw, adyw, ayw, and ayw2).
The presence of HBeAg in serum is indicative of infectivity. The detection of
HBV DNA by PCR was compared with HBe status in 115 patient samples. All
HBeAg positive and 25% of HBeAg negative samples were positive for HBV
DNA. To determine the source of the viral DNA in these samples, the DNA
extraction method was applied to free virus, and IgG and IgM complexed virus
to establish the association of viral DNA with free virus and HBeAg.
The HBsAg is a complex protein with a common determinant a, and 4 main
sub-determinants d, y, w, and r. A total of 38 HBV DNA positive samples had
been subtyped for the band y determinants by radioimmunoprecipitation
assay (RIPA). These samples were subtyped by PCR using a y-specific
primer for the nested amplification. Twenty samples were subtyped y by both
methods, 15 samples d by both methods, and 3 samples were d by RIPA and
y by PCR.
A total of 9 samples (including the 3 disputed samples) were subtyped by a
third method to determine their true subtype. The S-gene was amplified by
PCR, and the resulting band was digested by Sau 3A restriction enzyme. Six
samples were subtyped identically by each method, 2 of the 3 disputed
samples subtyped d in agreement with RIPA, and 1 sample subtyped y in
agreement with PCR.
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INTRODUCTION
CHAPTER 1: THE POLYMERASE CHAIN REACTION.
The polymerase chain reaction, invented by Kary Mullis in 1985, has rapidly
become a useful analytical tool for the detection and characterization of
nucleic acids (Saiki et al., 1985; Mullis & Faloona, 1987; Saiki et ai, 1988).
This is most apparent in the number of publications utilising the technique,
rising from 3 in 1986 to 1700 articles in 1990 (Eeles et at., 1992).
The reaction is an in vitro method of DNA synthesis in which a specific
segment of DNA is replicated. The resulting rapid generation of millions of
copies of target sequence, makes it possible to supply the large quantities of
template DNA required for molecular analysis. The reaction consists of 3
segments per cycle: denaturing the target DNA, annealing of 2 specific
primers to opposite strands of the flanking sequence of the target, and
synthesis from the 3' ends of the primers in such a way that their extension
products overlap. The products of each cycle are complementary to the
primers, and so the target DNA concentration is doubled in each successive
cycle. Repeated thermal cycling, therefore, results in an exponential
accumulation of the specific DNA sequence (Figure 1).
Some knowledge of the flanking sequences of the target DNA is required for
selection of specific primers. Optimally, the primers are 20-30 bases long, with
a G+C content of 50-60%, and their sequences impart specificity to the
reaction. Amplification with these primers can be followed by a secondary or
"nested" amplification with internal primers. The nested primers amplify a
small sequence internal to the primary amplification product, resulting in a
more sensitive test with greater specificity imparted by the 4 primers.
The amplification products are detected by ethidium bromide visualisation in
agarose gels (Chehab et al., 1987; Kogan et al., 1987; Orkin, 1987), oligomer
restriction analysis (Kwok et al., 1987; Duggan et al., 1988), or by Southern
blot hybridization (Mullis et al., 1986: Larzul et al., 1988; Thiers et al., 1988).
l
Figure 1. THE POLYMERASE CHAIN REACTION





2 COPIES OF TEMPLATE DNA
REPEAT FOR 25 CYCLES
Repeated cycling of the denaturing, annealing and extension temperatures
results in the doubling of the template DNA each time, corresponding to a
theoretical exponential increase in the target sequence.
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PCR has considerable advantages over existing techniques of nucleic acid
detection. The reaction can be used to detect sequences varying in length
from 25 to several thousand bases, and offers greater sensitivity, requiring
only a single template for detection (Simmonds et a/., 1990a). The starting
material can be DNA or cDNA derived from RNA templates, while the sample
can be derived from any source (tissue and body fluids), and can be in any
state as long as the target sequence is intact. Clinical samples, where the
target sequence is a very minor component of the total nucleic acid extract
(Simmonds et al., 1990a), or paraffin embedded tissue and palaeontological
material, where the nucleic acid may be of very poor quality, have been used
(Shibata et al., 1988; Paabo, 1989).
1.1 DNA polymerase.
The original design of PCR utilised the Klenow fragment of the E. coli DNA
polymerase I (Saiki et al., 1985). The thermolability of this enzyme required
fresh enzyme to be added after each denaturing step. Although a number of
other enzymes were tested (Keohavong et al., 1988), the most important
modification to the reaction was the use of the thermostable DNA polymerase
(Saiki et al., 1988). The enzyme (Taq polymerase) was first isolated from the
thermophilic eubacterium Thermus aquaticus YT-1 strain which grows at 75°C
(Chien et al., 1976), and incorporates nucleotides at a rate of more than 60
per second at 70°C and 24 per second at 55°C (Gelfand & White, 1990). The
enzyme lacks 5'-3' exonuclease activity and is, therefore, responsible for the
introduction of point mutations in the amplification product (Chien et al., 1976).
The rate of incorrect incorporation is such that a 106-fold amplification of a
100bp dsDNA sequence would result in 0.8 point mutations (Keohavong &
Thilly, 1989). Despite this rate being higher than with other polymerases (T4,
modified T7, and Klenow fragment), the overall efficiency and thermostability
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of Taq polymerase favours its use for PCR. The gene was, therefore, cloned
into E. coli, resulting in the production of a standardized enzyme activity. This
allowed the automation of PCR, making it a simple and rapid method of
nucleic acid amplification.
1.2 Limitations of PCR.
PCR is the method of choice for almost all problems involving the detection of
small quantities of nucleic acids because of its speed and sensitivity. The
enormous amplification power of the reaction, however, is also its main
disadvantage, resulting in false-positive and negative results.
1.2.1 False-positive amplifications.
There are 3 main sources of contaminating template DNA: positive samples
handled in tandem by the medical staff at source, cloned material, and
accumulating amplification products in the laboratory. It is, therefore,
important that all personnel associated with the collection and processing of
samples are aware of the need to avoid cross-contamination.
The main source of contamination is from the accumulation of PCR products
in the laboratory. A PCR vial contains up to 1012 copies of template
sequence, so that an aerosol droplet (10"6ul) may contain 105 templates
(Persing, 1991). It is imperative to safeguard against this form of contaminant.
Various measures can be taken to reduce the risk, including: the allocation of
laboratory space to various stages of PCR work where appropriate; the use of
absorbent disposable work surfaces; decontamination of surfaces with a weak
acid solution (0.25M HCI); the preparation, aliquoting and storage of reaction
mixtures in PCR-free areas; autoclaving of all materials and reagents not
damaged by heat; and processing of numerous well characterized negative
controls with samples in small batches.
Although contamination is controlled by good laboratory practice, it can
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become a major problem in laboratories generating vast quantities of
amplified material, resulting in the reporting of false results (Tidy & Farrell,
1989). In response to this, 2 methods have been developed which alter the
amplification product preventing its ability to act as a template in the event of
contamination (Longo eta!., 1990; Cimino etal., 1991; Isaacs eta!., 1991).
1.2.2 False-negative amplifications.
There are 2 main sources of false-negative results: the amplification of non¬
specific sequences in preference to the target DNA, and inefficient
amplification of target sequences.
PCR is a biphasic reaction with the initial stage screening the sample for the
target sequences, and the subsequent cycles replicating the chosen
sequence. The most likely by-products from inaccurate early amplifications
arise from high primer:template ratios resulting in primers colliding with
themselves forming primer-dimers, and from mis-priming with other
sequences present, giving rise to non-specific bands (Li et al., 1990). This is
most apparent when the desired sequence is present at a low-copy-number in
large quantities of non-specific DNA (eg. HIV-1 DNA in PBMC DNA extracts).
Under these circumstances, it is very important that during the initial cycles
the primers hybridize to and amplify specific sequences in preference to the
non-specific cellular sequences. This can be achieved using high stringency
thermal cycling and low primer concentration for the initial cycles (Ruano et
al., 1989).
The efficiency of PCR is dependent on many variables: denaturation
temperature; annealing temperature of the primer/template duplex; extension
rate and concentration of Taq polymerase; length and secondary structure of
the target DNA sequence; and the actual and transition temperatures reached
by samples (Williams & Anderson, 1992). These factors may vary with each
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primer pair. Careful optimisation is, therefore, required to obtain maximum
amplification efficiency.
The reaction theoretically results in the exponential amplification of the target
DNA sequence. A simple relationship has been determined between the
efficiency of amplification and the expected increase in the target sequence
(Figure 2). From this, it is clear that a small decrease in the amplification
efficiency results in a dramatic decrease in the amplification product
concentration (Table 1).
In a typical PCR cycle, the samples are denatured at 94-95°C for 1min, the
primers are annealed at 40-60°C for 1min, and DNA then synthesized at 60-
72°C for 1-3min.
The most critical steps are the denaturing and extension temperatures.
Insufficient heating can prevent complete denaturation, reducing the available
template concentration. A low re-annealing temperature confers low
stringency and, therefore, permits mis-priming and subsequent amplification
of non-specific sequences. If the temperature is too high, the annealing of
primers is inhibited, again resulting in a lack of amplification of the target DNA.
It is, therefore, important to optimise the cycling temperatures to maximise the
stringency and amplification for each primer pair.
The reaction vials can also influence the amplification efficiency. The
thickness of the tubes can affect the transfer of heat from the block to the
sample producing a considerable temperature lag, resulting in samples not
achieving the required temperature for the desired time (Williams & Anderson,
1992).
Although Taq is a thermostable polymerase, continual heating to
temperatures of 95°C results in a loss of activity. The enzyme half-life has
been calculated to be 40min at 95°C. However, even after 50 cycles of
6
Figure 2. Calculation of the amplification rate of the polymerase chain
reaction (Clewley, 1989).
Y=(1 +X)n
Where, Y= extent of amplification in n cycles
X= mean efficiency per cycle
n= number of cycles.
For example, at an amplification efficiency of 95% (X) for 25 cycles (n),
Y=(1+0.95)25
Y=17818260
Therefore, the target DNA sequence will have been amplified approximately
1,7x107-fold after 25 cycles at an average cycle efficiency of 95%.
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denaturing at 94-95°C for 1min, more than 50% of the enzyme activity
remains (Gelfand & White, 1990). Therefore, the loss of enzyme activity
through thermal cycling is unlikely to be limiting. Enzyme activity can be
restrictive when the template concentration exceeds the enzyme
concentration. Under these conditions, the efficiency of the reaction is
reduced, and DNA synthesis is aborted prematurely. The increased melting
temperature of the template duplex in the later cycles often prevents complete
denaturation preventing priming of DNA synthesis.
Although alterations to the reaction can overcome these problems, all
amplifications reach a plateau concentration of target sequence at which point
the reaction should be terminated. Further cycling after this results in the
exponential amplification of non-specific bands until they too reach their
plateau concentration. It is, therefore, important to optimise the cycle number
to maximise specific amplification combined with minimum non-specific
amplification.
1.3 Applications of PCR.
Numerous modifications to PCR have led to a variety of uses beyond the
original application of generating large amounts of a specific DNA sequence.
The use of multiple sets of primers in a single reaction has led to the
screening of environmental samples for bacteria (Bej et al., 1990) and for
multi-factorial genetic disorders (Chamberlain et al., 1988). Degenerate
primers have also been used to detect sequence similarities in virus families
(Mack & Sninsky, 1988) while inverse-PCR permits the analysis of unknown
sequences flanking a region of known sequence (Triglia et al., 1988; Ochman
et al., 1990). Another modification, using an anchored-PCR, amplifies nucleic
acid with variable termini (Loh et al., 1989) and ligation-mediated PCRs can
direct the synthesis of DNA from the end of an unknown sequence (Bukrinsky
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etal., 1991).
PCR can also be used to incorporate restriction enzyme sites to facilitate
cloning (Scharf et at., 1986); direct sequencing of amplification products
(Wrischnik et at., 1987; Simmonds et at., 1990b); analysis of point mutations
(Almoguera et at., 1988); and in the synthesis of gene fusion products (Horton
etal., 1989).
The sensitivity, specificity, and versatility of PCR has resulted in its application
to numerous scientific challenges. It has been used in the fields of forensic
medicine for DNA fingerprinting and paternity claims (Higuchi et at., 1988; Li
et at., 1988), in phylogenetic and evolutionary studies (Bruns et at., 1989;
Paabo etal., 1989), and in oncology (McMahon etal., 1987; Lee et ai, 1988;
Neri et a!., 1988). It has also been applied to the identification of genetic
disorders such as sickle cell anaemia (Saiki et at., 1985), B-thalassaemias
(Wong et at., 1987; Cai et al., 1988) and Duchenne muscular dystrophy
(Chamberlain et al., 1988), and is expected to play a major role in the human
genome project (Rose, 1990).
PCR has probably been most useful in its application to the detection of
infectious agents. The reaction has been used to supplement existing
technologies, particularly where samples are of insufficient size, or when
existing methods are time consuming and difficult. An example of this is the
use of PCR to detect DNA sequences of Mycobacterium tuberculosis in
samples to confirm the clinical diagnosis. PCR is used to replace the
conventional laboratory diagnosis by culture which can take up to 6 weeks to
confirm (Pao et al., 1990; Sjobring et al., 1990; de Wit et al., 1990).
PCR has also been applied to the detection of numerous viruses which are
difficult or impossible to culture such as HBV (Larzul et al., 1988 & 1989;
Kaneko et al., 1989a & b; Liang et al., 1989; Lo et al., 1989; Ulrich et al.,
1989; Zeldis et al., 1989), or like HIV, which is present in such small quantities
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that it is difficult to detect (Kwok et al., 1987; Byrne et at., 1988; Hart et al.,
1988; Laure et al., 1988; Murakawa et al., 1988; Taylor, 1988).
Arguably the most reported application of PCR to date has been in the
detection and characterization of the human retrovirus HIV. PCR was
developed shortly after the discovery of HIV, and has proved to be very useful
in the detection of HIV DNA: (a) prior to seroconversion (Loche & Mach, 1988;
Imagawa et al., 1989; Wolinsky et al., 1989); (b) in newborn infants with
maternal antibody (Laure et al., 1988; de Rossi et al., 1988), and (c) in the
confirmation of infection in individuals with indeterminate antibody status
(Farzadegan et al., 1988).
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CHAPTER 2: HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1).
2.1 HIV-1 and AIDS.
The aetiological agent of AIDS is the human immunodeficiency virus type-1
(HIV-1). It was first isolated from patients presenting with unusual
opportunistic infections and depleted CD4+ cell counts indicative of a severe
immunodeficiency (Gottlieb et al., 1981; Masur et al., 1981; Friedman-Kien et
al., 1982).
The infectious agent was isolated in T lymphocytes from a lymph node biopsy
of a patient with AIDS related lymphadenopathy, was reverse transcriptase
dependent, and was observed budding from the cell membrane in a manner
characteristic of retroviruses (Barre-Sinoussi et al., 1983; Popovic et al., 1984;
Gallo et al., 1984; Klatzmann et al., 1984a; Levy et al., 1984). The retrovirus
subsequently isolated from these patients was named HTLV-III (Popovic et
al., 1984), LAV (Barre-Sinoussi et al., 1983), or ARV (Levy et al., 1984). It is a
member of the Lentiviridae, is the aetiological agent of human AIDS, and is
now universally known as the human immunodeficiency virus type-1 (Coffin,
1991).
HIV-1 was first detected through its ability to infect CD4+ T lymphocytes,
although other cell types such as monocytes/macrophages, Langerhan's cells
and glial cells can be infected in vitro and in vivo and may play an important
role in pathogenesis (Koenig et al., 1986; Nicholson et al., 1986; Gendelman
et al., 1988; Orenstein et al., 1988; Rappersberger et al., 1988; Kunsch et al.,
1989).
The first 3 cases of AIDS in Scotland were diagnosed in 1981 (2 male & 1
female). Cumulative data up to 30 September 1992 show a dramatic increase
in infected individuals (1845; 1368 male, 471 female & 6 sex not known) with
an additional 324 individuals with clinical AIDS (278 male & 46 female) and a
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further 224 AIDS associated deaths (196 male & 28 female). This equates to
a total of 2393 known HIV-1 infections in Scotland since 1981, of which 941
were attributable to Lothian (CDU, 1992; LRC, 1992). The World Health
Organization figure for all reported AIDS cases up to July 1992 is 501 272
although this will be subject to under-reporting (WHO, 1992).
2.2 Screening for HIV-1 infections.
HIV-1 has had a profound impact on medicine, science, and society. The
immense public awareness has forced the rapid dissemination of scientific
information which has been both beneficial and central to the genesis of
myths surrounding the infection. In the UK and USA, HIV was first diagnosed
in male homosexual and drug using communities. Issues concerning HIV and
AIDS have, therefore, touched on facets of modern society which were
already subject to moralization through fear, prejudice, and ignorance. Despite
HIV being primarily a heterosexual disease, the damaging effects of the
epidemiology of infection in the developed world has led to the views of
members of the public and scientific communities being coloured by their
prejudices. One of the main consequences of this is the continued
underestimation of the spread of HIV due to the lack of widespread screening.
However, until the stigma and prejudices associated with the infection are
dissipated, individuals are unlikely to be willing to be tested because of their
fear of the repercussions.
The diagnosis of HIV is routinely based on a variety of immunoassays specific
for viral antigens and their corresponding antibodies. The initial screening for
antibodies to viral surface and core proteins is by RIA or ELISA, with
confirmation by alternative immunoassays using different antigens and test
formats. The Western blot using viral lysate or proteins prepared from cDNA
has been widely used in this way (Davey & Lane, 1990).
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2.3 Classification of HIV-1 infection.
The immunodeficiency associated with HIV infection gives rise to a broad
spectrum of disorders resulting directly from the viral cytopathology or
indirectly mediated by the host immune system and secondary infections.
To categorise these stages for both medical and scientific clarity, the Centers
of Disease Control in Atlanta defined 4 main clinical stages (CDC groups I to
IV; CDC, 1986). CDC group I defined the acute glandular fever-like illness
associated with seroconversion which is observed in 10-15% of infections.
The asymptomatic period which may last for months to years was classified
CDC group II, with group III describing patients with unexplained persistent
generalised lymphadenopathy (PGL). CDC group IV was further subdivided
(A-E) to describe the spectrum of disorders and secondary infections
associated with the immunodeficiency (Table 2). Subgroup A includes patients
with HIV constitutional disease, with all symptoms attributable to the advanced
HIV infection in the absence of secondary infections. The disease is defined
by persistent fever (>1 month), weight loss of greater than 10% baseline, and
chronic diarrhoea (>1 month). Subgroup B consists of patients with
neurological disease such as dementia, myelopathy, or peripheral neuropathy
which is the result of HIV invasion of the nervous system. Subgroup C is
subdivided into 2 categories, and includes patients with clinical disease
associated with secondary infections. Patients in subgroup D are classified by
secondary cancers usually indicative of a defect in cell-mediated immunity,
and subgroup E is an open category for conditions not previously defined.
Patients can be classified into any number of CDC IV subgroups, and may
range from moderately ill to severely immunodeficient and life threatening
infections and disorders (CDC, 1986; Mildvan & Solomon, 1987).
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The CDC have since revised the classification system to incorporate the
significance of CD4+ cell counts to the clinical condition and to include more
clinical conditions (CDC, 1992).
2.4 Epidemiology and transmission.
The transmission of HIV is predominantly sexual, or by inoculation with
contaminated materials. HIV has been successfully isolated from most body
tissues and secretions including; blood, plasma, bone marrow, lymph nodes,
neurological tissue, breast milk, semen, saliva, urine, cerebrospinal fluid,
cervical secretions and tears (Groopman et al., 1984; Ho et al., 1984; Feorino
et al., 1985; Fujikawa et al., 1985; Ho et al., 1985; Salahuddin et al., 1985;
Thiry et al., 1985; Zagury et al., 1984; Vogt et al., 1986; Wofsy et al., 1986;
Allain, 1987; Li et al., 1992). Exposure to any of these tissues or secretions
would, therefore, be considered an exposure to the virus, however, in
practice, efficient transmission occurs mainly by sexual contact (both hetero-
and homosexual), parenteral inoculation of infected blood or blood products,
artificial insemination, transplantation of infected tissues, and from mother to
offspring (Handsfield et al., 1985; Redfield et al., 1985; Stewart et al., 1985;
Allain, 1987; Mok et al., 1987; Simonds etal., 1992).
2.5 Classification of Retroviruses.
The Retroviridae, like other viral families, share common morphology,
biochemistry, and physical properties. The viruses are characterised by their
ability to reverse transcribe genomic RNA to DNA, a property resulting in the
family name retro, (Latin; backwards).
They were originally classified into 3 subfamilies based on their ability to
cause disease (Matthews, 1979). The Oncoviridae (from the Greek word
onkos meaning tumour) were grouped for their ability to cause tumours;
Spumaviridae (from the Latin spuma meaning to foam) formed vacuolated or
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foamy cells in vitro but have so far not been associated with disease in
animals or humans; and Lentiviridae (lenti being the Latin word for slow)
which caused slowly progressive diseases in their hosts. The family has since
been re-classified, and is now divided into 7 genera based on molecular
analysis (Table 3; Coffin, 1991).
The Lentiviridae, of which HIV-1 is the human prototype, have the most
complex genomic structure and cause immunodeficiencies, neurological
disorders, and arthritic diseases in a number of mammalian hosts (Table 4).
2.6 Morphology of HIV-1.
HIV-1 is an enveloped lentivirus of diameter 80-120nm, with 72 envelope-
glycoprotein projections of approximately 8-1 Onm (Collin etai., 1991;
Gelderblom, 1991). The virions have a density of 1.16-1.18g/cm3 in sucrose
gradients, and are readily disrupted with lipid solvents and detergents
(Matthews, 1979). Viral particles are predominantly protein (60% weight) with
cellular derived lipid (35%), cellular and viral carbohydrate (3.5%) with
approximately 2% of the weight contributed by the RNA genome (Matthews,
1979). Thin sections of the virus reveal the presence of an outer lipid bilayer
derived from the host cell envelope, with an inner membrane or shell, and a
central nucleoid structure. The viral core is characteristically rod shaped,
although EM sections demonstrate a variety of morphologies depending on
the angle of the section (Gelderblom, 1991). The RNA genome associated
with reverse transcriptase, protease and integrase activity is surrounded by
the nucleocapsid protein forming the ribonucleo-protein complex (RNP). This
is contained within the core and is surrounded by the matrix protein
(Gelderblom, 1991). The core structure is attached at the narrow end to the
matrix protein by a core-envelope-link protein (Hoglund etai., 1990) and
surrounded by lateral bodies of irregular shape which may result from excess
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Table 3. Classification of Retroviruses (Coffin, 1991).
Retrovirus genera
Mammalian type B oncovirus group
MLV-related viruses
(mammalian type C retrovirus group)
Type D retrovirus group





MLV, murine leukaemia virus; ALV, avian leukosis virus; HTLV, human T cell
lymphotropic virus; BLV, bovine leukaemia virus.
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Table 4. Clinical manifestations of lentivirus infections (Coffin, 1991;
Egberink, 1991)
Virus Host Disease
HIV-1 and 2 human immunodeficiency, opportunistic infections,
lymphadenopathy, neurological syndrome
SIV monkey immunodeficiency, neurological syndrome
Visna-maedi sheep progressive pneumonia,
encephalomyelitis, generalised wasting
CAEV goats arthritis, encephalomyelitis, pneumonia
EIAV horses fever, weight loss, anaemia
FIV cats immunodeficiency, generalised
lymphadenopathy, opportunistic infections,
emaciation, neurological syndrome
BIV cattle lymphadenopathy, persistent
lymphocytosis, wasting
HIV, human immunodeficiency virus; SIV, simian immunodeficiency virus;
CAEV, caprine arthritis/encephalitis virus; EIAV, equine infectious anaemia
virus; FIV, feline immunodeficiency virus; BIV, bovine immunodeficiency virus.
19
gag or regulatory proteins (Gelderblom, 1991). The viral structure is then
enveloped by a cellular derived lipid bilayer with viral spikes composed of the
transmembrane and surface glycoproteins (Leis et al., 1988; Gelderblom,
1991). The protein nomenclature for retroviruses was standardized by Leis et
al., (1988) and is summarised in Table 5.
2.7 Genomic organisation of HIV-1.
The HIV-1 genome consists of linear positive-sense single-stranded RNA
molecules that are capped and polyadenylated (approximately 9.2kb). Each
viral particle contains 2 identical copies of RNA which are held together by
hydrogen bonding (Matthews, 1979). Like all retroviruses, the HIV-1 genome
contains 3 main protein coding genes, gag, pol, and env, flanked by regulatory
sequences (R and U5 at the 5' end; U3 and R at the 3' end). During reverse
transcription of the genome the regulatory sequences are duplicated resulting
in the presence of the viral long terminal repeats (U3-R-U5) at both ends of
the viral DNA (Schupbach, 1989; Figure 3).
2.8 Replication of HIV-1.
HIV, like all intracellular parasites, must attach and gain entry to susceptible
cells to initiate replication. Two mechanisms of viral attachment have been
elucidated from in vitro studies. Firstly, the virus tropism for T helper/inducer
lymphocytes, monocytes, and macrophages expressing the CD4 differential
antigen is mediated by an interaction with the viral surface glycoprotein gp120
(Dalgleish et al., 1984; Klatzmann et al., 1984a & b; Levy et al., 1985;
McDougal et al., 1985; Deen et al., 1988). The second mechanism involves
the interaction of HIV specific antibodies with Fc receptors on the surface of
some cells (Homsy et al., 1989; Jouault et al., 1989; Laurence et al., 1990;
McKeating et al., 1990). The extent of viral attachment in vivo by either of
these methods is, however, not known.
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Table 5. Standardization of retroviral protein nomenclature using the
example of HIV-1 proteins (Leis etal., 1988).
Standard Protein function HIV-1 protein
MA Matrix protein P17
CA Capsid protein p24
NC Nucleocapsid protein p7
PR Protease p12
RT Reverse transcriptase p66
IN Integration protein p32
SU Surface protein gp120



























The figure depicts the coding exons for HIV-1 proteins. The structural
proteins are coded for by gag, polymerase, integrase and proteinase
enzymes by pol and the envelope glycoproteins by env. The other
exons code for regulatory proteins active in the control of viral replication.
22
Once attached the virus must gain entry to the cell. The mode of penetration
in vivo has yet to be proven, although 2 methods have been demonstrated in
vitro. HIV can enter cells by direct fusion of the viral envelope with the cellular
plasma membrane (Stein et a!., 1987; McClure et al., 1988; Sinangil et al.,
1988) or by CD4 receptor-mediated uptake in clathrin coated pits (Pauza &
Price, 1988; Sinangil et al., 1988). It may be that both methods are utilised,
and that the concentration effect observed in vitro also determines the
mechanism of uptake in vivo (Goto et al., 1988; Grewe et al., 1990).
Aspects of the replication mechanism of retroviruses were determined by
extensive research on a number of avian viruses, particularly avian sarcoma
virus (ASV) of chickens, and spleen necrosis virus (SNV) of ducks.
Upon entry to the host cell the virion RNA is reverse transcribed to synthesize
an anti-sense DNA copy in the cytoplasm of the cell. This is transcribed into
dsDNA in parallel with the digestion of the template RNA, and is transported
to the nucleus of the cell for integration (Varmus et al., 1974a; Varmus &
Shank, 1976). The replication mechanism duplicates the terminal sequences
of the RNA genome, resulting in the formation of the long terminal repeats
characteristic of the proviral DNA (Varmus & Swanstrom, 1982).
Although it is now widely accepted that retroviruses replicate via a DNA
intermediate, it took almost a decade of careful experimentation to provide
unequivocal evidence for the existence of a reverse transcriptase enzyme.
Much of the initial work was carried out on Rous sarcoma virus (RSV) in which
early experiments with inhibitors of DNA synthesis suggested that not only
was DNA synthesis required for a productive infection, but the DNA was
synthesized by viral components (Temin, 1963, 1967, 1968; Bader, 1965;
Murray & Temin, 1970). The ultimate discovery which convinced most
scientists of the proviral theory was the demonstration of RNA dependent
DNA polymerase activity associated with RSV (Baltimore, 1970; Temin &
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Mizutani, 1970). Despite opposition to the DNA provirus theory, Howard
Temin was eventually rewarded with the Nobel prize in 1975, and his
acceptance lecture was published in Science (Temin, 1976).
2.9 Integration of viral DNA.
Analysis of the structure of retroviral unintegrated DNA (UVD) revealed the
presence of covalently closed circular forms in infected cells (Varmus et at.,
1974b; Kakefuda et al., 1977; Shank et ai, 1978a & b). Two main forms of
circular molecules were detected, differing by the presence of 1 or 2 LTR
sequences (Shank et al., 1978a & b, 1981; Hsu et al., 1978; Yoshimura &
Weinberg, 1979). These unintegrated circular forms demonstrated a variety of
mutations with up to 50% expressing deletions and inversions, and some
molecules, possibly resulting from autointegration, were of a greater size than
the linear forms (Shoemaker et al., 1980, 1981; Olsen et al., 1990). The viral
DNA was, therefore, present as relaxed circular (CUVD) and linear (LUVD)
structures, and it was postulated that a circular form was the integration
precursor as with bacteriophage lambda (Nash, 1975).
Evidence to support this theory came from the use of ethidium bromide which
intercalates with DNA, thereby interfering with subsequent DNA interactions.
The addition of ethidium bromide to cultures before infection was shown to
inhibit integration of the provirus, and this was associated with a decline in
CUVD (Guntaka et al., 1975). Sequence analysis of the LTR-LTR junction of
the 2LTR CUVD molecules showed a sequence similar to att in phage
lambda, again supporting integration by homologous recombination
(Panganiban & Temin, 1984).
In contrast to these findings, purification and separation of UVD prior to
transformation assays, showed that the LUVD had a 5-10 fold higher specific
infectivity than CUVD forms (Fritsch & Temin, 1977). Subsequent
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development of a cell free in vitro integration system established that the
linear DNA associated with viral protein was the integration intermediate
(Brown et at., 1987, 1989; Fujiwara & Mizuuchi, 1988; Lee & Coffin, 1991).
The in vitro assays showed that the initial step in proviral integration was the
removal of 2 bases from the 3' end of the linear molecule (Hsu et al., 1978;
Lee & Coffin 1990, 1991). The viral genome was then integrated into the
target DNA duplicating the cellular sequence flanking the provirus. The length
of sequence duplicated was shown to be characteristic of the virus; avian
leukosis virus has a 6 base repeat (Lee & Coffin, 1990), murine leukaemia
virus 4 bases (Fujiwara & Craigie, 1989), and HIV-1 a 5 base duplication (Vink
et al., 1990), and the protein required was coded for by the 31 sequence of the
viral pol gene (Donehower & Varmus, 1984; Schwartzberg et al., 1984; Quinn
& Grandgenett, 1988; Vink et al., 1990). Sequence analysis of the flanking
cellular DNA revealed no apparent sequence specificity, although integration
was associated with DNase 1-hypersensitivity sites (Vijaya et al., 1986;
Rohdewohld et al., 1987), and replicative or transcriptionally active sites
(Varmus et al., 1977; Shih et al., 1988; Scherdin et al., 1990).
2.10 Protein products of gag, pol, and env genes.
Once integrated into the cellular genome, the provirus can be transcribed by
cellular enzymes to synthesize viral components. The gag and pol genes are
transcribed to give 2 products, the p55 gag precursor, and the p160 gag-pol
precursor (Hammarskjold & Rekosh, 1989). Both are proteolytically cleaved
by the viral protease to produce 4 gag proteins; p17, the matrix protein; p24,
the capsid protein; p7, the nucleocapsid protein,; and p9, a proline-rich protein
of unknown function (Hammarskjold & Rekosh, 1989; Oroszlan & Luftig, 1990;
McClure & Dalgleish, 1992). The pol protein precursors are also cleaved by
the viral protease to produce p12 (protease), p66/51 (reverse transcriptase)
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and p32 (integrase) (Hammarskjold & Rekosh, 1989; Oroszlan & Luftig, 1990;
Vaishnav & Wong-Staal, 1991).
The pol gene is in a -1 reading frame relative to the gag gene, and so a
ribosomal frameshift is required to allow expression of pol sequences. A short
sequence at the gag-pol overlap directs this frameshift approximately 5% of
the time. In this way, large amounts of structural gag proteins are synthesized,
and relatively small quantities of catalytic pol proteins are made (Oroszlan &
Luftig, 1990; Vaishnav & Wong-Staal, 1991).
The primary product of the env gene is the glycoprotein gp160 which is
cleaved by cellular enzymes to form the transmembrane and surface
glycoproteins gp41 and gp120 respectively. Although the glycoproteins remain
non-covalently linked, their cleavage is mandatory for viral binding, entry, and
infection of susceptible cells (Modrow et ai, 1987; McCune et al., 1988; Willey
et al., 1988; Hart et al., 1991).
2.11 Regulatory genes of HIV-1.
A number of potential regulatory genes have been determined for HIV-1. The
genes identified to date include tat, rev, nef, vif, vpu, vpr, vpt, and tev or tnv
(Figure 3).
The tat gene codes for a 14kDa nuclear protein from 2 coding exons and is
essential for viral replication (Arya et al., 1985; Sodroski et al., 1985; Fisher et
al., 1986; Dayton et al., 1986; Hauber et al., 1987). The protein trans-activates
expression of viral genes via a transactivating response region (TAR) situated
in the LTR sequences (Rosen et al., 1985; Hauber & Cullen, 1988). The exact
mechanism of this activation is not known although in vitro studies have
demonstrated effects at the transcriptional, post-transcriptional, and
translational levels (Cullen, 1986; Feinberg et al., 1986; Peterlin et al., 1986;
Wright et al., 1986; Hauber et al., 1987; Kao et al., 1987; Muesing et al.,
26
1987).
The rev gene product, like tat, is a nuclear protein coded by 2 exons and is
essential for viral replication (Cullen et at., 1988; Feinberg et at., 1986;
Sodroski et at., 1986b). The protein (19-20kDa) is phosphorylated and
appears to act via a c/'s-acting sequence in env named rev responsive
element (RRE). Activation results in the switch from early to late protein
synthesis, thereby stimulating the production of structural proteins (Feinberg
et at., 1986; Kim etal., 1989; Malim et at., 1989).
The nef gene product is coded for by a single ORF at the 3' end of env
continuing into the 3' LTR sequence and is not essential for viral replication
(Allan et at., 1985; Terwilliger et at., 1986). The cytoplasmic protein (25-
27kDa) is phosphorylated, and mutants replicate to a greater extent than wild
type virus, demonstrating a negative regulatory role (Franchini et at., 1986;
Guy etal., 1987; Niederman etal., 1989).
The tat, rev, and nef regulatory genes are the most clearly defined, although
other sequences have now been identified. The vif (virus infectivity factor)
gene codes for a 23kDa protein expressed in vivo which appears to have an
effect on the infectivity of the virus (Lee et at., 1986; Sodroski et al, 1986c;
Fisher et al., 1987). Mutants are characterised by a reduction in infectivity
despite normal levels of intracellular viral protein and extracellular virus (Kan
et al., 1986; Sodroski et al., 1986c; Strebel et al., 1987). A 15-20kDa
cytoplasmic protein is coded for by the vpu gene (Cohen et al., 1988; Matsuda
et al., 1988; Strebel et al., 1988). Mutational analysis demonstrated a role for
the gene product in the export of virus particles, with an associated decrease
in intracellular viral protein accumulation, and subsequent syncytium formation
and cell death (Strebel et al., 1988; Terwilliger et al., 1989; Klimkait et al.,
1990). Vpu mutants expressed levels of viral protein equivalent to the wild
type and were observed undergoing intracellular budding, suggesting a
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possible role in assembly and/or budding of progeny virus (Klimkait et al.,
1990).
Unlike all other regulatory genes, the product of the vpr gene is associated
with the virion. The protein (15kDa) is present in multiple copies, and is
thought to play a role in the early stimulation of viral replication and
subsequent CPE (Ogawa et al., 1989; Cohen et al., 1990). The tev or tnv
protein (28kDa) has both tat and rev activities and is known to be present
early in the replication cycle although a regulatory role has yet to be
determined (Benko et al., 1990; Salfeld et al., 1990). A final highly conserved
ORF has been demonstrated and named vpt although no expression has
been established in vitro (Cohen et al., 1990).
In addition to the regulatory proteins so far described for HIV, non-coding
sequences have been detailed which are important for viral replication. A
packaging sequence has been demonstrated between the 5' LTR and gag
gene (Lever et al., 1989; Clavel & Orenstein, 1990) and binding sites have
been determined for the cellular transcriptional activators Sp1 and NF-kB
(Jones et al., 1986; Nabel & Baltimore, 1987).
2.12 Cytopathogenicity.
To understand the mechanism by which cell death occurred in retroviral
infections, a number of groups attempted to determine the proviral copy
number, and infectivity in susceptible cells. It had been observed that cells
infected with SNV or ALV resulted in a biphasic infection, with an initial acute
phase associated with cell death. The cells surviving this cytopathic phase
appeared to be chronically infected, resulting in little or no cell death.
Hybridization and transformation studies demonstrated quantitative and
qualitative differences in the viral DNA content of the 2 populations of cells.
The acute phase infection resulted in multiple provirus integration sites, of
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which only a fraction were infectious, in contrast to the chronically infected
cells which contained only one infectious integrated provirus. Since multiple
integrations were associated with the cell pathology, it was proposed that they
impaired the function of cellular genes, and over produced viral products
leading to cell death (Battula & Temin, 1978; Keshet & Temin, 1978).
Further analysis of viral DNA in infected cells demonstrated that the
accumulation of UVD correlated with the observed cytopathic effects (Keshet
& Temin, 1979; Temin et al., 1979). Quantitation of viral DNA during the
transition from the acute to chronic stages of infection demonstrated a 70 to
80-fold decrease in UVD, and a 7 to 8-fold decrease in integrated DNA
(Keshet & Temin, 1979; Weller et at., 1980).
The accumulation of UVD was efficiently blocked by the addition of
neutralising antibody to the culture (Weller et al., 1980; Temin, 1988), which
led to the theory that the build up of UVD resulted from a second round of
infection, or superinfection. Superinfection was thus prevented in chronically
infected cells by the establishment of viral interference, a property believed to
be related to the envelope of the virus (Temin et al., 1979; Weller & Temin,
1981; Chen & Temin, 1982). However, quantitation of UVD and virus
production failed to establish a relationship suggesting that UVD was
transcriptionally defective, and/or that virus production was solely directed by
the integrated provirus (Keshet & Temin, 1979; Temin et al., 1979; Weller &
Temin, 1981; Chen & Temin, 1982).
Although a role for UVD in the retroviral life cycle has yet to be established, a
relationship has been demonstrated with the clinical outcome in some
retroviral infections. UVD is associated with osteopetrosis in chickens infected
with ALV (Robinson & Miles, 1985), but more importantly it has been
implicated in the cytopathogenicity observed in cats suffering from feline AIDS
(Mullins et al., 1986; Hoover et al., 1987).
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2.13 Detection and characterization of HIV-1 nucleic acid.
HIV-1 DNA was initially detected by hybridization assays. Dot blot
hybridization was able to detect viral DNA in 1 infected cell in 900 negative
cells, and in situ hybridization 1 in 50000 cells (Pezzella et ai, 1989; Singer et
al., 1989). This was found to be insufficient sensitivity for HIV-1 DNA detection
in some patients (Simmonds et al., 1990a). The polymerase chain reaction,
developed in parallel to early HIV research, has rapidly been adopted by
researchers as the only available method with sufficient sensitivity for HIV-1
DNA detection in clinical samples from patients at all stages of infection.
HIV-1 DNA was first detected by PCR in 1987 using 20-25 cycles of
amplification followed by hybridization (Kwok et al., 1987). Although relatively
insensitive, this led the way in the rapid optimisation of PCR for the detection
of single copy DNA templates (Simmonds et al., 1990a). HIV-1 DNA was
detected in samples both positive and negative for virus isolation (Ou et al.,
1988) and was rapidly confirmed to be more sensitive than virus isolation as it
was possible to detect HIV-1 DNA in up to 100% of seropositive patients who
were negative by virus culture (Psallidopoulos et al., 1989; Schneweis et al.,
1989; Stoeckl et al., 1989). PCR has also been invaluable in the diagnosis of
infection in infants born to HIV positive mothers where maternal antibodies
prevent conventional diagnosis, and small sample volumes make virus
isolation techniques difficult (de Rossi et al., 1988; Laure et al., 1988). It has
also been applied to the diagnosis of infected individuals up to 42 months
prior to seroconversion (Loche & Mach, 1988; Imagawa et al., 1989; Wolinsky
et al., 1989), and in confirmation of infections in previously seropositive
patients who have lost HIV specific antibodies (Farzadegan et al., 1988). PCR
is, therefore, a more rapid and sensitive technique than virus isolation and
hybridization assays for the direct detection of HIV-1 in all groups of infected
patients.
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The direct detection of HIV-1 DNA by PCR in PBMCs is most probably due to
the presence of integrated proviral DNA in susceptible cells, and is highly
indicative of infection. It is, however, possible that the amplification bands
observed arise from the detection of UVD as observed in other retroviral
infections (Varmus et al., 1974a & b; Kakefuda et a/., 1977; Shank et al.,
1978a & b; Robinson & Miles, 1985; Mullins et al., 1986; Hoover et al., 1987).
To determine the forms of viral DNA present in clinical samples it was decided
to modify PCR to detect HIV-1 DNA and to differentiate between different
structural forms present.
The detection of HIV-1 DNA alone is not indicative of a productive infection.
To demonstrate active viral replication, total RNA was extracted from patient
samples and assayed for by reverse transcription and amplification of cDNA
(RT-PCR). HIV-1 RNA was similarly detected from whole virus using
gp120/160 specific antibody coated beads for extraction of infectious particles.
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CHAPTER 3: THE HEPATITIS B VIRUS (HBV).
3.1 HBV and hepatitis B.
The hepatitis B virus (HBV) is the aetiological agent for serum hepatitis, first
described in the early 20th century (Propert, 1938). It was differentiated from
other agents responsible for hepatitis by studies in human volunteers showing
different routes of transmission (Neefe, 1946), incubation periods (Paul et al.,
1945), and a lack of cross immunity (Havens, 1945). The discovery of the
Australia antigen by Blumberg in 1964, and its subsequent association with
hepatitis (Blumberg, 1964; Blumberg, et al., 1967; Bayer et al., 1968; Okachi
& Murahani, 1968; Prince, 1968; Gerin et al., 1969; Barker et al., 1973), led to
the detection of the viral particle (Dane et al., 1970). The Australia antigen,
now known as the hepatitis B surface antigen (HBsAg), was first identified in
the form of 20nm virus-like spherical and tubular particles. These are non¬
infectious, containing no genetic information, and are composed solely of
HBsAg and host-derived lipid (Shih & Gerin, 1977; Aggerbeck & Peterson,
1985). They are very abundant in the blood of infected individuals (50-300ug
HBsAg/ml of serum), and elicit a strong antibody response which confers
immunity to reinfection (Ganem & Varmus, 1987). The role of these particles
in HBV infection is not known, although it is speculated that they adsorb
neutralising antibody, facilitating the free movement of infectious virions. This
theory is supported by the development of arthritis due to immune complexes
formed in the joints of acutely infected individuals (Gocke, 1975).
HBV was thought to be unique from all other virus groups due to its unusual
liver tropism, genome structure, and proposed replication strategy. The
discovery of hepatotropic viruses in woodchucks (Summers et al., 1978),
ground squirrels (Marion et al., 1980) and domestic ducks (Mason et al.,
1980) with similar morphology and molecular biology, led to the formal
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recognition of a new virus family called the Hepadnaviridae (Gust et al., 1986).
The term hepadna virus was first used by Robinson, (1980) to combine the
cell tropism of the virus (hepa) with their unusual (DNA) genomes for hepatitis
viruses.
The lack of an in vitro culture system for HBV has retarded the understanding
of its molecular biology, however, comparative studies of other
hepadnaviruses in their appropriate hosts has allowed considerable advances
to be made.
3.2 Clinical spectrum.
Hepatitis B is highly contagious and is transmitted vertically and horizontally in
body fluids such as blood, saliva, semen, vaginal secretions, and breast milk.
Currently, the main modes of transmission are sexual, vertical transmission at
birth, and the sharing of needles by drug users. The rate of transmission has
been reduced, largely due to educating those at risk, the screening of blood
donations, and the use of passive and active immunization. Hepatitis B
immunoglobulin is given to protect exposed individuals, while the plasma
derived and now the recombinant yeast subunit vaccines (HBsAg) are offered
in developed countries to sub-populations of the community who are
professionally or socially at risk (Teo, 1992).
Most adult HBV infections are self-limited and 90-95% resolve completely
within 6 months of the onset of symptoms. Such individuals may experience
clinical features ranging from an asymptomatic infection to an explosive and
life threatening form known as fulminant hepatitis. A typical acute infection has
4 distinct phases: 1) the incubation period of 30-180 days; 2) the pre-icteric
phase of 3-10 days with symptoms of malaise and weakness, followed by
anorexia, intermittent nausea, vomiting, and a dull abdominal pain; 3) the
icteric phase usually lasting 1-3 weeks characterised by the presence of
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jaundice, pale stools, and dark urine; and 4) the convalescence phase (Koff,
1978; Jungle & Deinhardt, 1985).
The disease is diagnosed by laboratory detection of elevated bilirubin and
amino transferases (indicating liver cell damage), and the detection of HBsAg
and anti-HBc in the serum (Hoofnagle, 1990). The typical chronology of
infection with HBV is represented in Figure 4. The first diagnostic indicator of
infection is the detection of HBsAg in patients' serum. The antigen is present
prior to symptoms, with a maximum titre corresponding to the height of liver
damage. The HBeAg is a product of the core gene, is associated with viral
replication and usually appears shortly after the detection of HBsAg. The
detection of IgM anti-HBc antibodies is transient, and is a clear indicator of the
acute phase of the infection. Seroconversion to anti-HBe marks the resolution
of the infection, which is later confirmed by the disappearance of HBsAg and
the subsequent appearance and increase in titre of anti-HBs neutralising
antibodies.
A distinguishing feature of HBV is its ability to establish a chronic infection. Up
to 10% of acute infections, particularly infections of the old and young,
progress to a chronic state. This is characterised by the persistence of HBsAg
and abnormal liver function for 6 months or more. Two categories of chronicity
have been defined: chronic persistent hepatitis (CPH), and chronic active
hepatitis (CAH). Both forms are clinically similar, but CAH, unlike CPH, is
associated with a high risk of developing liver disease such as cirrhosis and
hepatocellular carcinoma (Hirschman, 1990).
The carrier state is, therefore, a very important development of the infection,
establishing a large reservoir of infection, and increasing the risk of
developing chronic liver diseases.
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Figure 4 The chronology of events in a patient with
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3.3 Morphology of HBV.
Hepadna viruses have a distinctive morphology with an electron-dense
spherical inner core (27nm diameter) surrounded by an outer shell (Dane et
al., 1970). The outer shell, or envelope, is composed of cellular derived lipids
and carbohydrates with a viral protein HBsAg (Dane et al., 1970). Treatment
of the virion with non-ionic detergents revealed an antigen distinct from
HBsAg called the core antigen (HBcAg). HBcAg forms the inner core or
nucleocapsid structure, and is only found as part of the virion in the blood of
infected individuals (Almeida et al., 1971). Disruption of the nucleocapsid
leads to the release of a third HBV protein, the hepatitis B e antigen (HBeAg),
which is found in a non-particulate form in the blood (Magnius & Espmark,
1972; Takahashi et al., 1979).
The viral genome, contained within the core, is a circular molecule of partially
double stranded DNA (Robinson et al., 1974), and is associated with DNA
polymerase and protein kinase activity (Hirschman et al., 1971; Kaplan et al.,
1973; Robinson & Greenman, 1974; Albin & Robinson, 1980).
3.4 HBV genomic structure.
The HBV DNA genome is unique in that the small circular molecule is only
partially double stranded (Summers et al., 1975; Sattler and Robinson, 1979;
Figure 5). The long (L) minus strand (3128 bases) contains all the coding
capacity, and is held in a circular form by the variable length (1700-2800
bases) short (S) strand (Marion & Robinson, 1983). The L strand has 4 open
reading frames (ORF), termed P, S, C, and X, and the S strand has no ORF
of any considerable length. ORF P overlaps the other 3 coding sequences,
and encodes the viral polymerase (Tiollais et al., 1985). ORF S codes for 3
forms of the HBsAg, and is divided into the pre-S1, pre-S2, and S-gene
regions (Galibert et al., 1979; Valenzuela et al., 1979).
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The genome is represented by the lines labelled L and S strands (long and short
strands respectively). The dotted line depicts the incomplete region of the S strand
which is synthesized during replication by the virion polymerase. This region varies in
length in different hepadnaviruses The arrows represent open reading frames (ORF 1
to 4) of the L strand. The nucleotide positions are given with amino acid lengths in
brackets. ORF1 codes for the polymerase enzyme, ORF2 for HBsAg, and ORF3 for
HBcAg. The function of ORF4 has still to be determined. This figure was adapted from
Marion & Robinson, (1983).
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The major or S protein is coded for by the S-gene, and is the main protein
present in each of the 3 forms of HBsAg containing particles (Cattaneo et at.,
1983). The middle protein initiates at the second start codon at pre-S2, and is
mainly present in the spherical particles (Stibbe & Gerlich, 1983). The large
protein is coded for by pre-S1, pre-S2, and the S-gene, and is found
predominantly in filaments and virus particles (Heermann et al., 1984). ORF C
codes for the HBc and HBe antigens, and like the S region has a pre-C coding
sequence (Pasek et al., 1979). The function of the X-gene remains to be
determined, although there is evidence to suggest a possible role in the trans-
activation of the virus (Spandau & Lee, 1988).
3.5 Replication of HBV.
Upon entry to the cell, the viral nucleocapsid is transported to the nucleus of
the cell where the genome is converted to covalently closed circular DNA by
the viral DNA polymerase (Summers et al., 1975; Hruska et al., 1977; Landers
et al., 1977). The genome is then transcribed into 5 main species (2.4kb,
2.1 kb, 0.9kb, and 2 at approximately 3.5kb). Two (2.1kb and 2.4kb) transcripts
are translated to produce the 3 HBsAg polypeptides (Cattaneo et al., 1983;
Standring et al., 1984), and the 0.9kb transcript codes for the X gene product
(Gough, 1983; Araki et al., 1989). The two longest transcripts exceed the
genomic length due to terminal redundancy, and differ by the presence or
absence of the pre-core translation initiation site (Buscher et al., 1985; Moroy
et al., 1985; Enders et al., 1987). The shorter transcript is the mRNA for
synthesis of core and polymerase proteins, and also acts as the template for
reverse transcription to produce the viral genome (Gowans et al., 1981;
Summers & Mason, 1982). The longer transcript is the mRNA for the
synthesis of HBeAg (Nassal et al., 1990; Yaginuma et al., 1987). The genomic
RNA template is assembled with viral polymerase and HBcAg to form the
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nucleocapsid. Once encapsidated, reverse transcription of the RNA template
is initiated, generating the long minus strand which then acts as a template for
the shorter plus strand synthesis (Summers & Mason, 1982; Lien et at., 1986;
Seeger et al., 1986). The lipid and HBsAg envelope can be acquired any time
after core assembly, irrespective of the replicative state of the viral genome
(Miller et al., 1984).
3.6 The hepatitis B viral e and surface antigens.
The hepatitis viral antigens were initially identified and characterised by
immunodiffusion techniques. When these tests were carried out in agar gels, it
was possible to distinguish separate antigen-antibody reactions represented
by precipitin lines, and to determine the relationship between antigens. For a
review of the methodology see Ouchterlony, (1958).
3.6.1 The hepatitis B e antigen.
Competitive radioimmunoassays have now been developed for the
determination of HBe status of patient sera. The assays detect HBeAg and its
corresponding antibodies, and samples negative for both are classified HBe
negative. The antigen is found free in infectious sera, and its presence has
been analysed in relation to the patient's sex, serum liver enzyme
concentrations, age, HBsAg titre, cirrhosis, and specific HBsAg subtypes
(Nielsen et al., 1974; Courouce-Pauty & Plangon, 1978; Miller et al., 1978;
Nath et al., 1978; Barr et al., 1979; Sasaki et al., 1979; Aldershvile et al.,
1980; Realdi et al., 1980). The only consistent association established is with
active viral replication and, therefore, infectivity (Magnius et al., 1975b). In
support of this, HBeAg positive sera used for transmission studies in
chimpanzees were found to be 10®-fold more infectious than anti-HBe positive
sera (Shikata et al., 1977), and HBeAg has also been associated with a higher
rate of transmission from mother to child (Okada et al., 1976) and in needle-
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stick injuries (Alter et al., 1976). The correlation of HBeAg with infectivity was
further supported by its association with the detection of HBV DNA
polymerase in serum samples (Alter et at., 1976; Imai et a!., 1976; Cappel et
al, 1977; Tong et al., 1977; Alberti etal., 1979).
3.6.2 The hepatitis B surface antigen.
HBsAg is a complex molecule of protein, lipid, and carbohydrate found in 3
forms in the sera of patients infected with HBV (Steiner et al., 1974;
Dreesman et al., 1975). The antigen is a component of the viral envelope, but
also forms spherical particles of diameter 22nm, and filamentous structures of
variable length (diameter 22nm), both of which are non-infectious and found in
abundance in sera of infected individuals (Bayer et al., 1968). There are 3
forms of the HBsAg, the major, middle, and large surface antigen (Cattaneo et
al., 1983; Stibbe & Gerlich, 1983; Heerman et al., 1984). The major protein is
found in all 3 forms in the blood, whereas the middle protein is mainly found in
the spherical particles, and the large protein in filamentous particles and
virions.
All HBsAg molecules contain a group specific determinant (a), and one of
each pair of determinants d/y and w/r which are usually mutually exclusive
(Levene & Blumberg, 1969; Purcell et al., 1969; Raunio et al., 1970; Le
Bouvier, 1971; Greenberg & Gocke, 1971; Kim & Tilles, 1971; Bancroft et al.,
1972; Le Bouvier et al., 1972; Gordon et al., 1972; Holland et al., 1972). This
was apparent from the diffusion techniques, as spurs occurred indicating
partial identity between test antigens. Further determinants (g and q) and
subdeterminants {wf-w4) were later defined (Soulier & Courouce-Pauty,
1973; Magnius etal., 1975a; Shorey, 1976).
Once the subtypes had been determined, more rapid assays were sought for
their detection. The complement fixation test was developed offering a more
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sensitive and rapid subtyping method (Purcell et al., 1969; Schmidt &
Lennette, 1970), however, it was the production of antibodies to HBsAg
(Millman et al., 1970), and in particular high affinity monoclonal antibodies
(Wands & Zurawski Jr., 1981) which led to the use of highly sensitive and
specific radioimmunoassays (Shorey, 1976; Hoofnagle et al., 1977; Burrell et
al., 1978; Fang et al., 1978; Ukkonen & Koistinen, 1979).
The advent of molecular techniques, such as the cloning and sequencing of
HBV DNA, permitted sequence analysis of the amino acid and base
composition of the antigen and its gene (Maxam & Gilbert, 1977; Sanger et
al., 1977; Burrell et al., 1979; Charnay et al., 1979; Galibert et al., 1979). This
led to the discovery that the d and y subtypes were both associated with
amino acid 122 (Okamoto et al., 1986), and that w and r subtypes were
defined in the hydrophilic region from amino acid 110 to 160 (Takeshima et
al., 1985). Comparisons of known subtypic sequences of HBsAg and site
directed mutagenesis determined that nucleotide 365 of amino acid 122
determined the d/y subtype, and nucleotide 479 of amino acid 160 determined
the w/r subtype (Peterson et al., 1984; Okamoto et al., 1987a, 1987b). In both
cases, the nucleotide was either G (y and r) or A (cfand w) coding for arginine
or lysine which determined the subtype. Later studies suggested that although
amino acids 122 and 160 were critical to the subtype determinants, other
residues may be involved in conforming these determinants (Okamoto et al.,
1989a; Ashton-Rickhardt & Murray, 1989).
Although no clinical significance has been demonstrated, the 9 subtypes
[aywf, ayw2, ayw3, ayw4, ayr, adw2, adw4, adrq-, and adrq+) have distinct
geographical distributions (Courouce-Pauty et al., 1983) and have been used
to trace sources of infection (Mayumi & Nakajima, 1973) and ancestral
migration (Yamashita et al., 1975). In addition to these well documented
subtypes, atypical subtypes such as adyw, adyr, adwr, aywr, adywr, ad, ar,
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and aw have been described (Nordenfelt & Le Bouvier, 1973/74; Mazzur et
al., 1975; Robinson, 1980; Tachibana et at., 1989).
3.7 Detection and subtyping of HBsAg DNA.
HBV DNA has been detected in serum samples by hybridization assays. Viral
DNA was detected in 91-100% of HBeAg positive samples, 5-100% of HBe
negative samples, and up to 58% of anti-HBe antibody positive samples
(Weller et al., 1982; Hadziyannis et al., 1983; Lieberman et al., 1983; Scotto et
al., 1983; Karayiannis et al., 1985; Bonino et al., 1986; Carloni et al., 1987;
Cheng et al., 1989). Similarly, the application of PCR to HBV DNA detection in
serum demonstrated a 100% association with HBeAg, and up to 89% with
anti-HBe antibody positive samples (Larzul et al., 1988, 1989; Kaneko et al.,
1989a, 1989b; Liang et al., 1989; Okamoto et al., 1989b; Sumazaki et al.,
1989; Ulrich et al., 1989; Zeldis et al., 1989). It was, therefore, decided to
apply PCR to the detection of HBV DNA in a cohort of hepatitis B patients,
and to determine the association with HBe status.
A method to selectively extract viral DNA from whole virus and
immunoglobulin complexed virus was developed using antibody coated
polystyrene beads. The aim of this was to determine the form of viral DNA
present in the serum of patients at different clinical stages (free virus,
immunoglobulin complexed virus, or naked viral DNA), and to establish a
relationship with HBe status and infectivity of the patient.
The subtyping of HBsAg has been based on immunoassays due to the
abundance of HBsAg present in serum samples throughout the infection.
However, due to the increased sensitivity of HBV DNA detection offered by
PCR, it was decided to develop a method of PCR subtyping using primers
specific for the S-gene DNA sequence.
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MATERIALS AND METHODS
AIMS OF THE THESIS.
The polymerase chain reaction (PCR) is the most sensitive method for the
detection of specific nucleic acid sequences. In view of this, it was decided to
apply the technique to the detection and characterization of human
immunodeficiency virus and human hepatitis B virus nucleic acids in clinical
samples. Areas of research included:
Human immunodeficiency virus.
1) Detection of HIV DNA in patient peripheral blood mononuclear cells
(PBMCs) by nested PCR using po/and env specific primers.
2) Characterization of the structural forms of unintegrated viral DNA
(UVD) detected in cell lines and clinical samples.
3) Detection and characterization of viral DNA in PBMC subsets and in
nuclear and cytoplasmic extracts.
4) Detection of viral RNA sequences from infectious virus using anti-
gp120 antibody coated polystyrene beads.
Hepatitis B virus.
1) Detection of HBV DNA in patient sera and correlation to HBe status.
2) Subtyping of HBsAg determinants d and y by subtype specific
amplification of the S-gene by PCR, and restriction digest of subtype
common PCR products, and comparisons of these DNA subtyping
methods with conventional HBsAg subtyping by RIPA.
3) Detection of HBV DNA in sera after antibody coated polystyrene bead
extractions of whole virus and IgG and IgM complexed virus.
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CHAPTER 4: MATERIALS AND METHODS.
4.1 SOURCES OF PATIENT SAMPLES.
4.1.1 HBsAg and anti-HBs positive sera.
Sera submitted to the Hepatitis Reference Laboratory (HRL, Department of
Medical Microbiology, The University of Edinburgh) were tested by standard
radioimmunoassays for HBsAg (Blood Products Laboratory, Elstree), anti-HBs
(Hepatitis Reference Laboratory (HRL), Edinburgh), and HBeAg/anti-HBe
(Middlesex Hospital). The 115 samples studied (P35-P149) were selected to
include a range of HBV serological markers: 58 HBsAg/HBeAg positive; 6
HBsAg positive, HBeAg/anti-HBe negative; 25 HBsAg/anti-HBe positive; 11
anti-HBs positive, HBeAg/anti-HBe negative; 10 anti-HBs/anti-HBe positive; 3
HBsAg/anti-HBs negative, HBeAg/anti-HBe negative; and 2 HBsAg/anti-HBs
negative, anti-HBe positive (Appendix I).
4.1.2 HBV negative sera.
Samples from 10 low-risk seronegative individuals were used as negative
controls. These samples were supplied by co-workers at HRL, who had
submitted sera for assessment of their response to the HBV vaccine.
4.1.3 HIV-1 positive and negative heparinised whole blood samples.
Heparinised whole blood (HWB) samples were supplied by Dr A. McMillan
and colleagues, from patients attending the Genito-Urinary Medicine out¬
patient clinic, Royal Infirmary of Edinburgh. Samples (20ml) were collected by
venipuncture, and supplied in 25ml universals containing 300 units of heparin
(approximately 12U/ml of blood, Leo Laboratories Ltd.). Total lymphocyte and
CD4+ cell counts were supplied if available.
A total of 61 samples from 34 patients were received over a period of 31
months from July 1989 to February 1992. Thirty-two patients were known to
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be HIV-1 positive, and 2 were partners of HIV-1 positive patients, and were
included as high risk negative controls. Patients were aged between 21 and
54 years; 27 male and 7 female.
Cells from HIV-1 negative blood donors were supplied as leucocyte
concentrates on a weekly basis (Scottish Blood Transfusion Service).
4.2 VIRUS ISOLATION.
4.2.1 Separation of PBMCs from HWB samples.
Approximately 20ml of heparinised blood was layered onto an equal volume of
Lympho-paque (Nyegaard Diagnostica), and centrifuged at 450g for 30min.
After separation, the cells were washed 3 times in RPMI (Gibco BRL),
counted in a haemocytometer, and processed for culture and PCR analysis.
The plasma was tested for p24 antigen, and plasma and cells not used
immediately were stored at -70°C. Cells for storage were counted and
resuspended in freezing medium (heat inactivated foetal calf serum (40min at
56°C) supplemented with 8% DMSO, Sigma).
4.2.2 Cell counting.
A small volume of cells was diluted in white cell diluting fluid (0.01% gentian
violet, 1% acetic acid in dH20) to give approximately 50 to 100 cells per large
square on the Neubauer haemocytometer. Cells were counted in the centre
and 4 corner squares, and the total number divided by 5 to give an average
cell count per square. This was multiplied by 104 to calculate the number of
cells per millilitre of suspension. The number of cells per ml of undiluted
suspension was calculated as follows;
No. of cells per ml of 104ny
undiluted cell suspension =
5
Where, n is the total cell count, and y the dilution factor.
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4.2.3 HIV-1 p24 Ag detection.
Patient plasma samples and culture supernates were analysed for p24 viral
antigen by an enzyme immunoassay (Coulter HIV p24 antigen assay), and
confirmed by neutralization (Coulter HIV-1 p24 antigen neutralization kit),
according to the manufacturers instructions.
4.2.4 Complete medium for virus isolation.
RPMI 1640 (041-02402) was supplemented with 10% heat inactivated foetal
calf serum, 100IU/ml penicillin, 100ug/ml streptomycin, 1mM Sodium
pyruvate, 2mM L-glutamine, 1.25ug/ml amphotericin-B, and 11U/mI of
recombinant interleukin-2 (IL-2, NIBSC). All materials were purchased from
Gibco BRL unless otherwise stated.
4.2.5 Virus isolation from PBMCs.
Approximately half the cells recovered from the HWB samples were used for
virus isolation (3x10® - 107 cells). Cells were resuspended in complete
medium and stimulated on day 1 with phytohaemagglutinin (90ug of PHA/ml,
Wellcome). Cells (2x10®) from HIV negative donors prepared in the same way
3 to 7 days earlier were added giving a final volume of 10ml in T25 flasks
(Costar). Cultures were maintained at 37°C in 5% C02 for 28 days. On days
7, 14, 21 and 28 approximately 1ml of supernate was removed for p24 Ag
analysis, 1x10® stimulated donor cells were added, and the culture volume
replenished with fresh complete medium to a final volume of 10ml.
4.2.6 Virus isolation from plasma.
Plasma was cultured by the method of Ho et ai, (1989). Briefly, plasma
(equivalent to 1 in 3 and 1 in 6 final dilutions) was incubated with 2x10®
PHA/IL-2 stimulated cells from HIV negative blood donors in complete RPMI
to a final volume of 3ml in 24 well plates (Costar). After 24h incubation at 37°C
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in 5% CC>2, the cells were pelleted and resuspended in 3ml of complete
RPMI. Half the culture medium was removed and stored on a weekly basis for
p24 Ag detection, and the culture was replenished to 3ml with complete RPMI.
No additional donor cells were added.
4.2.7 Small volume virus isolation from PBMCs.
After separation, the cells were washed 3 times in RPMI then cocultivated in
complete RPMI with 2x106 stimulated donor cells in a final volume of 1.5ml in
24 well plates. The cultures were stimulated with 5IU/ml of IL-2, assayed for
p24 Ag every 3-4 days, and replenished with complete medium containing
11ll/ml of IL-2. No additional donor cells were added.
4.2.8 Virus isolation from HWB.
Whole blood (to give a final dilution of 1 in 3 and 1 in 6) was cocultivated with
3-7 day PHA/IL-2 stimulated HIV negative donor PBMCs (2x106) in a final
volume of 3ml of complete medium containing 20IU/mi of IL-2 in 24 well plates
for 28 days. Plates were incubated at 37°C in 5% C02 for 24h. The cells were
washed twice with RPMI, and resuspended in a total volume of 1.5ml.
Supernate was removed every 3-4 days for p24 Ag analysis, and the medium
replaced (containing 11U/mI of IL-2). Stimulated donor cells (5x105) were
added every 7 days.
4.3 VIRUS TITRATION AND INOCULATION OF CELL CULTURES.
4.3.1 Cell lines and virus stocks.
Two viral strains and ten cell lines were used: HIV-1RF, a viral isolate from
Haiti; and HIV-1 mB, an isolate from USA; Hut78, human cutaneous T-cell
lymphoma; U937, human monocyte-like cell; C8166, human T-lymphoblastoid
cell line; MT4, HTLV-1 transformed human T-cell; HeLa T8+, human
epithelial-like cell; Sup-T1, non-Hodgkins T-cell lymphoma; LC5, HIV
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susceptible clone of human embryonic lung fibroblasts; U138MG, human
glioblastoma cell; THP1, human monocytic leukaemic cell line; HB1, human B
cell line (James et a/., 1990). All cell lines and viral strains were supplied by
the MRC AIDS directed programme unless otherwise stated (Appendix II).
Uninfected blood donor PBMCs were obtained from the Scottish Blood
Transfusion Service.
4.3.2 Titration of HIV-1 virus inoculum.
Supernate from HIV-1 infected cells was titrated by assaying 5 replicates of
each dilution (1 in 10 to 107) in C8166 cells in 96 well plates (Costar). The
plates were incubated at 37°C in 5% CC>2, and scored for the presence of
syncytia over 7 days. The 50%-tissue culture infective dose (TCID50) was
calculated by the method of Reed and Muench as described in Appendix III.
4.3.3 DNase I treatment of viral supernates.
Viral supernates were treated with 50U/ml of DNase I (Gibco, BRL) in RPMI
1640 with 5mM MgC^ for 60min at room temperature and filtered prior to use
(0.45um, Costar).
4.3.4 Inoculation of cells with HIV-1.
The HIV-1 supernate was diluted to 4x104 TCIDgg/ml in complete RPMI
without FCS. Cells (5x10®) were resuspended in 2ml of viral supernate (m.o.i.
of 0.008), and incubated for 1h at 37°C in 5% CO2. The cells were washed
three times in RPMI and resuspended in 5ml of complete medium (serum-
starved cells were incubated in complete RPMI without FCS for 3 days prior to
inoculation, and throughout the experiment). At each time point, 2x105 cells
were removed, pelleted and resuspended in lysis buffer for DNA extraction.
4.3.5 Inoculation and fixation of cells for electron microscopy studies.
Viral supernate (HIV-1RF) was titrated and used to inoculate C8166 cells
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(m.o.i. of 1) at 4°C, to allow viral attachment without penetration. Cells (2x10®)
were removed at time 0 and the culture was transferred to an incubator (37°C
in 5% CO2). Cells were further harvested at times 5, 10, 15, 20, 25, 30, 40, 50
and 60min, and days 3, 4, 5, 7 and 8.
Harvested cells were pelleted, washed in cacodylate buffer (100mM Sodium
cacodylate, pH7.3), and resuspended in 2.5% glutaraldehyde (EM grade) in
cacodylate buffer for 5h at room temperature. Cells were washed twice in
buffer, and fixed for 1h at room temperature in 2% osmium tetroxide in
cacodylate buffer. The cells were washed, pelleted, and embedded in 2%
noble agar for processing. The embedded pellet was dehydrated in 50%,
70%, and 95% alcohol for 15min each, and twice in absolute alcohol for
20min. The pellet was cleaned in 2 changes of epoxy propane for 15min, and
left overnight in a 1:1 mixture of epoxy propane and araldite (araldite CY 212,
used as described in the manufacturers protocol). The pellet was incubated
twice with fresh araldite for 1 h, embedded in araldite in a beam capsule, and
polymerised at 60°C for 48h. Ultrathin sections of about 50nm were cut on an
Ultratome (LKB) and collected on gold grids of 600 mesh. The sections were
dried at room temperature, and stained in the dark for 30min with saturated
aqueous uranyl acetate. The grids were washed in buffer, and counter stained
in a CO2 free atmosphere for 5min with Reynolds lead citrate. The grids were
washed thoroughly in buffer, dried, and examined in a Hitachi 12A
transmission electron microscope. All reagents were purchased from Agar
Scientific (Essex).
4.4 SEPARATION AND ANALYSIS OF CELLULAR SUBSETS.
4.4.1 Dynabeads.
Dynabeads (Dynal (UK) Ltd.) are microspheres of uniform size (4.5um) with
identical physical and chemical properties. Each microsphere is coated with a
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polystyrene shell, allowing covalent binding of biomolecules (eg. antibodies)
resulting in a highly specific binding capacity. The core of each particle
contains maghemite, permitting the isolation of microspheres bound to target
cells by a magnetic particle concentrator (MPC, Dynal). Antibody coated
Dynabeads can, therefore, be utilised to purify cell subsets which express
unique surface antigens.
M-450 tosylactivated Dynabeads were coated with anti-CD14 antibodies for
monocyte/macrophage cell isolation and M-450 Dynabeads, pre-coated with
antibodies to CD19, CD8, and CD4 antigens, were used for the separation of
B cells, T-cytotoxic/suppressor cells, and T-helper/inducer cells respectively.
4.4.2 Covalent binding of anti-CD14 antibodies to tosyiactivated
Dynabeads.
M-450 tosylactivated Dynabeads were thoroughly resuspended and an aliquot
removed. The microspheres were collected by applying the MPC for 2-4min,
and the supernate was removed. The microspheres were resuspended in
ddw, and the process repeated several times. The washed Dynabeads were
finally resuspended in a volume of ddw equal to that of the original aliquot.
The monocyte-specific antibody (anti-CD14, SAPU, Law Hospital, Carluke)
was dissolved in 0.05M borate buffer (pH9.5) to a concentration of 150ug/ml,
and an equal volume of microspheres in suspension was added, giving an
estimated antibody to bead ratio of 5:1 (as described by the manufacturer).
The mix was incubated overnight at 22°C for 22h with end-over-end rotation,
the microspheres were collected with the MPC, and the supernate discarded.
The pellet was washed at room temperature in 5ml of 0.01 M PBS containing
0.1% BSA, 3 times for 10min, once for 30min, and overnight at 4°C. The
Dynabeads were collected and resuspended in 0.1% BSA in PBS at a
concentration of 4x10® Dynabeads/ml, and stored at 4°C.
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4.4.3 PBMC subset separation by antibody coated Dynabeads.
Antibody coated Dynabeads were mixed with PBMCs, at an estimated ratio of
1.5:1, for 30min at 2-8°C to reduce the non-specific binding, and periodically
observed under the light microscope for rosette formation. The number of
cells present in each cellular subset was estimated from the normal
distribution of PBMCs (70% T cells (CD4:CD8 ratio 2:1); 10% B cells; and
20% monocytic cells, Roitt eta!., 1987).
The bound cells were separated by applying the MPC for 2-5min, and the
process repeated until the cells had been incubated with Dynabeads coated
with each of the antibody specificities. The cells were isolated sequentially by
Dynabeads coated with antibodies to CD19, CD14, CD8 and CD4 antigens.
The separated cells were washed twice with PGN (PBS (pH7.2), containing
5% normal mouse serum (Serotec), and 20mM glucose), resuspended in
200ul of PGN, and split into 5 equal fractions for analysis.
4.4.4 Labelling cells for flow cytometric analysis.
Anti-CD4, anti-CD8, anti-CD14, and anti-CD19 fluorescein isothiocyanate
conjugated antibodies (Serotec) were used for fluorescein-activated cell
sorting analysis of the cell fractions.
Samples were processed in 5 equal fractions, one of which was incubated
with each of the 4 FITC-conjugated antibodies (10ug), and the fifth fraction
was kept as a negative control. The reaction vials were mixed and incubated
on ice in the dark for 30-60min, and the pellets washed twice with 1ml of PGB
(PBS pH7.2, containing 20mM glucose and 0.5% BSA). The samples were
transferred to a 0.75ml eppendorf tube, pelleted and resuspended in 300ul of
buffered paraformaldehyde (47mM Sodium cacodylate (pH7.2) and 1% (w/v)
paraformaldehyde) for flow cytometric analysis. (This was adapted from the
method of Serotec).
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4.4.5 Analysis by flow cytometry.
The samples were analysed within 24h of fixing using an EPICS "C" flow
cytometer (Coulter Electronics, Luton, UK) fitted with a 5 watt laser and
utilising a power output of 300mW at 488nm. The cells were passed under
pressure through the laser beam, and the light scattered, reflected, and
emitted by the cells was detected by various photosensors and analysed by
the computer to generate 3 pieces of data for each event.
The small angle deflected light (forward light scatter) was an indicator of cell
size, and large angle deflected light (90° light scatter) was representative of
the granularity of the cells. Cells were also analysed using FITC-conjugated
antibodies specific to surface markers. In this way, the cells were separated
by size and granularity into lymphocyte and monocyte sub-populations, and
further analysed for subset specific CD antigens using FITC-conjugated
antibodies to CD4, 8, 14 and 19 antigens (Moscicki et at., 1985; Mason et at.,
1987).
At least 1000 events were analysed for each sample, and the results
expressed as a percentage of events showing fluorescence greater than the
background level.
4.4.6 Separation of monocytic cells by adherence.
Patients' cells were cultured in T25 flasks in complete medium with 20% FCS
at 37°C and 5% CO2 with no cell mitogens. On day 3, the flask was tapped
repeatedly and non-adherent cells removed. Adherent cells were washed 3
times with pre-warmed RPMI, removed carefully using a cell scraper (Costar),
and stored in freezing medium at -70°C for PCR analysis.
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4.5 NUCLEIC ACID EXTRACTIONS.
4.5.1 Total DNA extractions from sera.
Sera were extracted and amplified in batches of 10. Each batch, numbered
randomly, consisted of 5 test samples and 5 controls. Three controls were
from low-risk seronegative donors, and 2 controls were HBV DNA positive
samples. The positive controls (cfand y subtypes) were patient samples which
were found to subtype consistently by RIPA and PCR in preliminary studies.
Sera (200ul) were incubated for 45min on ice with proteinase K (Sigma) at
100ug/ml in an equal volume of lysis buffer (200mM NaCI, 100mM EDTA,
100mM Tris, pH8.0). N-lauroylsarcosine was added to a final concentration of
1% (w/v), and samples were incubated at 65°C for 3h. After phenol/chloroform
extraction, the aqueous phase was precipitated with 2 volumes of ethanol and
0.1 volume of 4M potassium acetate (KAc) at -20°C for a minimum of 45min.
The precipitate was pelleted in a microfuge, washed and resuspended in
10Oul of ddw (each 10ul aliquot was equivalent to 20ul of neat serum).
4.5.2 Total DNA extraction from cells infected with HIVRF.
Cells were extracted from in batches of 10 consisting of cells from each
culture (uninfected C8166 and PBMC cells, HIV-1RF infected C8166 and
PBMC cells, and HIV-1RF infected C8166 cells in serum-starved medium) for
2 complete time points. Each batch, therefore, contained 2 negative cell
controls for each time point. Cells (2x105) were resuspended in lysis buffer
(100mM NaCI, 50mM EDTA, 50mM Tris, pH8.0) with 100ug/ml of proteinase
K (Sigma), and 1% (w/v) N-lauroylsarcosine and incubated at 60°C for 3h.
DNA was repeatedly extracted by a mixture of phenol, chloroform and isoamyl
alcohol (50:49:1, Sigma) until the interphase was clear. The DNA was
precipitated in 4M KAc (0.1 volume), and pure ethanol (2 volumes) at -20°C
for a minimum of 45min. The DNA was pelleted and washed in ethanol, then
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resuspended in a small volume of ddw (1 OOul) for PCR analysis (each 10ul
aliquot contained DNA from 2x104 cells).
4.5.3 Total DNA extraction from cell lines infected with HIVmB.
Cell lines infected with HIV-1mB were extracted by a rapid method described
by Collin et ai, (1991). Briefly, cells (2x105) were removed from the culture at
each time point and pelleted. The pellet was resuspended in 10Oul of RPMI
and an equal volume of buffer (100mM KCI, 20mM Tris-HCI, 500ug/ml
proteinase K and 0.1% (v/v) NP-40), and incubated at 60°C for 2h. The
reaction was terminated by inactivating the enzyme at 95°C for 15min. No
further purification was carried out, and samples were stored at -70°C prior to
amplification. Negative cells were included in each batch to control for cross-
contamination. Each 10ul aliquot was equivalent to 104 cells.
4.5.4 Total DNA extraction from patient PBMCs.
Cell samples were routinely extracted as described for cell lines infected with
HIVrf with the exception that patient cells were extracted in batches of 10: 5
test samples and 5 negative controls. No positive controls were included in
standard extractions to minimise the possibility of contamination. The samples
were numbered so that each was adjacent to 2 negative controls, and batches
were processed in numerical order at all times. Most of the samples tested
were from known HIV positive individuals, and so completely negative batches
were unlikely. Batches that did not yield a positive result were repeated with
the inclusion of a positive control. Positive control samples were obtained from
cell lines infected with HIV-1RF or HIV-1mB which had previously been shown
to be positive by PCR. The number of cells extracted varied from patient to
patient. However, the cell equivalents of each amplification aliquot is supplied,
when available, in Appendix IV.
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4.5.5 Nuclear and cytoplasmic DNA extraction.
The method of Ellison et al., (1990) was modified for the extraction of nuclear
and cytoplasmic DNA. The cells (1x106) were washed in buffer A (10mM Tris;
pH7.4, 150mM KCI, 5mM MgCI2, 1mM dithiothreitol, 20ug aprotinin per ml)
and pelleted at 175g (benchtop GC centrifuge, Beckman) for 15min. Cells
were resuspended in 1ml of buffer A with 0.5% (v/v) Triton X-100, incubated
at 4°C for 30min, and pelleted at 1000g for 10min. The nuclear pellet was
washed in buffer A, and both the cytoplasmic and nuclear fractions were
extracted as described for cell line studies (4.5.2), and resuspended in 10Oul
of ddw (each 10ul aliquot equating to 1x105 cells).
4.5.6 Quantitation of total extracted DNA.
Extracted DNA was quantified by measuring the ultraviolet absorbance at
260nm and 280nm. Samples were diluted 1 in 100 in ddw, and absorbance
measured in a spectrophotometer (CE 292, Cecil). The ratio of optical
densities (260/280) gave an indication of the sample purity, pure DNA giving a
ratio of 1.8. The concentration of DNA was calculated from the equation: True
a260 x D x 50 = DNA concentration (ug/ml), where A260 = absorbance at
260nm, True A2qq = (A260~A280) x 2> D = the dilution factor (=100) and 50
refers to the dsDNA concentration at A260 of 1.
4.5.7 Extraction of total RNA.
This method was kindly supplied by Dr Peter Balfe (Department of Medical
Microbiology, UCMSM, London). All plastics to be used were pre-treated with
chloroform to remove RNases, and where appropriate, buffers were treated
with 0.1% diethyl pyrocarbonate (DEPC) for 12h at 37°C, and autoclaved for
30min at 121°C.
PBMCs were washed with PBS (Mg2+, Ca2+ free), and resuspended in 1
volume of RNAzol solution (4M guanidium thiocyanate, 25mM sodium citrate,
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1% (w/v) N-lauroylsarcosine, and 0.72% (v/v) beta-mercaptoethanol), 1
volume of water saturated phenol (Sigma), and 0.1 volume of 2M sodium
acetate (pH4). A total volume of 2ml was used for extracts of 106 cells, and
1ml for each antibody coated bead extraction. Chloroform was added to a final
volume of 10% (v/v), the sample was inverted, incubated on ice for 15min,
and centrifuged for 15min (MSE microfuge, Scotlab). The upper phase
containing the RNA was transferred to a clean vial and precipitated with an
equal volume of propan-2-ol for 45min at -20°C. The sample was pelleted for
15min, washed twice with ice-cold 75% ethanol, and dried under vacuum for a
maximum of 10min. The RNA pellet was resuspended in 21 ul of DEPC
treated ddw in preparation for cDNA synthesis. One HIV negative control
PBMC sample was included per batch of 10 samples.
4.5.8 Antibody coated bead capture extraction of viral nucleic acids.
Samples were incubated at 37°C for 2h, or overnight at room temperature,
with antibody coated beads and 10U of DNase I. The beads were washed
(distilled H20) a minimum of 5 times, and transferred to eppendorf vials for
nucleic acid extraction.
Bead extracts for HBV DNA were carried out on 200ul of sera, and were
extracted in lysis buffer (200mM NaCI, 100mM EDTA, and 100mM Tris,
pH8.0) for 3h at 60°C as described in 4.5.2.
Bead extracts of HIV-1 RNA were from 300ul of sample, and were processed
as described in 4.5.7.
4.6 THE POLYMERASE CHAIN REACTION.
All batches were amplified for 25 cycles on a water cooled heating block
(PHC-1 or PHC-2, Techne, Scotlab). Each cycle consisted of denaturation of
the samples at 95°C for 36s, primer annealing at 50°C for 42s, and DNA
synthesis at 65°C for 3min. The final extension of cycle 25 was held for a total
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of 5min to ensure completion of all strands. All subsequent reactions were for
a further 25 cycles as above, utilising 2ul of the previous amplification product.
False-positive or negative results obtained in any controls resulted in the
batch being discarded and the amplification repeated on fresh aliquots.
4.6.1 Amplification buffer for HBsAg DNA detection.
This method was adapted from the method described by Simmonds et al.
(1990a). An aliquot (1 Oul) of extracted DNA was amplified in PCR buffer
(67mM Tris, 16.7mM ammonium sulphate, 6.7mM magnesium chloride,
10mM f3-mercaptoethanol) with 75nM of each primer, 45uM of each dNTP
(Boehringer Mannheim), 1 unit of Taq polymerase (Perkin Elmer Cetus,
supplied by MRC ADP), 170ug/m! of BSA (DNase free, Pharmacia), and 40ul
of paraffin layered on top. Batches were amplified as described (4.6).
4.6.2 Amplification buffer for HBV DNA detection after antibody coated
bead extractions.
An aliquot (1 Oul) of the extracted DNA was diluted in amplification buffer
(50mM KCI, 10mM Tris-HCI 15mM MgC^, and 0.1% Triton X-100, pH8.8,
Promega) with 75nM of each outer primer, 36uM of each dNTP, 170ug of BSA
(DNase free, Pharmacia), and 1 unit of Taq polymerase (Promega). Samples
were amplified as described (4.6).
4.6.3 Amplification buffer for HIV-1 DNA detection by PCR.
Samples were processed in batches as described in the methods for DNA
extraction. An aliquot (1 Oul, or 2x104 cell equivalents) of each extract was
transferred to 90ul of PCR buffer (50mM KCI, 10mM Tris-HCI (pH8.8 at 25°C),
1.5mM MgC^, and 0.1% Triton X-100, Promega Corporation), containing
75nM of the upstream and downstream primers, 45uM of each dNTP
(Boehringer Mannheim), 1 unit of Taq polymerase (Promega Corporation),
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170ug/ml of BSA (Pharmacia), and layered with paraffin. The samples were
amplified as described (4.6).
4.6.4 Source of DNA oligonucleotide primers.
All oligonucleotides used in this study were synthesized by Oswel DNA
service (Department of Chemistry, The University of Edinburgh) and purified
by high-performance liquid chromatography. Their sequences, coordinates
and sources are described in detail in Appendix V, and the method of
calculating their concentrations is given in Appendix III.
4.6.5 Primer pairings for HBsAg DNA detection.
The primary amplification of HBV DNA was with primers 058C/869C resulting
in a band of 548bp, and the nested amplification with 057C/870C (235bp).
4.6.6 Primer pairings for HIV-1 DNA detection.
HIV-1 DNA was detected in cell lines by primers specific for the po/gene. The
primary amplification with primers 160H/161H yielded a band of 244bp, and
the nested reaction used 002C/003C yielding a 128bp product. A second set
of primers was used for detection of the env gene, and for studies of the
variability within the envelope region. The primary amplification was with
primers 401C/404C (438bp), and the nested cycles with 402C/403C (317bp).
4.6.7 Analysis of PCR products by agarose gel electrophoresis.
Amplification products were analysed on agarose gels (Sigma) against 0.5ug
DNA VI molecular weight marker (Boehringer Mannheim) in 0.5 x TBE
containing ethidium bromide (50ng/ml). The samples were loaded in tracking
dye (6 X buffer; 0.25% bromophenol blue, 0.25% xylene cyanol FF, and 30%
glycerol in water), and electrophoresed at a constant voltage of 150V (Midi-gel
apparatus, Northumbria Biologicals Limited, and Bio-rad 200V power supply).
HIV-1 PCR products were analysed on 1.5% gels, and HBV PCR products on
58
2% gels.
4.6.8 Reverse transcription of RNA extracts and amplification of cDNA
(RT-PCR).
cDNA was synthesized from RNA extracts using a thermostable rTth reverse
transcriptase RNA PCR kit (N808-0069, Perkin Elmer Cetus). The kit
contained materials for the synthesis and amplification of cDNA in a single
reaction vial (RT-PCR). The thermostable enzyme contained both RNA and
DNA dependent synthesizing activities, enhanced by the use of manganese
and magnesium chelating ions respectively.
Each RNA extract was split into 3 equal fractions (7ul), 2 fractions were
diluted in 17ul of RT mix (10mM Tris-HCI (pH8.3), 90mM potassium chloride,
1mM manganese chloride, 200uM of each dNTP, 5 units of reverse
transcriptase enzyme, and 0.75uM of the upstream primer) and overlaid with
mineral oil. One vial contained primer 160H to reverse transcribe the po/gene
sequence, and one vial contained the env primer (401C). The third vial was
not reverse transcribed, and was used as an amplification control for
contaminating viral DNA. All samples, including DNA controls, were incubated
at 70°C for 15min on a heating block (PHC-1 or PHC-2, Techne, Scotlab). The
reaction solution was then diluted further with PCR mixture to a final volume of
10Oul (4% (v/v) glycerol, 8mM Tris-HCI (pH8.3), 0.6mM EGTA, 0.04% (v/v)
Tween-20, 2mM magnesium chloride, and 0.15uM of the downstream primer).
The primers utilised for the amplification reaction were 161H for the pol
sequences, and 404C for the env sequences (both pol primers were added to
the DNA control vial). The amplification was for 2min at 95°C for 1 cycle, 1min
at 95°C and 1min at 60°C for 35 cycles, and 7min at 60°C for 1 cycle. The
amplification products were then amplified with the appropriate nested
primers, and the products electrophoresed as described in 4.6.6 and 4.6.7.
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Each batch of samples amplified included 1 HIV negative control (included in
the extraction), and 1 non-reverse transcribed control for each patient sample.
4.6.9 The synthesis of a pol specific biotinylated oligonucleotide by
PCR.
The polymerase chain reaction was used to generate H1V-1 specific pol
sequences labelled with biotin. The reaction mixture was as described in 4.6.1
with the exception that 75% of the dATP in the nested amplification was
biotinylated (Biotin-14-dATP, BRL). The HIV-1 non-infectious clone BH10
(Hahn et at., 1984) was linearised with Sst 1 and utilised as the template
sequence, and primers 160H/161H were used for both amplification reactions
for 25 cycles.
4.6.10 Preliminary amplifications to detect 1 and 2LTR CUVD.
One and 2LTR CUVD were initially detected using a standard nested PCR
utilising a variety of primer pairs from gag, env, and the LTR sequences. The
primary amplification was with 782K/783K (bands of 996bp and 1630bp for 1
and 2 LTR CUVD respectively), and the nested amplification with primers
780K/781K for 1 and 2 LTR CUVD (277bp for 1 and 2 LTR forms), and
779K/781K for 2LTR CUVD (447bp).
4.6.11 Optimisation of 2LTR CUVD detection.
To enhance the detection of viral sequences over the non-specific sequences
amplified with the 2LTR CUVD specific primers, samples were amplified with
3 sets of primers.
The primary step was with primers 782K/783K (resulting in bands of 996bp
and 1630bp for 1 and 2LTR CUVD respectively), followed by a secondary
amplification using 1 primary and 1 nested primer (779K/782K (396 or
1030bp) or 781K/783K(413 or 1047bp)) with a tertiary amplification with
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primers 779K/781K (447bp).
These amplification protocols were applied to PBMC DNA extracts from
patient samples P1, P4b, P13, P20c, and P25b. All samples were amplified
and analysed as described in 4.6.3 and 4.6.7.
4.6.12 Simultaneous detection of 1 and 2LTR CUVD for confirmation.
Samples negative for one CUVD form and positive for the other were
amplified with primers from the gag and env sequences which were able to
detect both 1 and 2LTR CUVD forms simultaneously. The primary
amplification with primers 077F/782K resulted in bands of 1933bp and 2567bp
for 1 and 2LTR forms respectively. An aliquot was then amplified for 35 cycles
with the nested primers 782K/783K, resulting in bands of 996bp and 1630bp
(for 1 and 2LTR CUVD forms respectively).
4.6.13 Optimum primers for the detection of 1 and 2LTR CUVD.
The final sequence of primers utilised for optimum detection of 1 and 2LTR
CUVD forms in cellular extracts by PCR is presented as a flow diagram in
Figure 6. Due to the increase in sensitivity obtained for 2LTR CUVD detection
using a tertiary amplification, samples for 1LTR CUVD detection were also
tertiary amplified. All samples were, therefore, initially amplified with the
primary and secondary primers (782K/783K and 781K/783K respectively),
with further amplifications with 780K/781K for 1LTR CUVD detection (276bp),
and 779K/781K for 2LTR CUVD detection (447bp). For confirmation of these
results, samples were amplified for 25 cycles with primers 077F/782K (1933
and 2567bp for 1 and 2 LTR CUVD respectively), and 35 cycles with primers
782K/783K. Unlike the product from the tertiary amplification for 1LTR CUVD,
the amplification product from these primers was able to distinguish between
1 and 2LTR forms. The nested amplification with non-LTR primers was,
therefore, essential for the unequivocal detection of 1 LTR CUVD forms.
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Figure 6. Flow chart of amplification steps for 1 and 2 LTR
circular unintegrated viral DNA (CUVD) detection
The flow diagram depicts each step involved in the detection of CUVD
forms in the patient PBMC extracts. Amplifications are designated primary
(1°), secondary (2°), and tertiary (3°). CUVD amplifications are for both 1
and 2 LTR forms of CUVD. Amplifications for 1 or 2 LTR CUVD
sequences only, are listed as 1 LTR or 2 LTR respectively. After tertiary
amplifications, products were analysed by gel electrophoresis (gel), and
depending on the results, were either stopped or re-amplified with
alternative primers specific for both 1 and 2 LTR CUVD forms
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4.6.14 Determination of the minimum oligonucleotide length for priming
of DNA synthesis.
Three sets of amplifications were attempted to try and determine the minimum
length requirement for an oligonucleotide to initiate DNA synthesis. Small
sequences of 3-9 bases were selected to hybridize to the nested pol primer
(002C) sequence (Figure 7a). They were chosen to have a guanosine base at
the 3' end to reduce the amplification efficiency resulting from mispriming
events (Figure 7b, Newton et al., 1989; Kwok et at., 1990). The
oligonucleotides were used to amplify pooled DNA extracted from patient
samples 11b, 16 and 19a (see Appendix IV for patient details). The initial
experiment used the primers 160H/161H for the primary amplification, and
556-559LV003C for the nested amplification. The other 2 experiments utilised
a primary amplification with 556-559L/161H, and a nested amplification with
002C/003C or 559L7003C (Figure 7c).
For each experiment the PCR was as described previously (4.6.3) with the
exception that primers were added to individual reaction vials and not to the
overall PCR mix. In this way, it was possible to control for contamination in the
general PCR mixture, and to utilise the primers 160H/161H and 002C/003C
as positive controls for the detection of viral DNA.
4.6.15 Ligation-PCR for the detection of LUVD.
Samples (20ul, corresponding to 4x104 cells) were diluted in ligation buffer to
give a final concentration of 50mM HEPES, 20mM MgC^, 3mM DTT, 0.1 mM
ATP, 10% (v/v) DMSO, 10ug/ml BSA, and 75nM of ligation sequence (021N)
in a total volume of 30ul. The mixture was covered with paraffin, and
incubated at 95°C for 10min to denature the DNA. T4 RNA ligase (1 unit,
Gibco BRL) was added to each tube, and incubated for 1h at 4°C. The
reaction was terminated by destroying the enzyme at 95°C for 5min. The
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Figure 7. The base composition and relative positions of the primers and
oligonucleotides used to determine the minimum sequence requirement
for priming of DNA synthesis.
a) Schematic representation of po/primer orientations.
160H 002C 003C 161H





b) Base composition of oligonucleotides 556L, 557L, 558L, and 559L, and
their relative positions to primer 002C.





The oligonucleotides were chosen with a 3' guanosine base to reduce the
efficiency of amplification resulting from mis-priming events (Newton et al.,
1989; Kwok et al., 1990). The primers were utilised in 3 experiments designed
to determine the minimum sequence requirement for priming DNA synthesis.






For full details of these primers see Appendix IV.
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samples were amplified by PCR in a total volume of 10Oul as described
(4.6.3). The primary amplification was with primers 022N/782K (931 bp),
secondary PCR with 022N/586N (392bp), and tertiary PCR with 022N/781K
(348bp). The secondary and tertiary amplifications utilised a 2ul aliquot of the
preceding amplification product, and the results were analysed by gel
electrophoresis (4.6.7).
4.7 HYBRIDIZATION ASSAYS.
4.7.1 Loading of samples for dot blot hybridization.
Membranes were cut to size, and pre-wet in ddw (nitrocellulose, Schleicher
and Schull) or 0.1% Triton X-100 (nylon, Amersham). The samples (denatured
at 95°C for 10min) were loaded using a Hybri-dot manifold (Gibco, BRL), and
a minimum of 500ul of ddw was passed through each well to wash the sample
onto the membrane. Membranes were removed from the manifold with the
vacuum still pulling to prevent spreading of the samples due to back-wash.
They were then denatured (1.5M Sodium chloride, 0.5M Sodium hydroxide for
both nitrocellulose and nylon membranes) and neutralised (1.5M Sodium
chloride, 0.5M Tris (pH8.0) for nitrocellulose, and 1.5M Sodium chloride, 0.5M
Tris (pH7.2), 1mM EDTA for nylon membranes) for 1min each, and fixed.
Control wells were included for each membrane. Standard controls included
ddw, salmon testes DNA, and biotinylated DNA. Nested PCR products of
negative controls were also included as appropriate.
4.7.2 Hybridization conditions for nylon membranes.
The method of hybridization used was a modification of the Amersham
protocol for radioisotopic probes. Membranes were incubated overnight at
42°C in a rotary hybridization oven (Hybaid), with 10ml of pre-hybridization
buffer (45% deionised formamide, 6 x SSC (20 x SSC; 3M Sodium chloride
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(pH7.0), 300mM Sodium citrate), 5 x Denhardt's (100 x Denhardt's; 2% (w/v)
BSA, 2% (w/v) Ficoll, 2% (w/v) polyvinylpyrrolidine), 0.5% SDS, and 20ug/ml
of sonicated salmon testes DNA (Sigma)). Hybridization was at 42°C for 4h in
10ml of buffer (as above) with 600ng/ml of biotinylated single stranded DNA
probe (581 NBio, see Figure 8 for the sequence and coordinates of this probe).
Post-hybridization washes consisted of 2 washes in 2 x SSC/0.1% SDS for
3min, and 2 in 0.2 x SSC/0.1% SDS for 3min at room temperature. The
temperature was raised to 50°C for 2 washes in 0.16 x SSC/0.1% SDS for
15min, with a final rinse at room temperature in 2 x SSC/0.1% SDS.
Membranes were finally baked at 80°C for 10min, to reduce background
noise.
4.7.3 Hybridization conditions for nitrocellulose membranes.
Nitrocellulose membranes were pre-hybridized for 2 hours at 42°C in 45%
deionised formamide, 5 x SSC, 5 x Denhardt's, 25mM Sodium dihydrogen
phosphate (pH6.5), and 100ug/ml of salmon testes DNA. The hybridization
reaction was at 42°C for 4 hours in 5ml of 10% (w/v) dextran sulphate, 45%
deionised formamide, 0.02% Denhardt's, 5 x SSC, 23mM sodium dihydrogen
sulphate (pH6.5), 100ug/ml of salmon sperm DNA, and 600ng/ml of probe.
Post-hybridization washes were as described for nylon membranes.
4.7.4 Colour reaction for the detection of biotinylated DNA.
Following the BRL DNA detection system instruction manual, filters were
blocked and incubated as directed to detect biotinylated DNA. The
membranes were washed in buffer 1 (0.1M Tris (pH7.5), 0.1M NaCI, 2mM
MgC^, 0.05% (v/v) Triton X-100) for 1min, blocked at 65°C for 60min (42°C
for 20min for nitrocellulose membranes) in fresh pre-warmed buffer 2 (3%
(w/v) BSA in buffer 1), and incubated at room temperature with Streptavidin
(2ug/ml of buffer 1) for 10min. Membranes were washed with 20 to 40-fold
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Figure 8. Orientation, sequence and coordinates of the biotinyiated
probe 581NBio.










U5 R U3 U5 R U3
b) Sequence and coordinates of 581 NBio.
5' GGCGTGGCCTGGGCGGGACTGGGGGAGTGGCGAGCCCTCAG 3'
The biotinyiated oligonucleotide (sense) specific for the U3 sequence of the
viral LTRs at position -36 to -75 and 9041 to 9080 (based on the published
sequence of HIV-1 by Ratner et at., 1985) (synthesized by Oswel DNA
services).
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greater volume of buffer 1 than employed in the Streptavidin step, and gently
agitated for 3min. This step was repeated twice. Further incubation with
Biotin-alkaline phosphatase (1ug/ml of buffer 1) at room temperature for
10min was followed by two 3min washes with buffer 1, and similarly with
buffer 3 (0.1M Tris (pH9.5), 0.1M NaCI, 50mM MgC^)- Colour development
was in the dark, at room temperature, with freshly prepared dye solution
(330ug/ml of NBT in 7.5ml of buffer 3, mixed gently, then add 165ug/ml of
BCIP). The reaction was terminated by washing membranes in 20mM Tris (pH
7.5)-5mM EDTA, and baking for 10-20min at 80°C (1-2min at 80°C for
nitrocellulose).
4.7.5 Comparison of UV fixation of DNA to nylon, against baking of
nylon and nitrocellulose membranes.
Dilutions (neat, 1 in 10, 1 in 100, and 1 in 200) of a nested pol PCR sample
were denatured and spotted onto pre-wet membranes (2 nylon and 1
nitrocellulose). The samples were denatured and neutralised as described
(4.7.3). The nitrocellulose and one nylon membrane were baked at 80°C for
2h under vacuum, while the second nylon membrane was kept moist,
wrapped in clingfilm, and placed DNA side down on a Transilluminator (TM-
36, 302nm peak wavelength, Ultra-violet Products Inc., Cambridge) for 5min
to covalently fix the DNA. The membranes were then processed and
developed as described using the PCR generated pol specific biotinylated
probe (4.7.4 to 4.7.6).
4.7.6 Optimisation of UV fixation of DNA to nylon membranes.
Biotinylated DNA (20pg of 581NBio; Figure 8) was loaded onto a nylon
membrane in an array of 6 pairs of dots. The membrane was kept moist and
covered in clingfilm for UV fixation. To vary the time each pair of DNA dots
was exposed to the UV irradiation, aluminium foil was used to block the
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samples from the light source. The membrane was placed directly onto the
UV light source, and each pair of dots exposed to 10, 20, 30, 40, 50 or 60s of
UV irradiation. The membrane was cut into 2 identical strips, and one strip
was boiled in ddw for 1min to remove any non-covalently bound DNA. The
strips were developed together, and the results compared.
4.7.7 Detection of LTR sequences using a biotinylated probe specific for
the U3 region.
To ensure that the probe was specific and sensitive, 2 LTR CUVD specific
PCR positive DNA was spotted directly onto nylon as described (4.7.3). The
samples were from the cell line studies, using the laboratory RF strain of HIV-
1 (C8166 cells infected with HIV-1RF in complete RPMI from days 3, 4, 5, and
7). After denaturation and neutralisation, the membrane was fixed by UV light,
pre-hybridized at 42°C overnight, hybridized for 4h with 400ng/ml of 581NBio
probe, and developed.
4.7.8 Southern transfer of DNA to nylon membranes from agarose gels.
The biotinylated oligonucleotide (581NBio) was selected to demonstrate the
transfer of DNA to nylon membranes. Diluted samples of 581NBio (1.29ug,
967.5ng, 645ng, 322.5ng, 129ng, and 64.5ng per well) were electrophoresed
on a 1.5% agarose gel against a biotinylated ladder (20ng and 40ng of
biotinylated DNA marker VI, Boehringer Mannheim), and the resulting bands
were transferred to a nylon membrane using a semi-dry multi gel electroblotter
(Ancos, Denmark). Filter paper was soaked in transfer buffer (0.15M tri-
sodium citrate dihydrate, pH 7) and placed on the anode plate. The
membrane was cut to size, pre-wet in 0.1% Triton X-100, washed in transfer
buffer, and placed on top of the filter paper. The gel was washed 3 times in
transfer buffer, and layered on top of the membrane. Further layers of buffer
soaked filter paper were added, and the cathode plate attached. A transfer
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current of 0.8mA/cm2 was applied. The gel was transferred for 1 hour, and
viewed to observe the efficiency of band transfer. The membrane was UV
fixed, and developed for the direct detection of biotinylated DNA.
4.7.9 Southern blot hybridization of 2LTR CUVD nested amplification
products with the biotinylated probe 581NBio.
Nested 2 LTR CUVD amplifications (15ul of P4b, P20c, P1, and P13
amplification products) were separated on a 1.5% agarose gel against a
biotinylated ladder (DNA marker VI biotinylated, Boehringer Mannheim), and
transferred onto a nylon membrane at 0.8mA/cm2 for 5h. Membranes were
further processed as described for dot blot hybridization on nylon membranes.
4.8 HBsAg SUBTYPING METHODS.
4.8.1 HBsAg subtyping by radioimmunoprecipitation assay.
Samples were subtyped by RIPA by Mr S.H. Black (Virology Reference
Laboratory, Department of Medical Microbiology, The University of Edinburgh)
by the method described by Nicholson et al. (1992).
4.8.2 HBsAg DNA subtyping by PCR.
The primary amplified samples for HBsAg DNA detection (amplified for 25
cycles with primers 058C/869C) were further amplified with 3 sets of nested
primers for HBsAg DNA subtyping. Primer pairings 869C/907E and
869C/394J were selected to detect subtype y DNA, and 869C/029H for
subtype d (each amplification resulting in a band of 350bp). The 3'
mismatches of the HBsAg DNA subtyping primers conferring specificity are
depicted in Figure 9. The samples were amplified and electrophoresed as
described for HBsAg DNA detection.
70
Figure 9. Position of subtype specific primers of the HBsAg gene from




adyw t c g
adw2 t
ayw egg t a
Consensus AGCACGGGAC CATGCAAAAC CTGCACGACT CCTGCTCAAG
sequence
Primer 907E GCCTG GACGTACTGA TGACGAGTTC
029H TTTTG GACGTGCTGA GGACGAGTTC
394J CCTG GACGTACTGA TGACGAGTTC
The consensus sequence of the above 5 HBV subtypes is given in
uppercase, and their subtypic variation in lowercase. The primers selected to
amplify the band / subtypes are given (907E, 029H, and 394J reading 3' to
5') demonstrating their 3' mismatches with codon 122 (in bold).
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4.8.3 Sau 3A digest of PCR products for confirmatory subtyping (PCR-
RD).
To generate sufficient HBsAg DNA to visualise the restriction digest products
on an agarose gel, an aliquot (2ul) of primary amplified product was re-
amplified with the outside primer pair 058C/869C (548bp). The amplification
product was restricted with 2.5 units of Sau 3A (Boehringer Mannheim) at
37°C for 1.5h, and the restriction product (15ul) was electrophoresed on a 2%
agarose gel at a constant voltage of 150V.
4.9 ANTIBODY COATED BEAD EXTRACTIONS OF VIRAL NUCLEIC ACID.
4.9.1 Bradford's Coomassie Brilliant Blue protein concentration assay.
The assay was used to determine the protein concentration of the
recombinant gp120 and anti-HIV antibodies supplied by the MRC ADP
(ADP603, 335, 361, 362, 403, and 604, Appendix II). A standard protein (BSA
DNase free, Pharmacia) was diluted in ddw to give a range of concentrations
from 1mg to 100ng/ml. Protein dilutions (0.1ml) were added to 5ml of
Bradford's reagent (0.01% (w/v) Coomassie Brilliant Blue G (Sigma), 4.7%
(w/v) ethanol, and 8.5% (w/v) phosphoric acid) in a conical plastic centrifuge
tube. The tubes were inverted and left for 2-60min before measuring the
absorbance at 595nm (visible range). The spectrophotometer (SP 30V, Pye
Unicam) was set against 5mI of reagent mixed with 0.1ml of ddw. The protein
concentrations were plotted against their optical densities to give a standard
curve for determination of the test protein concentrations. This was based on
the method of Bradford, (1976).
4.9.2 Antibody coating of beads.
Polystyrene etched beads (6.5mm diameter, Northumbria Biologicals Ltd.)
were freshly coated with antibody for each experiment. The beads were
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incubated for 2h at room temperature with antibody diluted in carbonate-
bicarbonate buffer (4mM anhydrous sodium carbonate, 46mM sodium
bicarbonate, pH9.2) and air dried prior to incubation with samples.
4.9.3 Optimisation of antibody dilutions for HBV bead extractions.
Beads were coated with antibodies to HBsAg (anti-HBs horse antibody,
Wellcome), and human IgM and IgG (anti-human IgM and IgG sheep
antibodies, Scottish Antibody Production Unit, Law Hospital, Carluke). They
were initially coated with serial dilutions of each antibody to determine the
optimum antibody concentration (actual antibody concentrations were not
supplied).
Anti-HBs coated beads (diluted 1 in 10 to 1 in 100) were incubated with 200ul
of HBsAg (1 and 4ng/ml, BPL, Elstree) and negative sera for 2h at 37°C. The
beads were washed (dH20) and incubated for a further 2h at 37°C with 200ul
of iodinated anti-HBs antibody (30000cpm/200ul, BPL, Elstree). They were
washed a final time, and gamma irradiation was counted over 60s (NE1612
turbo, Nuclear Enterprises).
Further dilutions of antibody (1 in 150 to 1 in 600) were used to coat fresh
beads for direct detection with iodinated HBsAg (12000cpm/200ul, supplied by
Mr P. McCulloch, Department of Medical Microbiology, The University of
Edinburgh).
Beads coated with anti-human IgM and IgG antibodies were similarly
assessed using iodinated human anti-HBc (66700cpm/200ul, supplied by Mr
P. McCulloch).
4.9.4 Blocking of beads to prevent non-specific binding.
To demonstrate the specificity of the antibodies used for coating the beads, a
panel of 5 sera (from patients 68, 71, 73, 146, and 147, Appendix I) were
incubated with beads coated with: anti-HBs antibodies, anti-human IgG
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antibodies, anti-human IgM antibodies, 5% BSA (Fraction V, Sigma) in
carbonate/bicarbonate buffer, carbonate/bicarbonate buffer, and uncoated
beads. Sera from patients 68, 146, and 147 had previously been shown to be
HBV DNA positive after selective extraction for whole virus and IgM and IgG
complexed virus. Sera from patient 71 had tested positive for IgM complexed
virus, and patient 73 for free virus only. HBV DNA negative serum was
included in each experiment.
The dried beads were incubated with test and control sera, and the resultant
DNA extracts prepared and amplified as described (4.5.2 and 4.6.2
respectively).
4.9.5 lodination of recombinant gp120 (rgp120).
Recombinant gp120 protein (rgp120) was iodinated by a modified method of
Burrell et. al., (1973). Ten microlitres of chloramine-T (0.25% (w/v)
chloramine-T, 0.1M Tris-HCI (pH7.2), 0.85% (w/v) sodium chloride, 0.1% (w/v)
sodium azide) was drawn into a glass pasteur pipette, with approximately 2ug
of recombinant gp120 (ADP 604, Appendix II) separated by an air gap. The
antigen and chloramine-T were carefully layered onto 500uCi of sodium iodide
(125 Iodine, Amersham) in a 0.5ml eppendorf tube (Alpha Laboratories). The
solution was mixed gently for 30-60s behind lead shields, and the reaction
terminated by the addition of 10ul of sodium metabisulphite (0.6% (w/v)
sodium metabisulphite, 0.1M Tris-HCI (pH7.2), 0.85% (w/v) sodium chloride,
0.1% (w/v) sodium azide) with gentle agitation as before. The reaction was left
standing for 5min, diluted with 200ul of 0.2% potassium iodide in RIP buffer
(PBS with 0.5% BSA and 0.1% Sodium azide) and carefully layered onto a
10ml Sephadex G-100 column (Pharmacia). The column was plugged with
glass wool, washed with 20ml of Dulbecco solution, and equilibrated with a
similar volume of 0.2% potassium iodide in RIP buffer prior to use.
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Once loaded onto the column, the iodinated protein was washed through with
excess 0.2% potassium iodide in RIP buffer. Fractions of approximately 1ml
were collected, and 10ul aliquots were removed, diluted 1 in 10, and analysed
for gamma irradiation over 60s (Gamma counter, NE1612 turbo, Nuclear
Enterprises).
4.9.6 Optimization of HIV-1 specific antibody coating of polystyrene
beads.
To determine the optimum antibody concentration, beads were coated with
antibodies ADP335, 361, 362, or 403 at varying dilutions (1 in 50, 1 in 100, 1
in 200, and 1 in 400). The beads were then incubated with iodinated rgp120 to
determine the specificity and efficiency of the antibody coating. Coated beads
were incubated in triplicate, with 2 dilutions of labelled rgp120 (200ul of 20000
or 50000cpm) for 2h at 37°C. The beads were washed and analysed for
gamma irradiation over a period of 60s, and the results expressed as a
percentage of the labelled protein available.
Beads were coated with further dilutions of antibodies ADP335 and 403 (1 in
400, 1 in 500, 1 in 600, 1 in 800, 1 in 1000). Beads were coated in duplicate,
with half the beads being counter blocked with BSA (5% BSA solution in
carbonate/bicarbonate buffer) after antibody coating.
4.9.7 Extraction of HIV-1 whole virus from patient PBMC cocultures
using beads coated with antibodies specific to the surface glycoprotein
(gp120).
Polystyrene beads were coated with antibodies ADP335 (1 in 400 dilution),
ADP361 (1 in 50 dilution), ADP362 (1 in 50 dilution), and ADP403 (1 in 500
dilution). The antibody coated beads were each incubated with culture
supernate (300ul) from two p24 antigen positive patient PBMC cocultures
(P11b and P20b). The incubation was overnight at room temperature, with
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DNase I (10 units) and 5mM MgC^- The beads were washed and transferred
to chloroform pre-treated eppendorf tubes for RNA extraction (4.5.8). The
RNA extracts were reverse transcribed and amplified for pot and env
sequences as described (4.6.8).
4.9.8 Quantification of whole virus capture and RNA extraction with anti-
gp120 antibody coated beads.
To quantify the sensitivity of the whole virus capture reaction, dilutions of
titrated viral supernate from HIV-1RF infected C8166 cells were incubated with
beads coated with antibody ADP361 (1 in 50 and 1 in 500 dilutions). The viral
supernate (TCID5q of 107-17/ml) was diluted (10 fold dilutions), and aliquots
(300ul) were incubated overnight at room temperature with a bead at each
antibody dilution with DNase I (10 units) and 5mM MgC^. RPMI and
supernate from uninfected C8166 cells were included as negative controls.
The beads were processed as described previously (4.9.7), with the exception
that the entire extract was amplified for polsequences only.
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RESULTS
CHAPTER 5: VIRUS ISOLATION.
In this study, virus was initially isolated from patient PBMCs to demonstrate
infection by direct virus detection. Later isolation was attempted from small
volumes of plasma and heparinised whole blood (HWB) to minimise the
sample volume utilised for each isolation, and to maximise the number of cells
recovered for PCR analysis.
5.1 Virus isolation from PBMCs, plasma, and heparinised whole blood
(HWB).
Virus isolation was attempted in 41 samples from 29 patients. A single sample
was received from 19 patients, and 2 or 3 samples from the remaining 10
patients. The average time between multiple samples was 6 months (range 1-
10 months). Virus isolation from PBMCs, plasma, or heparinised whole blood
was demonstrated by the presence of p24 Ag in the culture supernate over 28
days, and was positive in 22 of the 41 samples (Table 6). A sample from P2
was included as a high risk negative control, and numerous low risk negative
controls were included (data not shown). All negative controls were isolation
negative throughout.
Isolation from patient PBMCs was successful in 20 out of 34 samples (59%).
The 14 culture negative samples were from 13 patients receiving no antiviral
therapy (7 from CDC group II and 6 from CDC group III) and 1 patient who
had received AZT for 2 months (CDC group IV).
Plasma isolation was successful in 3 out of 8 seropositive samples tested
(38%). The 3 positive samples (P6, P15, & P21b) were from patients in CDC
groups II, IV, and III respectively, who were not receiving anti-viral therapy.
Samples P1, P4b, P13, and P25b were from patients receiving AZT treatment
at the time of sampling, and were plasma culture negative.
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Table 6. Virus isolation results from patient PBMCs, plasma, and
heparinised whole blood (HWB).
Sample No. PBMC HWB Plasma
Positive by
any method
P1 nd - no
P2b* - - - no
P3a + nd nd yes
P3b - nd nd no
P4a - nd nd no
P4b nd - - no
P5 - nd nd no
P6 nd 1 (a & b) 1 (b & c) yes
P7a + nd nd yes
P8a + nd nd yes
P8b + nd nd yes
P8c + nd nd yes
P10 - nd nd no
P11b 1 nd nd yes
P13 nd - - no
P14a + nd nd yes
P14b + nd nd yes
P15 nd nd 1 (b) yes
P16 - nd nd no
P17a + nd nd yes
P18a + nd nd yes
P19a 1 nd nd yes
P20a - nd nd no
P20b 1 nd nd yes
P20c nd - - no
P21a + nd nd yes
P21b 1 (s & T) nd 1 (b & c) yes
P22a + nd nd yes
P23a + nd nd yes
P23b - nd nd no
P24b - nd nd no
P25a - nd nd no
P25b nd - - no
P27a - nd nd no
P27b - nd nd no
P28a + nd nd yes
P28d + nd nd yes
P29b - nd nd no
P30b + nd nd yes
P31 - nd nd no
P32a - nd nd no
P34b + nd nd yes
Letters represent the dilution of sample, or type of culture vessel: (a) 1 in 1.5
dilution, (b) 1 in 3 dilution, (c) 1 in 6 dilution, (s) for 24 well plate. All PBMC
cultures were in T25 (T) flasks unless otherwise stated. +, positive culture; -,
negative culture; and numbers refer to the week at which the culture was first
positive. *, Patient 2 was included as a high risk HIV negative control. Low
risk negative controls were isolation negative throughout (data not shown).
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The final sample (P20c) was culture negative, CDC group III, and was from a
patient receiving no anti-viral therapy.
HWB isolation was successful in 1 out of 6 seropositive samples (17%). The
successful isolation was from P6, a patient receiving no AZT therapy in CDC
group II. Four of the negative results (P1, P4b, P13, & P25b) were from
patients on AZT therapy (CDC groups II & III), and 1 from a patient in CDC
group III receiving no anti-viral therapy (P20c).
5.1.1 Comparison of the 3 isolation methods.
The overall rate of isolation by any method for the 41 seropositive samples
cultured was 54% (22/41). Comparison of the efficiencies of the 3 methods
was difficult as the techniques were not quantified, and the 7 samples tested
by more than 1 method gave identical results.
Sample P2b was a high risk seronegative control and was negative by each of
the 3 methods. P4b, P13, P20c, and P25b were each negative and P6 was
positive by both HWB and plasma culture, and virus was isolated in both
PBMCs and plasma of P21b.
Although the PBMC coculture method was the most successful in this study, it
is possible that the low isolation rates obtained for HWB and plasma isolations
were biased by the small number of samples tested.
5.1.2 Comparison of virus isolation with plasma p24 antigen detection,
CD4+ cell counts, AZT treatment, and CDC group.
Virus isolation was compared with CD4+ cell counts (33 samples), plasma
p24 antigen detection (41 samples), use of AZT therapy (41 samples), and
CDC group (41 samples). The complete data is in Appendix IV, and the
results tabulated (Tables 7-10) and analysed by the Chi-square test (Appendix
III).
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Table 7. Comparison of virus isolation result with detection of plasma
p24 antigen.
p24 antigen
Virus isolation positive negative Total
positive 7 15 22
negative 3 16 19
Total 10 31 41
Chi-square= 1.420, Degree of freedom = 1, and 0.50>P>0.10.
Table 8. Comparison of virus isolation and AZT treatment.
AZT treatment
Virus isolation positive negative Total
positive 9 13 22
negative 5 14 19
Total 14 27 41
Chi-square = 0.966, degree of freedom = 1, and 0.50>P>0.10.
The results of Tables 7 and 8 were analysed by the Chi-square test using
Yates correction (Appendix III). Virus isolation results were based on a single
positive isolation from PBMCs, plasma, or HWB.
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Table 9. Comparison of virus isolation and CD4+ cell counts per millilitre
of blood.
CD4+ cell count
Virus isolation >200 200 Total
positive 7 9 16
negative 12 5 17
Total 19 14 33
Chi-square = 2.431, degree of freedom = 1, and 0.50>P>0.10.
Table 10. Comparison of virus isolation from patient PBMCs with CDC
groups.
CDC group
Virus isolation II III IV Total
positive 3 9 10 22
negative 8 10 1 19
Total 11 19 11 41
Chi-square = 9.524, degree of freedom = 2, and 0.01 >P>0.001.
The results of Tables 9 and 10 were analysed by the Chi-square test using
Yates correction (Appendix III). Virus isolation results were based on a single
positive isolation from PBMCs, plasma, or HWB.
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Statistical analysis showed that there was no correlation between virus
isolation and detectable plasma p24 antigen detection (0.50>P>0.10), CD4+
cell counts (0.50>P>0.10), or AZT therapy (0.50>P>0.10). There was,
however, a significant association with CDC group (0.01>P>0.001),
demonstrating an increase in isolation rate from patients with advanced
disease.
5.1.3 Detection of viral DNA sequences by PCR in culture negative
samples.
To prove that negative cultures contained HIV DNA, it was decided to extract
DNA from the cells and amplify for viral sequences. Total cellular DNA was
extracted from p24 antigen negative PBMC cocultures of 6 seropositive
patients, and amplified for po/and env sequences. PBMCs of cocultures of 3
isolation positive samples (P11 b, P19a, and P20b), a high risk seronegative
sample (P2b), and numerous low risk donor PBMCs were included as
controls.
The DNA extracts from control cocultures gave the expected amplification
results throughout. Each of the 6 seropositive coculture extracts was positive
for pol and/or env sequences by PCR despite the patient cells being diluted by
uninfected donor cells (Table 11). The results demonstrate the presence of
infected cells in the sample, suggesting that the coculture method used was
inefficient in stimulating infected cells to produce new virions.
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Table 11. HIV-1 DNA nested amplification results of cocultivated cells.
Amplification gene
Patient No. pol env VI result
*P2b ~ ~ -
P4a + - -
P5 + + -
P10 + + -
P11b + + +
P16 + + -
P19a + + +
P20b + + +
P25a + - -
P31 + + -
*
, high risk seronegative control patient; VI, combined results of PBMC,
plasma, and heparinised whole blood virus isolation; +, positive: -, negative.
PCR results were based on nested amplifications of the polymerase and
envelope genes. Cultured PBMCs from low risk donors were included as
negative controls, and were PCR negative throughout (data not included).
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CHAPTER 6: ELECTRON MICROSCOPY STUDIES OF HIV-1 (RR VIRAL
UPTAKE AND RELEASE IN C8166 CELLS.
This work was carried out in the Electron microscopy (EM) suite, (Department
of Medical Microbiology, The University of Edinburgh), under the careful
supervision of Mr Derek Notman and Mrs Oonagh Gray. Samples were
supplied to the EM suite fixed in 2.5% glutaraldehyde in cacodylate buffer,
where they were processed and sectioned by Mrs Gray. Mr Notman
supervised all viewing sessions, and both were involved in the development of
electron micrographs of the material viewed.
6.1 Electron microscopy studies of viral uptake and release.
This section was designed to observe the mechanism of viral entry into
susceptible cells. The C8166 cells were inoculated at 4°C to allow attachment
without penetration. They were then transferred to an incubator, harvested at
sequential time points, and positively stained for EM studies.
6.1.1 Viral entry into C8166 cells.
HIV-1 RF infected cells were harvested at time points 0, 5, 10, 15, 20, 25, 30,
40, 50, and 60min, and viewed for evidence of viral penetration. Sections of
infected and uninfected cell pellets showed evidence of clathrin coated pits
(Figure 10), and internal structures were observed in some intracellular
vesicles of infected cells, although at no time point were these identified as
viral particles (Figure 11). There was, therefore, no evidence of viral uptake by
endocytosis.
Although not quantified, it was noted that the presence of virus decreased




HiV-1RF infected C8166 cell, harvested 25min post infection. Magnification
60K bar=100nm.
A Arrow indicates the formation of a clathrin coated pit for uptake and
transport into the cell.
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Figure 11.
HIV-1rf infected C8166 cell, harvested at 25min, magnification 60K,
bar=100nm.
A Two intracellular inclusions, probably clathrin coated vesicles, B unidentified
inclusion within vesicle (approximately 45nm diameter).
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6.1.2 Viral budding from C8166 cells.
Cells were infected 3 days prior to sampling to allow viral replication, thereby
increasing the viral load. Virus was observed budding from the majority of
sectioned cells. The budding process was characterised by an initial
thickening and arching of the cell surface membrane (Figure 12), progressing
to the formation of a horseshoe-like structure (Figure 13). The latter stages of
the budding process completed the envelope structure releasing the immature
virion from the cell membrane (Figure 14). The characteristic core structure
formed upon release from the host cell, and was first observed in free virus
surrounding infected cells (Figure 15).
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Figure 12.
HIV-1RF budding from C8166 infected cell, day 8 at 45K magnification,
bar=100nm.
A Initial thickening of the cell membrane, B thickened cell membrane arching
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Figure 13.
HIV-1rf infected C8166 cell, day 8. Magnification 75K bar =100nm.
A Budding HIV-1 particle demonstrating the characteristic horseshoe-like
structure. Mature free virus can also be seen around the infected cell.
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Figure 14.
Budding HIV-1RF from C8166 infected cell, day 8. Magnification 90K, bar
=100nm.
The electron micrograph demonstrates the latter stages of the HIV-1 budding
process.
A Horseshoe-like budding structure nearing completion, B completion of the
viral envelope immediately prior to release from the cell, C complete release
of new immature virion from the cell membrane.
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Figure 15.
New virions released from C8166 HIV-1RF infected cell, day 8. Magnification
60K, bar =100nm.
New virions, demonstrating the characteristic core structures formed after
completion of the viral budding process from the host cell.
A Cross-section of core, B longitudinal section of core, C immature core
structure of newly released virion.
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CHAPTER 7: DETECTION AND CHARACTERIZATION OF HIV-1 DNA BY
PCR.
The methods used to characterize HIV-1 DNA in laboratory cell lines and
patient PBMCs, were developed in collaboration with Drs. D.W-J. Aw and A.J.
Shepherd. The data on infection of cell lines with HIV-1 mB was supplied by
Drs. Aw and Shepherd, and is included with their kind permission.
To differentiate between HIV-1 DNA forms by PCR requires that the primers
hybridize to, or amplify across, a unique sequence. Primers for the coding
sequences (gag, pol, and env) are, therefore, type common primers
amplifying all forms of viral DNA identically (Figure 16).
The CUVD forms differ from other viral DNA forms as they are covalently
closed circular molecules. This produces junction sites which can be exploited
by PCR to allow the differential detection of CUVD (Figure 17a).
The LUVD form does not have a unique sequence, but is unique as the viral
LTR sequences are not flanked by viral or cellular DNA (unlike unintegrated
circular and integrated linear viral DNA, Figure 17b). The integrated provirus is
flanked by cellular sequences (Figure 17c) and is exclusively in the high
molecular weight fraction of cellular DNA extractions.
The aim of this chapter was to exploit these differences to develop PCR as a
method of detecting and characterizing HIV-1 DNA forms in cell extracts.
7.1. Development of dot blot and Southern hybridization assays.
Southern hybridization assays were required during the development of PCR
as a method of detecting CUVD forms. This section describes the
development and optimisation of the hybridization assays used for the
detection of DNA sequences by a biotinylated oligonucleotide probe on nylon
membranes.
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Figure 16. Detection of HIV-1 DNA using primers specific for gag, pol,
and env sequences.
a) Linear integrated provirus.
LTR LTR
b) Linear unintegrated viral DNA.
LTR LTR
c) Circular unintegrated viral DNA (1 and 2 LTR forms).









Figure 17. Characterization of HIV-1 DNA forms by PCR.
a) Circular unintegrated viral DNA (1 and 2 LTR forms) with unique junction
sequences.
1&2 LTR
b) Linear unintegrated viral DNA. Exploitation of the blunt ends using a
ligation mediated nested PCR.
LTR LTR










7.1.1 Comparison of the detection of DNA sequences fixed by UV light to
nylon membranes with baking to nylon and nitrocellulose membranes.
Fixation of samples on both nitrocellulose and nylon membranes by baking at
80°C is non-covalent, and so during the hybridization reaction samples may
leach off the membrane, effectively reducing the sensitivity of the assay.
Alternatively, DNA can be covalently bound to nylon membranes by exposure
to ultra-violet (UV) light (Church and Gilbert, 1984). It was, therefore, decided
to compare the sensitivity of detection of DNA sequences baked on
nitrocellulose membranes against DNA baked and UV bound to nylon
membranes.
Dilutions (1 in 10, 1 in 100, and 1 in 200) of a nested pot amplification product
were spotted onto nylon and nitrocellulose membranes and fixed by UV light
for 5min, or baking at 80°C for 2h. The samples were probed using a PCR
generated biotinylated pol sequence, and the results of the colour reaction
compared.
Although the background levels were considerably lower on nitrocellulose
membranes, the most sensitive method of detection was with UV fixed
samples on nylon membranes. Both nitrocellulose and nylon baked
membranes detected the PCR product diluted 1 in 10, however, the UV fixed
nylon membrane was also positive for the 1 in 100 diluted sample. All
membranes were negative for the sample diluted 1 in 200. In addition to the
sensitivity of detection, the rate and intensity of the signal obtained with UV
fixation was greater than with baking. It was, therefore, decided to develop the
method of UV fixation of DNA to nylon membranes in preference to baking of
nitrocellulose or nylon membranes.
7.1.2 Optimisation of UV fixation of DNA to nylon membranes.
It was proposed that UV fixation of DNA to nylon membranes would increase
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with time until maximum fixation had occurred, and a plateau effect would be
observed. To demonstrate this, biotinylated DNA was loaded onto 2 identical
nylon membranes. The dots were exposed for varying times to UV light, and
one membrane was placed in boiling water prior to development of the colour
reaction.
The resulting intensities of positive dots on each membrane were similar. The
boiled membrane was positive for samples exposed to UV light for 20s or
more, whereas the non-boiled strip was positive for all exposures (10 to 60
seconds). This showed that the fixation of DNA onto nylon membranes was
not only covalent, but was also very rapid. In future experiments, samples
were routinely exposed to UV light for 2min to ensure maximum fixation to the
membrane.
7.1.3 Detection of LTR sequences by dot blot hybridization on PCR
amplified extracts of C8166 cells infected with HIV-1RF.
The HIV-1 specific probe (581NBio) was selected to hybridize to the U3
sequence of the viral LTR. To determine its specificity and sensitivity, the
probe was used to detect PCR products from amplifications of the LTR
sequences. Samples were used that had been amplified by the 2 LTR CUVD
specific primers (782K/783K and 779K/781K) which synthesized a band of
447bp from the two U3 sequences flanking the 2LTR junction (Figure 8).
The 2 samples positive for 2 LTR CUVD by PCR (C8166 day 2 & MT4 day 4)
were also positive by dot blot hybridization assay. The amplified sample of
C8166 cells from 4 hours was clearly negative as expected, however the MT4
24h sample was indeterminate. Owing to the background noise and to the
indeterminate nature of the result for MT4 24h sample, it was decided to
increase the probe concentration from 400ng to 600ng/ml of hybridization
solution.
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7.1.4 Optimisation of DNA transfer by the semi-dry gel electroblotter.
Dilutions of biotinylated DNA (1.29ug to 64.5ng of 581NBio) were used to
observe the efficiency of DNA transfer using the electroblotter. After 1h
transfer, the agarose gel was viewed under UV light, demonstrating that the
bands representing 129ng and 64.5ng of DNA had transferred completely,
whereas the bands of higher concentrations had only transferred in part. The
membrane was developed, and on initiating the colour reaction, all bands
were visible within 30min. Subsequent studies varying the time of transfer
showed that a minimum of 5h was required for the total transfer of DNA when
15ul of PCR product was electrophoresed (data not shown).
7.2 Optimisation of CUVD detection by PCR.
7.2.1 Detection of 2LTR CUVD by a nested PCR.
Patient samples were amplified with the nested PCR primers for 2LTR CUVD
detection (782K/783K and 779K/781K). Preliminary amplification batches
resulted in bands in all wells indicative of contamination, and so these batches
were discarded and repeated. One batch (P3b, P11 b, P16, P19a, and P31)
demonstrated a second band which led to the realisation that the apparent
contaminating band was heavier than the expected specific band of 447bp
(Figure 18). To show that the faint band was the specific amplification product,
and that the additional heavy band observed in each well resulted from
aberrant hybridization of LTR primers, it was decided to transfer the bands by
a Southern blot, and probe with an LTR specific biotinylated oligonucleotide.
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Figure 18. Detection of 2LTR CUVD by nested PCR.
DNA extracts were amplified with the 2LTR CUVD specific primers
782K/783K and 779K/781K (447bp) and electrophoresed on a 1.5% agarose
gel. A non-specific band of approximately 800bp was detected in all wells,
with the predicted band of 447bp detected in sample P16 (lane 9).
LANES 8 10 11
Lane 1, DNA VI molecular weight marker (2176, 1766, 1230, 1033, 653, 517,
453, 394, 298, 234/220, 154); lanes 2, 4, 6, 8, & 10, negative controls; lane
3, P31; lane 5, P11 b; lane 7, P19a lane 9, P16; lane 11, P3b
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7.2.2 Detection of the U3 region of HIV-1 by Southern blot hybridization
of 2LTR CUVD nested PCR products.
2LTR CUVD amplification products of 4 patient samples were transferred onto
nylon and probed for a U3 specific sequence. One sample (P13) was PCR
positive for 2LTR sequences, and 3 samples were PCR negative for 2LTR
sequences (P1, P4b, and P20c) as determined by gel electrophoresis. The
samples were transferred onto nylon with a biotinylated ladder to assist in the
analysis of band lengths after the colour development (Figure 19).
As expected, sample P13 was positive for the 2LTR CUVD specific band
(447bp). A heavier band (less than 1000bp) which cannot be excluded as the
non-specific band observed in all samples was also detected by the LTR
specific probe (Lane 3, Figure 19). However, the band was only visible in the
2LTR CUVD PCR positive sample (all samples and controls were positive for
the non-specific band) and so may represent the primary amplification product
for 1 LTR CUVD forms (996bp). In support of this argument, sample P13 was
later shown to be 1 and 2LTR CUVD positive by PCR (Appendix IV).
Of the 3 PCR negative samples, P1 was negative as expected, but P4b and
P20c were both hybridization positive for the 2LTR CUVD band (Lanes 4, 5
and 6 respectively, Figure 19). Since PCR is the most sensitive method
available for the detection of DNA, the positive results obtained for samples
P4b and P20c were unexpected. This suggests that PCR did not amplify the
samples sufficiently for detection by agarose gel electrophoresis, possibly due
to the competition for materials arising from the amplification of the non¬
specific band.
The hybridization results showed that the non-specific band was not due to
HIV-1 LTR sequences, and so it was hypothesized that the band resulted from
aberrant priming of cellular sequences, and that it was competing for
resources such as primers, Taq polymerase, and dNTP's.
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Figure 19. Southern blot hybridization of 2 LTR CUVD nested PCR
amplified samples.
Samples were amplified by the 2LTR CUVD specific primers (782K/783K and
779K/781K), electrophoresed on a 1.5% gel, and transferred to a nylon
membrane. The samples were probed by the biotinylated oligonucleotide
(581 NBio) specific for the LTR U3 sequence (Figure 8).
The 2LTR CUVD specific band (447bp) was detected in lanes 3, 5, and 6, and
an additional band (approximately 800bp) was detected in lane 3.
LANES 1 2 3 4 5 6 7 8
Lanes 1 & 8, biotinylated DNA VI, molecular weight marker (2176, 1766,
1230, 1033, 653, 517, 453, 394, 298, 234/220, 154); lane 2, & 7, negative
controls; lane 3, P13; lane 4, P1; lane 5, P4b; lane 6, P20c.
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The primers utilised in the 2 step amplification were from the U3, gag and env
sequences. The primary primers (gag and env specific) had previously been
utilised by other groups, and so the nested primers from the U3 LTR
sequence were thought to be the more likely source of the non-specific
priming. Alternative LTR primers were tested (585N/586N, Appendix V) but
gave similar results with strong non-specific background bands (data not
shown).
Sequence analysis of the viral LTRs has demonstrated some homology with
T-cell growth factor and gamma interferon sequences (Starcich et a/., 1985).
These sequences would be present in all samples and negative controls, and
could explain the presence of the additional band.
Amplification aliquots from patient samples contained DNA from 7x10^ to
1x106 cells, of which approximately 70% were T cells (5x10^ to 7x105). As a
result of the large number and diploid nature of human cells present, the
concentration of cellular sequences competing for materials was far in excess
of viral sequences, which may have been present at a frequency as low as 1
copy of dsDNA per 80000 cells (Simmonds et ai, 1990a). This would explain
why PCR, the most sensitive method available for DNA detection, was failing
to detect viral DNA sequences in patient PBMC extracts.
It was thought that the reaction could be biased towards viral amplification by
increasing the initial amplification with viral-only specific primers prior to using
LTR specific sequences. To avoid using the same set of primers for 2
amplification reactions, the secondary amplification was designed to utilise a
primary reaction primer with a nested primer. In this way, it was hoped to
generate sufficient viral sequences to have a higher viral than cellular
template concentration for the tertiary amplification with the original nested
primers.
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7.2.3 Tertiary 2LTR CUVD amplifications.
Aliquots of patient DNA extracts (P1, P4b, P13, P20c, and P25b) were tertiary
amplified with 2 different sets of primers (3 pairs per set), to compare their
sensitivity for the detection of 2LTR CUVD forms. All samples were amplified
in duplicate, and the results were compared with the standard nested
amplification (Figure 20).
The nested PCR method only detected 2LTR CUVD in the P20c aliquots
amplified (Gel b, Figure 20). The tertiary amplification with secondary primers
779K/782K detected 2LTR CUVD sequences in samples P4b, P13, and P20c,
although the non-specific bands were still quite prominent (Gel a, Figure 20).
However, using the secondary primers (781K/783K), 2LTR CUVD forms were
detected in samples P4b, P13, and P20c (as with 779K/782K secondary
primers), and the specific band was of a higher intensity than the non-specific
bands (lane 10 of gel a and c, Figure 20). Therefore, the use of the secondary
primer pair 781K/783K, prior to the original "nested" amplification with primers
779K/781K, appeared to bias the amplification reaction towards viral
sequences, largely overcoming the aberrant amplification of cellular
sequences in PBMC DNA extracts. This method was subsequently adopted
for all 2LTR CUVD amplifications.
7.2.4 Comparison of the sensitivity of secondary and tertiary
amplifications.
To determine if a nested amplification with the secondary primers 781K/783K
was sufficient for 2LTR CUVD detection, extracts of cell lines infected with
HIV-1 niB were amplified with primers 782K/783K, 781K/783K, and 779K/781K,
and the secondary and tertiary amplification products were compared (Table
12).
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Figure 20a. Comparison of the standard nested amplification for the
detection of 2LTR CUVD with the tertiary amplification protocols.
Gel a:Primary amplification 782K/783K, secondary amplification 779K/782K,
tertiary amplification 779K/781K (447bp).
LANES 1 2 3 4 5 6 7 8 9 10 11 12 13
Lanes 1 & 7, negative controls; lane 2 & 8, P25b; lane 3 & 9, P20c; lane 4 &
10, P13; lane 5 & 11, P4b; lane 6 & 12, P1; lane 13 DNA VI molecular weight
marker (2176, 1766, 1230, 1033, 653, 517, 453, 394, 298, 234/220, 154).
The non-specific band observed in all amplifications was approximately
800bp, and the 2LTR CUVD specific band was 447bp.
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Figure 20b. Comparison of the standard nested amplification for the
detection of 2LTR CUVD with the tertiary amplification protocols.
Gel b:Primary amplification 782K/783K, secondary amplification 779K/781K.
LANES 1 2 3 4 5 6 7 8 9 10 11 12 13
Lanes 1 & 7, negative controls; lane 2 & 8, P25b; lane 3 & 9, P20c; lane 4 &
10, P13; lane 5 & 11, P4b; lane 6 & 12, P1; lane 13 DNA VI molecular weight
marker (2176, 1766, 1230, 1033, 653, 517, 453, 394, 298, 234/220, 154).
The non-specific band observed in all amplifications was approximately
800bp, and the 2LTR CUVD specific band was 447bp.
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Figure 20c. Comparison of the standard nested amplification for the
detection of 2LTR CUVD with the tertiary amplification protocols.
Gel c:Primary amplification 782K/783K, secondary amplification 781K/783K,
tertiary amplification 779K/781K.
LANES 1 2 3 4 5 6 7 8 9 10 11 12 13
Lanes 1 & 7, negative controls; lane 2 & 8, P25b; lane 3 & 9, P20c; lane 4 &
10, P13; lane 5 & 11, P4b; lane 6 & 12, P1; lane 13 DNAVI molecular weight
marker (2176, 1766, 1230, 1033, 653, 517, 453, 394, 298, 234/220, 154).
The non-specific band observed in all amplifications was approximately
800bp, and the 2LTR CUVD specific band was 447bp.
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Table 12. Comparison of secondary and tertiary amplifications for 2LTR
CUVD detection in MT4 and C8166 cell lines infected with HIV-1 |MB.
hours days
01248 12 123458 12
MT4
(2° amp) ------ . + + + + + +
(3° amp) ---.-+ + + + + + + +
C8166
(2° amp) ------ + + + + + + +
(3° amp) --- + + + + + + + + + +
Samples were tertiary amplified with 2LTR CUVD specific primers 782K/783K,
781K/783K, and 779K/781K. 2° amp, secondary amplification; 3° amp, tertiary
amplification; -, negative; +, positive. Details of the cell lines are given in
Appendix II.
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The tertiary amplification gave more intense specific bands with fewer non¬
specific bands, increasing the sensitivity of detection by 2 to 3 time points.
This confirmed that the tertiary amplification was more sensitive and specific
for 2LTR CUVD detection in both cell line and patient PBMC DNA extracts.
7.2.5 Simultaneous detection of 1 and 2LTR CUVD forms in patient
PBMC DNA extracts.
Multiple aliquots of sample extracts from patients 13 and 20 (P13 and P20c)
were amplified for 1 and 2LTR CUVD forms using primers from the gag and
env sequences (077F/783K and 782K/783K). Bands of 996bp and 1630bp
were expected for the detection of 1 and 2LTR CUVD forms respectively, and
both forms were detected simultaneously (Figure 21).
Both bands were detected in extracts of PBMCs from patients 13 and 20,
however, in each case 1 form repeatedly amplified more efficiently for each
patient. Extracts from P13 resulted in a clearer 2LTR band, while P20c
extracts had a dominant 1LTR amplification band. Flad both samples resulted
in the same predominant band, it could have been concluded that the
amplification reaction was more efficient for this form. This may have been
due to the primers, or, for 1LTR forms, the fact that the amplification sequence
was considerably smaller. However, as the 2 samples differed, this suggests a
possible link to the actual proportions of each form present in the PBMCs of
the infected individual. If this is true, it may be possible to relate the detection
and form of CUVD to the clinical disease or cytopathology of HIV infection.
7.3 Optimisation of the detection of LUVD.
It was proposed to detect LUVD by ligating a unique sequence to the blunt
LTR end, and to prime DNA amplification from this site (Figure 22). To
determine whether or not the proposed primer 022N for the amplification of
ligated LUVD could prime DNA synthesis without the presence of the ligation
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Figure 21. Simultaneous detection of 1 and 2 LTR CUVD forms by PCR.
Patient PBMC extracts were amplified in replicate by gag and env primers
(077F/782K, and 782K/783K) resulting in 1 and 2LTR CUVD specific bands of
996bp and 1630bp respectively.
Gel a: nested amplification results for P13 extracts.
Gel b: nested amplification results for P20c extracts.
LANES 1 2 3 4 5 6 7 8 9 10 11 12
Gel A
Gel B
Lanes 1 & 12, DNA VI molecular weight marker ((2176, 1766, 1230, 1033,
653, 517, 453, 394, 298, 234/220, 154); lanes 2, 4, 6, 8, & 10, negative
controls; lanes 3, 5, 7, & 9. Both 1 and 2 LTR CUVD specific bands were
detected in both patients. The 2 LTR CUVD form was more dominant in P13
amplifications (Gel a), and the 1 LTR CUVD band in P20c amplifications (Gel
b).
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Figure 22. Detection of linear unintegtrated viral DNA.
a) Schematic representation of the 5' LTR of HIV-1.
U3 R U5
b) Ligation of oligonucleotide (021N) to the viral LTR. Followed by primary
amplification of viral LTR from the ligation sequence (021N) with primers
782K/022N, secondary amplification with primers 586N/022N, and tertiary












sequence, small oligonucleotides (3, 5, 7 & 9 bases long, Figure 7) were
analysed for their ability to prime DNA synthesis in the po/gene. Throughout
the 3 amplification protocols tested, the positive and negative controls
included gave the expected results.
The first experiment, utilising primer pairs 160H/161H and 556-559170030,
was to determine the ability of the short oligonucleotides to prime DNA
synthesis (Figure 23a). The primary amplification with primers 160H/161H
supplied a high concentration of template DNA with only 1 correct priming site
for each oligonucleotide. Despite this, all test amplifications were negative for
the expected bands of 112, 114, 116, and 118bp for primers 556L, 557L,
558L, and 559L respectively. From this it was concluded that an
oligonucleotide of 9 bases or less was insufficient to prime DNA synthesis for
efficient amplification by PCR.
The second experiment (primary primers 556-559L/161H and secondary
primers 002C/003C) was designed to observe the effects of a primer
overhanging the 3' end of the template DNA (Figure 23b). This was to mimic
the possible priming event of primer 022N on a viral LTR sequence without
the attachment of the ligation sequence (021N, Figure 22). All samples tested
in this way were negative for the expected band of 128bp. Since the primers
002C/003C had previously been demonstrated to amplify pol sequences
efficiently, these results suggested that a 16 base hybridization with an
overhanging tail of 11 bases was inefficient at priming DNA synthesis.
The final experiment evolved from the second in an attempt to identify the
limits of an oligonucleotide's ability to prime when it has an overhanging tail.
This experiment utilised the nested primer 559L (in conjunction with 003C)
which hybridized by 3, 5, 7, or 9 bases to the primary amplified target DNA
(primary primers 556-559L7161H) with an overhang of 6, 4, 2, or 0 bases
respectively (Figure 23c). Although very similar to the previous experiment,
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Figure 23. Determination of the minimum requirement for priming of
DNA synthesis for PCR.















> 002C <• 003C
Nested PCR products
with primers 002C/003C.
c) Experiment 3. Primary amplification with primers 556-559L/160H and









the percentage of bases contributing to the overhanging tail was 0%, 22%,
44%, and 67%, whereas the previous experiment had overhangs of 38%,
46%, 54%, and 62%. All test results were negative, suggesting once more
that an overlapping primer was not stable enough to initiate DNA synthesis.
Although these studies appeared to suggest that primers used for the
amplification of ligated LUVD would be insufficient to initiate DNA synthesis
without the ligation step, it was possible that the oligonucleotides 556-559L
failed to prime DNA synthesis for other reasons. These may have included the
occurence of interactions utilising the free primers in solution, or mis-priming
in contaminating cellular DNA, both of which would alter the concentration of
available sequences to prime DNA synthesis.
In view of this, preliminary ligation studies included the appropriate controls to
demonstrate the requirement for the ligation sequence. Each sample was
tested in triplicate. One vial contained all the necessary reagents while the
other 2 vials lacked the ligation sequence or the ligase enzyme. All such
controls were negative irrespective of the presence or absence of LUVD. Due
to the small sample size available from many patients these controls were
excluded from subsequent studies. HIV-1 negative controls were included
throughout.
7.4 Cell lines infected with HIV-1 mB.
Ten cell lines were infected with HIV-1 mB to observe the timing and form of
viral DNA synthesized in different cell types infected with the same viral strain.
7.4.1 Syncytium formation.
The formation of syncytia was only observed in T-cell derived lines (C8166,
Hut78, MT4 and SupT1) infected with the IIIB isolate which led to the
complete destruction of MT4 and C8166 cells by day 8. No syncytia were
observed in non-T-cell derived lines (U937, THP1, HB1, LC5, U138MG, and
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HeLa T8+). This suggests that the formation of syncytia was specific to the
cell type and not to the virus strain, although the results obtained may reflect a
combination of cellular and viral factors.
7.4.2 Overall viral DNA detection.
Cell lines derived from T lymphocytes were all HIV-1 DNA positive by 2h post¬
infection using the pol gene primers (Table 13). U937 and THP1 cell lines
were also positive by 2h, whereas HB1 and LC5 lines were not positive until 8
and 12h post-infection respectively. The cell lines U138MG and HeLa T8+
failed to become infected and were HIV-1 DNA negative throughout the study
(Table 14).
7.4.3 CUVD detection.
The overall detection of viral DNA in T-cell derived lines was within 2h of
infection for each line. In contrast to this, the detection of either 1 or 2 LTR
CUVD varied from between 2 and 12h, depending on the cell line. In both
MT4 and SupT1 lines, the presence of 1 and 2 LTR forms appeared
simultaneously whereas 2 LTR CUVD appeared before 1 LTR forms in C8166
and Hut78 cell lines. In all cell lines, once CUVD of either form had been
detected it remained positive throughout the experiment (Table 13).
For non-T cell derived lines a similar pattern of positivity was observed. U937
cells were positive for 1 LTR CUVD 8 hours prior to the detection of 2 LTR
forms, and THP1 and HB1 cells were first positive for both forms at the same
time point (12h and day 3 respectively). LC5 cells became positive for viral
DNA at 12h but did not produce detectable levels of CUVD during the
experiment (Table 14).
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Table 13. Detection of total viral DNA, and circular and linear
unintegrated viral DNA, in T-cell derived lines infected with HIV-1 mB.
hours days
0 1 2 4 8 12 1 2 3 4 5 8 12
MT4
HIV-1 DNA - + + + + + + + + + + nd nd
1 LTR CUVD - - - - + + + + + + nd nd
2 LTR CUVD + + + + + + nd nd
Linear UVD + - + + + - - + + + nd nd
C8166
HIV-1 DNA - + + + + + + + + + nd nd
1 LTR CUVD - - + + + + + + + + nd nd
2 LTR CUVD - + + + + + + + + + nd nd
Linear UVD - + - - + + - - - + + nd nd
Hut78
HIV-1 DNA - + + + + + + + + + + +
1 LTR CUVD + + + + + + + +
2 LTR CUVD - - - + + + + + + + + +
Linear UVD - + - + + - - - + + + +
SupT1
HIV-1 DNA - + + + + + + + + + + + +
1 LTR CUVD - - + + + + + + + + + +
2 LTR CUVD - - + + + + + + + + + +
Linear UVD - + - - + - - - - + + +
Details of the cell lines (in bold) are given in Appendix II. HIV-1 DNA,
detection of viral DNA with po/primers (160H/161H and 002C/003C); 1 and 2
LTR CUVD, detection of circular unintegrated viral DNA with 1 and 2 LTR
sequences respectively (for primer details see Table 12); Linear UVD,
detection of linear unintegrated viral DNA after ligation. MT4 and C8166
cultures were destroyed by day 8. nd, not done.
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Table 14. Detection of total viral DNA, and circular and linear
unintegrated viral DNA in monocytic lines (U937, THP1, & U138MG), B
cell line (HB1), lung fibroblastoid line (LC5), and epithelial line (HeLa
T8+) inoculated with HIV-1mB.
hours days
01248 12 123458 12
U937
HIV-1 DNA -- + + + + + + + + + + +
1 LTR CUVD --- + + + + + + + + + +
2 LTR CUVD + + + + + + + +
Linear UVD ...... .... + + +
THP1
HIV-1 DNA -- + + + + + + + + + + +
1 LTR CUVD + + + + + + + +
2 LTR CUVD + + + + + + +
Linear UVD --- + +- + +
HB1
HIV-1 DNA ---- + + + + + + + + +
1 LTR CUVD -- + + + + +
2 LTR CUVD - -- + + + + +
Linear UVD --- + + + +
LC5








Details of the cell lines (in bold) are given in Appendix II. HIV-1 DNA,
detection of viral DNA with po/primers; 1 and 2 LTR CUVD, circular
unintegrated viral DNA with 1 and 2 LTR sequences respectively; Linear UVD,
detection of linear unintegrated viral DNA after ligation. Control cultures of the
non-susceptible (HeLa T8+) and uninfected (U138MG) cell lines were
negative for HIV-1 DNA, CUVD, and LUVD at all time points.
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7.4.4 LUVD detection.
All T-cell derived lines were positive for LUVD at various time points in the
study. Unlike the CUVD results, the detection of LUVD was not constant after
the initial detection, demonstrating a pattern of positive and negative time
points (Table 13). In each cell line, the initial detection of LUVD lasted for 1
time point, and was followed by 1 or 2 time points of negativity before a
second detection. The gap between the second and third detection was
greater than between the first and second, and the length of time of detection
also increased. If this pattern of appearance and disappearance represents
rounds of infection involving the synthesis of LUVD for integration, then the
increase in time of positivity may simply be due to the loss of synchrony of the
culture.
Of the non-T-cell derived lines, the only lines to show a pattern of appearance
and disappearance of LUVD was THP1. However, the pattern of detection
was not similar to that of the T-cell lines, as the initial detection lasted for 2
time points, and the reappearance was more delayed. In contrast, HB1 and
U937 were both negative for LUVD until day 4 and day 5 respectively, and
once positive remained so. LC5 cells, as with CUVD detection, were negative
throughout the experiment.
7.5 Cell lines infected with HIV-1RF.
This section was designed to complement the study of HIV-1 mB in cell lines, to
observe the differences in viral DNA synthesis attributable to the viral strain. In
addition to this, cells were serum-starved to reduce cell growth and
demonstrate the role of cellular factors in the synthesis of viral DNA. The viral
strain was also used to infect donor PBMCs to compare the forms of viral




Syncytia were observed in C8166 cells infected with HIV-1RF in complete
medium but not in serum-starved cells or in uninfected cultures. No syncytia
were observed in infected or uninfected donor PBMCs. This supports the data
from 1MB infections indicating a cellular role in syncytium formation. The
absence of syncytia in the serum-starved cells suggests that the state of the
cells may be important for the life cycle of the virus.
7.5.2 Overall viral DNA detection.
HIV-1 DNA was not detectable in uninfected C8166 and PBMC cultures
throughout the experiment. Viral DNA was first detected in the infected blood
donor cells at 2h, but was not consistently positive until day 2. This was
probably due to a small number of cells being infected resulting in some cell
aliquots containing little or no viral DNA. Infected C8166 cells in complete
medium were positive at 1 h, and serum-starved cells at 3h (Table 15).
7.5.3 CUVD detection.
Infected C8166 cells in both complete and serum-starved medium were
positive for both CUVD forms at the same time point although cells in
complete medium were positive 1 day earlier than serum-starved cells (day 2
and day 3 respectively). The presence of CUVD in serum-starved cells
(syncytia negative) rules out CUVD as the cause of these giant cells, although
they may be a contributing factor. Human PBMCs, the host cells in human
HIV infection, were not positive for CUVD forms until day 14. This again
suggests that the cell type plays an important role in determining the timing
and forms of viral DNA synthesized.
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Table 15. HIV-1 pF DNA detection in infected C8166 cells (C8166/RF),


















01234 11 12 123457 14
+ -+ -+ -+ + + + + +
+
+
+ + + + + + + + + + + +
- + + + + + +
- + + + + + +
+
+ + + + + + + + + + + +
- + + + + +
- + + + + +
PBMCs/RF, HIV-1 RF infected donor peripheral blood lymphocytes; C8166/RF,
HIV-1 RF infected cells in complete medium; C8166/SS, HIV-1 RF infected cells
in serum deficient medium; HIV-1 DNA, detection of viral DNA with pol
primers; 1 and 2 LTR CUVD, circular unintegrated viral DNA with 1 and 2 LTR
sequences respectively; Linear UVD, detection of linear unintegrated viral
DNA via ligation step. Control cultures of uninfected C8166 and donor PBMCs




LUVD was only detected on day 14 in C8166 cells infected with HIV-1RF in
complete medium. This is in contrast to the results obtained with the 1MB strain
of HIV, and may demonstrate differences attributable to the viral strain.
However, it must also be remembered that the methods adopted for extracting
total DNA differed, and so direct comparisons of the results must take account
of this. Donor PBMCs and C8166 cells in serum-starved medium were
negative for LUVD at each time point.
7.6 Detection and characterization of HIV-1 DNA in patient PBMCs.
The aim of this section was to detect HIV-1 DNA in PBMC extracts of
seropositive patients, and to demonstrate the presence of different structural
forms of UVD.
7.6.1 HIV DNA detection with po/and env primers.
HIV DNA was detected in patient cell samples using the po/and env primers.
Where possible DNA was extracted from 2x105 cells, and the resulting pellet
was resuspended in ddw to give 2x104 cell equivalents per amplification
aliquot. The condition of some stored samples was such that DNA was
extracted and amplified from a set volume. Extracted DNA was then quantified
at a later date by absorbance at 260/280nm, and cell equivalents of DNA
concentrations were calculated by the method described by Simmonds et a!.,
(1990a). Basically cells were assumed to be diploid, containing 6.6pg of DNA
each. A DNA concentration of 1ug was, therefore, equivalent to 1.5x105
PBMCs.
Samples were amplified from aliquots ranging from 7x103 to 1x106 cell
equivalents. The result of this was that samples were not amplified from a
fixed cell number, and so the HIV DNA load was not quantified (cell
equivalents for each amplification result are given in Appendix IV).
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All 32 seropositive patients were PCR positive for HIV-1 DNA sequences in
PBMC extracts. However, only 59 of the 61 samples tested were positive for
HIV-1 DNA (97%); 58 (95%) were pol positive, 56 (92%) env positive, and 55
(90%) were positive for both gene sequences. Four samples were negative for
one gene sequence, and 2 samples were amplification negative by both pol
and env primer pairs (Table 16).
Two samples (P24a and P25a) were PCR negative after nested amplifications
with both pol and env primer pairs.
Patient 24 was asymptomatic, receiving no anti-virals, and had a CD4+ count
of 280/ml at the time of sampling. The amplification aliquot was equivalent to
1.2x10^ cells, and so was sufficient for detection of HIV DNA from PBMCs in
83% of cases described by Simmonds et al., (1990a). It is possible that
sample P24a had no infected cells in the amplification aliquots, as a
subsequent sample from P24 (P24b, taken 3 months later) was found to be
HIV DNA positive using the pol primers on an aliquot of 4x104 cells. This
suggests that although the sample size was possibly too small (the env
amplification was negative), the number of infected cells may have increased
during the 3 months, allowing HIV-1 DNA detection in a smaller aliquot than
previously found to be negative in P24a.
Sample P25a was also negative for HIV DNA when an aliquot equivalent to
4x104 cells was amplified. It seems likely that the sample size was too small
for detection of viral sequences since a sample taken 9 months later (P25b)
was positive for both pol and env sequences using an amplification aliquot of
2x105 cell equivalents. During this time, the patient's CD4+ cell count had
decreased from 470 to 276 cells per ml of blood, and AZT therapy had been
initiated (4 April 1991). This suggests a decline in the general health of the
individual, associated with a marked decline in CD4+ cell numbers. It is,
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Table 16. HIV DNA detection of po/and envgene sequences in PBMCs
of HIV positive patients.
Gene sequence Total No.
amplified of samples Positive Negative
pol 61 58 (95%) 3 (5%)
env 61 56 (92%) 5 (8%)
pol and env 61 55 (90%) 2 (3%)
A nested PCR was used for both pol and env detection. Samples were
amplified with primers 160H/161H and 002C/003C for pol detection, and
401C/404C and 403C/404C for env detection. Details of the primers are given
in Appendix IV.
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therefore, possible that the proportion of infected cells had increased during
this time, making detection by PCR easier.
Four samples were scored PCR positive on the basis of detection of viral
sequences by only 1 set of primers (P23b, P24b, P32b, and P33b). Sample
P33b was negative for pol sequences after amplification of DNA extracted
from 2x105 cells. The patient had been shown to be positive for both pol and
env sequences 12 months previously with a similar amplification aliquot
(P33a). During this time, no change had been observed in the patient's CD4+
cell count or general health.
An aliquot of 5x104 cell equivalents of P23b was insufficient for env detection
although pol sequences were detected. A previous sample from the same
patient 2.5 months earlier had been positive for both gene sequences in an
aliquot of 4.5x105 (P23a). P23a (unlike P23b) yielded virus in culture,
suggesting that active viral replication may have been occurring in vivo. Also,
during the 2.5 month period between the specimens, the patient had been
receiving AZT therapy and so the total HIV DNA load in the patient's PBMCs
may have been reduced in response to therapy, such as has been observed
by Dickover et a/., (1992). In view of these facts, the amplification aliquot used
for P23b may have been at the threshold of detection for PCR.
Sample P24b was negative for env sequences when 4x104 cell equivalents
were amplified. The patient had been tested 3 months earlier (P24a) and was
found to be PCR negative (see above). P24a was PCR negative using
1.2x105 cell equivalents, whereas P24b was pol positive using an aliquot of
only 4x104 cells. The patient was CDC group II on both sampling dates with
similar CD4+ cell counts (280 and 250). These results may be explained by an
increased number of infected cells over the 3 months, or the aliquot amplified
for P24b may, by chance, have contained 1 of the few circulating infected
cells. The possibility of cross contamination from other samples is unlikely due
122
to the processing of samples between 2 negative donor cell controls. It is also
highly unlikely that P24a is a false negative result, as fresh reaction mixtures
were made for each batch. If any reagent had been omitted, the entire batch
would have been negative, and amplification repeated. It therefore seems
most likely that the samples contained very few infected cells and that only 1
amplification aliquot contained viral DNA.
The final sample with only 1 positive result was sample P32b. The patient was
from CDC group II, and had a high CD4+ cell count of 620/ml. A large
amplification aliquot of 3.75x105 was positive for pol sequences only, whereas
a previous sample (P32a) was positive for both pol and env at 2x105 cells.
Sample P32a had a considerably lower CD4+ cell count of 470/ml in
comparison with 620 cells/ml for P32b which, although unusual, may explain
the negative env amplification result from such a large aliquot.
In general, positive pol amplifications would be expected in all aliquots
containing HIV DNA as the gene is highly conserved in all HIV-1 isolates. In
contrast, the sequence variation observed in the env gene would be expected
to give rise to false-negative results due to poor amplification efficiencies
arising from primer template mismatches (Newton et at., 1989; Kwok et al.,
1990).
7.6.2 Length variation in the env gene.
Due to the sequence variation found in the env gene of viral isolates (Starcich
et al., 1986; Meyerhans et al., 1989; Simmonds et al., 1990a, 1990b), the
band lengths obtained after env amplifications varied sufficiently to observe
differences after agarose gel electrophoresis (approximately 30-50 base
differences, Figure 24). Considerable band length variation was observed
between patient samples (eg. the cytoplasmic amplification of P1 and the
nuclear amplification of P4b, lanes 14 and 15 of Figure 24 respectively). In
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Figure 24. Length variations observed for the envgene nested
amplifications with primers 401C/402C, and 403C/404C (Appendix IV).
LANES 1 2 3 4 5 8 9 10 11 12 13 14 15 16
All extracts were from patient PBMCs unless otherwise stated.
Lane 1, P25b cytoplasmic extract; lane 2, P25b nuclear extract; lane 3,
negative control; lane 4, DNA VI molecular weight marker (2176, 1766, 1230,
1033, 653, 517, 453, 394, 298, 234/220, 154); lane 5, P20c total DNA from
adherent cells (separated by adhesion to plastic flask); lane 6, P20c total DNA
extract; lane 7, P20c cytoplasmic extract; lane 8, P20c nuclear extract; lane
9, DNA VI molecular weight marker; lane 10, P13 cytoplasmic extract; lane
11, P13 nuclear extract; lane 12, negative control; lane 13, P4b cytoplasmic
extract; lane 14, P4b nuclear extract; lane 15, P1 cytoplasmic extract; and
lane 16, P1 nuclear etxract.
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addition to this, length variation may be observed within a single patient
sample (eg. P25b cytoplasmic and nuclear amplifications in lanes 1 and 2
respectively). Band lengths varied from 300-400 bases for all samples.
7.6.3 CUVD detection.
A total of 52 samples from patients were amplified for the detection of 1 and
2LTR CUVD. Thirty-four samples (65%) were positive for 1 or both forms (P8a
and P26a were positive for 1 LTR CUVD only), and 18 samples (35%) were
negative for both forms. The detection of CUVD was compared with CDC
groups, virus isolation, p24 plasma Ag detection, CD4+ cell counts, and the
use of AZT treatment (Table 17).
7.6.4 LUVD detection.
Despite the tertiary amplification used for the detection of LUVD, all patient
PBMC samples were tested negative.Both positive and negative controls were
as expected, and so the absence of positivity in patient samples may be due
to insufficient template. As with CUVD detection, the reaction utilised LTR
specific primers which may have been used by cellular sequences, thereby
reducing the efficiency of amplification. The detection of LUVD in cell line
studies, where the infection had been synchronised, may have been due to
the cells synthesizing linear viral DNA simultaneously, giving a higher
concentration of sequences for detection than expected in unstimulated
patient cells.
7.6.5 Detection and characterization of viral DNA in nuclear and
cytoplasmic extracts of patient PBMCs.
Cells from 7 patients were extracted to separate their cytoplasmic and nuclear
DNA. The fractions were amplified for total viral DNA and 1 and 2LTR CUVD
detection (Table 18). Two samples had detectable HIV DNA in the nuclear
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Table 17. Detection of CUVD in samples separated by CDC groi
detection of p24 plasma antigen, isolation of virus, CD4+ cell r its,
and use of AZT anti-viral therapy.
CDC group
II III IV po' neg.
CUVD pos. 6 10 18 7
CUVD neg. 6 10 2 7 7
Total 12 20 20 21 14
p24 Ag r j *■ counts AZT treatment
pos. neg. - 200 *200 Yes No
CUVD pos. 11 22 9 13 19 15
CUVD neg. 1 17 11 6 4 14
Total 12 rj 20 19 23 29
CDC groups, clinical grr jps as defined by the Centers for Disease Control
(CDC, 1986); VI, virus .solation from patient PBMCs, plasma, and/or
heparinised whole olood; p24 Ag, detection of p24 viral core antigen in the
patients plasma- Cr4+ counts, number of cells per millilitre of blood
expressing the JP4 differential antigen on their surface; *, less than or equal
to; AZT theraoy, patients receiving AZT therapy for a minimum of 3 weeks
prior to veniouncture; pos., positive; neg., negative.
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Table 18. HIV-1 CUVD detection in nuclear and cytoplasmic extracts
from patient PBMCs.
Patient Extract HIV-1 1 LTR 2 LTR
No. type DNA CUVD CUVD
P1 N +
C +
P4b N + + +
C +
P7d N + + +
C
P13 N + + +h
C + + +
P15 N + + +
C
P20c N + + +
C + + +
P25c N + - -
C +
Nuclear and cytoplasmic DNA was extracted from 1x106 PBMCs. N, nuclear
extract; C, cytoplasmic extract; HIV-1 DNA, detection of viral DNA with pol
primers; +, positive; negative; -i-h, positive band present but approximately
400bp as opposed to the expected 447bp; CUVD, detection of circular
unintegrated viral DNA with 1 or 2 LTR sequences using gag, env, and LTR
specific primers.
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fractions only, and 5 were positive for both nuclear and cytoplasmic extracts.
Both samples positive for nuclear extracts only were positive for CUVD. Of the
5 samples with HIV DNA in both fractions, 1 had CUVD in the nuclear extract
only, 2 were positive for CUVD in both fractions, and 1 sample had no
detectable circular forms. The nuclear extract from P7d resulted in a distinct
amplification product of approximately 600bp. Although this band is greater
than the expected 2LTR CUVD product, it may result from an aberrant CUVD
molecule which has additional sequences present. This has been proposed by
Pauza and Galindo, (1989) for the generation of multi-meric CUVD forms.
Analysis by dot or Southern blot hybridisation is required to confirm this.
7.7 Comparisons of CUVD detection with CDC groups, virus isolation,
plasma p24 antigen detection, CD4+ cell counts, and AZT therapy.
The detection of UVD forms was compared to markers of infection and
disease progression to try and establish a role for these forms in the
pathogenesis of HIV. Samples were only included in the comparison if they
were positive for both pol and env sequences after a nested PCR.
7.7.1 CDC groups.
Of the 34 CUVD positive samples, 6 (18%) were CDC II, 10 (29%) CDC III,
and 18 (53%) CDC group IV (Table 17). The increase in detection of CUVD
forms with disease progression was more apparent when the results were
expressed as a percentage of samples positive in each CDC group. Six out of
12 (50%) of CDC II, 10 out of 20 (50%) of CDC III, and 18 out of 20 (90%) of
CDC IV samples were CUVD positive. These results were significant
(0.02>P>0.01) indicating that the detection of CUVD is more likely in the later
stages of disease (Table 19).
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Table 19. Comparisons of CUVD detection with CDC groups, CD4+ cell


























CDC group, clinical definitions of patients as described by the Centers of
Disease Control (CDC, 1986); VI, virus isolation from patient PBMCs, plasma,
or heparinised whole blood; p24 Ag, detection of viral core antigen in patient
plasma; CD4+ cell counts, the number of cells per ml of whole blood
expressing the Clusters of Differentiation antigen 4 (CD4) on their surface.
Samples were separated into groups with more than 200 CD4+ cells/ml, and
those with 200 or less CD4+ cells/ml (>200 and 200); AZT, patients receiving
AZT therapy for a minimum of 3 weeks prior to venipuncture; DF, degree of
freedom; and P, probability.
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7.7.2 Virus isolation.
The virus isolation results of 35 samples from heparinised whole blood,
plasma and PBMCs were compared to the detection of CUVD in patient
PBMCs. Virus was isolated from 21 out of 35 samples (60%), 14 (67%) of
which were also positive for CUVD. Isolation negative samples (14 or 40%)
showed no difference in the presence or absence of CUVD (Table 17).
Statistical analysis showed no significant correlation between detection of
CUVD forms and the ability to isolate virus (Table 19).
7.7.3 p24 plasma Ag detection.
Fifty-one samples were compared. CUVD was detected in 11 out of 12 (92%)
antigen positive samples, and 22 out of 39 (56%) antigen negative samples
(Table 17). The majority of CUVD negative samples were also antigen
negative (94%). The results were not statistically significant (0.10>P>0.05,
Table 19).
7.7.4 CD4+ cell count.
Comparisons were made of the relationship of CUVD detection and CD4+ cell
counts by grouping the results according to the CD4+ counts of more than 200
and less than or equal to 200. Data were available for both CUVD detection
and CD4+ cell counts for 39 samples. The results for samples with CD4+ cell
counts greater than 200 showed that 9 out of 20 (45%) were positive, and 11
out of 20 (55%) negative for CUVD forms (Table 17). Thirteen out of 19 (68%)
samples with counts less than or equal to 200 were positive for CUVD, and 6
out of 19 (32%) were negative. Of the 22 CUVD positive samples, 9 (41%)
had counts greater than 200, and 13 (59%) had counts of less than or equal to
200. These results were not statistically significant (Table 19).
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7.7.5 AZT treatment.
Fifty-two samples were compared, 23 of which were from patients who had
been receiving AZT treatment for a minimum of 3 weeks. The levels of AZT
treatment were not known, and consequently have not been taken into
consideration. Thirty-four samples were CUVD positive, 19 (56%) on AZT
treatment, and 15 (44%) receiving no known anti-retroviral treatment (Table
17). Of the 23 samples from patients receiving AZT, 19 (83%) were positive
for CUVD, and 4 (17%) were negative. There were 29 samples obtained from
patients on no therapy, 15 (52%) had CUVD forms, and 14 (48%) were
negative. These results were statistically significant (0.05>P>0.02),
demonstrating a relationship between patients on AZT therapy and the
presence of CUVD (Table 19).
7.8 Comparison of viral markers, CD4+ cell counts, and anti-viral therapy
with CDC groups II, III, and IV.
Samples were categorized into their CDC groups, and analysed for detection
of plasma p24 viral antigen, virus isolation, CD4+ cell counts, and AZT
therapy. The results are presented in Table 20, and the data were analysed
by the Chi-square test, as described in Appendix III.
7.8.1 Virus isolation.
Virus was isolated from 22 out of 41 (54%) samples with a known CDC group
status. Three (14%) of the positive cultures were from samples in CDC group
II, 9 (41%) from CDC group III, and 10 (45%) from CDC group IV (Table 20).
Virus was isolated from 3 out of 8 (38%) CDC II samples, 9 out of 20 (47%)
CDC III samples, and 10 out of 11 (91%) CDC group IV samples. The data
were statistically significant (0.01 >P>0.001), demonstrating an increase in the
success rate of virus isolation from patient PBMCs in the later stages of
disease (Table 21).
131
Table 20. Comparison of CDC groups with viral markers, CD4+ cell
counts, and anti-viral therapy.
CD4+ count
CDC group VI p24 Ag >200 200 AZT
CDC II 3/11 2/17 13 4 1/17
CDC III 9/19 3/22 10 9 7/23
CDC IV 10/11 8/21 3 9 16/21
Total 22/41 13/60 26 22 24/61
The results are expressed as the number of positive samples out of the total
number of samples for which data were available, with the exception of CD4
antigen positive cell counts which are expressed as the number of samples
with counts greater than 200 and less than or equal to 200 cells per ml of
whole blood. VI, samples from which virus was isolated from heparinised
whole blood, plasma, or PBMCs; p24 Ag, samples positive for plasma p24
viral core antigen; AZT, patients receiving AZT for a minimum of 3 weeks prior
to collection of the sample; CUVD, samples positive for 1 or 2 LTR circular
viral DNA forms by PCR.
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Table 21. Comparisons of CDC groups with CD4+ cell counts, viral p24





















The detection of CUVD was compared with; VI, virus isolation of virus from
patient PBMCs, plasma, or heparinised whole blood: detection of p24 viral
core antigen in the patients plasma (p24 plasma Ag); CD4+, number of cells
per ml of whole blood expressing the differential antigen 4 (cell count at a cut
off value of >200/ 200); CDC groups II, III, and IV as defined by the Centers of
Disease Control (CDC, 1986); and AZT, patients receiving AZT therapy for a
minimum of 3 weeks prior to venipuncture. DF, degree of freedom; P,
probability. The results were analysed by the Chi-square test with Yates
correction for continuity for fourfold tables (Appendix III).
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7.8.2 p24 plasma Ag detection.
Of the 60 patient samples included, 13 (22%) were p24 Ag positive of which 2
samples (15%) were from CDC group II, 3 (23%) from CDC III, and 8 (62%)
from CDC IV (Table 20). While most Ag positive samples were from patients
in CDC group IV, only 8 out of 21 (38%) of CDC group IV samples were Ag
positive. This is still much higher than the other groups, with 2 out of 17
samples (12%) Ag positive in CDC group II, and 3 out of 22 (14%) in CDC
group III. Statistical analysis showed no significant difference in antigen
detection with disease stage (0.10>P>0.05; Table 21).
7.8.3 CD4+ cell count.
The CDC grouping was known for 48 patients with CD4+ cell counts: 17 were
in CDC group II, 19 in CDC group III, and 12 in CDC group IV (Table 20).
CDC II samples were predominantly of higher CD4+ cell counts, 13 out of 17
(76%) had counts >200. CDC III samples were more evenly distributed, 10 out
of 19 (53%) had a count >200, and CDC IV samples had consistently lower
CD4+ cell counts, 9 out of 12 (75%) less than or equal to 200. These results
were statistically significant (0.05>P>0.02; Table 21) demonstrating a
relationship between clinical progression and a loss of CD4+ cells.
7.8.4 AZT treatment.
The CDC groupings and treatment with AZT were known for 61 patients.
Twenty-four samples were from patients receiving treatment; 1 (4%) in CDC
group II, 7 (29%) in CDC III, and 15 (67%) from CDC group IV (Table 20).
When the samples were divided into CDC groups, 1 out of 17 (6%) CDC II
samples, 7 out of 23 (30%) CDC III samples, and 16 out of 21 (76%) CDC IV
samples were from patients receiving AZT treatment. The use of AZT
treatment was significantly greater in the later stages of disease (0.001 >P;
Table 21).
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7.8.5 Further analysis of data adjusted for sample size.
Statistical analysis is used to establish significant correlations, however,
failure to do so does not prove the null hypothesis as it is quite possible that
the data are insufficient to establish the relationship.
The results obtained for patient samples were insufficient for the standard Chi-
square test which requires a minimum of 100 events. The data were,
therefore, analysed using the Yates "correction for continuity" (Swinscow,
1991). The data which failed to establish a significant result were amplified by
a factor of 2 or 3 to obtain in excess of 100 events (CUVD analysis with CD4+
cell counts, p24 plasma antigen detection, and virus isolation; and CDC group
with p24 plasma antigen detection). Three out of 4 sets of the adjusted data
were significant when analysed, with the exception of virus isolation with the
detection of CUVD (Tables 22 and 23). The adjusted data demonstrated a
relationship of CUVD detection with lower CD4+ cell counts (0.02>P>0.01);
with the detection of p24 antigen in the plasma (0.01 >P>0.001); but not with
virus isolation (0.10>P>0.05). The data also confirmed a relationship of
disease progression with the detection of p24 plasma antigen (0.01 >P>0.001).
Although not conclusive, the adjusted data gave an indication of the possible
significance of the results had there been sufficient observations, with the
same distribution of results, available for direct analysis by the Chi-square
test.
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Tables 22 and 23. Data from Tables 17 & 20 which were not significant were
adjusted to contain in excess of 100 samples for each analysis. This was
achieved by amplifying the data by a factor of 2 or 3. The results were then
analysed as before (Appendix III) with the following results;
Table 22. Adjusted comparisons of CUVD detection with CD4+ cell
counts, viral p24 plasma antigen detection, and virus isolation.
CUVD Number of Chi-
with samples square DF Probability
CD4+ (200) 117 6.521 1 0.02>P>0.01
p24 plasma Ag 102 9.989 1 0.01>P>0.001
VI 105 2.917 1 0.10>P>0.05
Table 23. Adjusted comparisons of CDC groups with CUVD detection,
CD4+ cell counts, viral p24 core antigen detection, AZT treatment, and
virus isolation.
CDC group Number of Chi-
with samples square DF Probability
p24 plasma Ag 120 10.315 2 0.01>P>0.001
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CHAPTER 8: DETECTION OF HIV-1 DNA IN PERIPHERAL BLOOD
MONOCYTIC CELLS.
The aim of this section was to determine whether or not monocytic cells in the
peripheral blood of HIV positive individuals were infected with the virus.
Initially, monocytic cells were isolated from PBMCs by their adherent
properties to plastic. Adherent cells were collected and further analysed for
viral DNA content by a nested polymerase chain reaction.
To improve the purity of these cell preparations, a highly specific cell
separation technique was sought, based on the detection of surface antigens
characteristic of cellular subsets. These antigens, known as clusters of
differentiation or CD antigens, have been carefully characterised and used to
describe cellular subsets (Bernard et at., 1984). PBMCs can, therefore, be
separated into cellular subsets by immunoselection using antibodies specific
to a particular cell population. There are 2 forms of immunoselection; 1)
negative selection, where a mixed population is depleted of a certain cell type
and the remaining cells are further analysed, and 2) positive selection, where
a specific sub-population is selected and removed for further studies.
Irrespective of the method utilised, it is important that it is both rapid and
gentle for the recovery of viable cells, that the selection is specific to obtain a
high resolution, and that the method can be applied to both small and large
samples.
There are 3 main methods available for immunoselection of PBMC subsets
(Lea et at., 1985). 1) Cell sorting using flow cytometry (FACS), which
compares the size and granularity of each cell and sorts them accordingly.
FACS analysis is well established although it is costly, requires considerable
expertise, and is unsatisfactory for the analysis of infectious material due to
the potential to form aerosols (Reinherz et a!., 1979; Moscicki et a!., 1985;
Ohta et a!., 1986). 2) The separation of cells by incubation of a mixed cell
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population in a flask coated with a subset specific antibody. This method,
known as panning, has been successfully used to isolate cellular subsets with
purities of up to 95% (Wysocki & Sato, 1978; Lum et al., 1982; Nielsen et a/.,
1989) although they are more frequently in the range of 50-70% (Mason et a!.,
1987). Unfortunately, the technique is prone to non-specific binding of
adherent cells, and often results in low yields (Basch et al., 1983). 3) Cellular
subsets may also be separated using specific antibodies bound to sheep red
blood cells (SRBC). The SRBC bind to the cells expressing the specific
antigen, forming large complexes or rosettes. These are readily removed by
centrifugation, with a reported purity of >99% (Mason et al., 1987). The
technique is, unfortunately, not adaptable to the separation of large samples.
In view of these limitations, it was decided to apply a relatively new technique
to the separation of patient PBMCs using immunomagnetic microspheres, or
"Dynabeads". The beads offer a rapid, flexible and highly specific cell
separation method which can be applied to the purification of any cell subset
expressing a unique surface marker.
PBMCs were separated into T helper/inducer, T suppressor/cytotoxic cells,
monocytic cells and B cells using specific monoclonal antibodies bound to
commercially available magnetic microspheres (Dynabeads), and the purity of
these cell preparations was assessed using fluorescence activated cell
sorting.
8.1 Analysis of Dynabead sorted cells.
PBMC subsets can be distinguished on the basis of their surface antigens
known as Clusters of Differentiation or CD antigens. By coating Dynabeads
with monoclonal antibodies to CD antigens specific for certain cell subsets, it
was proposed to remove T-cytotoxic/suppressor cells, T-helper/inducer cells,
monocytic cells, and B cells by positive selection.
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Dynabead-sorted cells were analysed by flow cytometry to demonstrate the
specificity of the separation technique. The computer analysis of fluorescein
labelled samples was carried out by Dr John Stewart (Department of Medical
Microbiology, The University of Edinburgh) and was set to analyse the
labelling of lymphocytic and monocytic cell populations.
8.1.1 Flow cytometric analysis of cells separated by antibody coated
Dynabeads.
Uninfected PBMCs were separated by Dynabeads coated with antibodies to
differential antigens 4, 8, 14, and 19. The purified cell fractions were analysed
as two populations based on their size and granularity, and their percentage
labelling with each FITC-conjugated antibody was determined (anti-CD4,
CD8, CD14 and CD19).
The initial analysis of cells purified by anti-CD4 coated Dynabeads showed
that lymphocytic cells stained with antibodies to CD4 (23.9%); CD8 (16.7%);
CD14 (8%); and CD19 (1.2%): monocytic cells stained with antibodies to CD4
(8.7%); CD8 (6.4%); CD14 (16%); and CD19 (2.7%). Analysis of cells
separated by Dynabeads coated with antibodies to CD8, CD14 and CD19
surface antigens gave similar patterns of low and non-specific labelling.
The labelling observed with antibodies to CD4, CD8 and CD19 in the
monocytic cell fraction of anti-CD4 purified cells could have resulted from non¬
specific binding of the Fc portion of the antibody to the Fc receptor expressed
on the surface of monocytic cells (Roitt et a!., 1987). However, the specific
labelling of these cells with anti-CD14 was significantly greater than the
labelling with any of the other conjugated antibodies, showing that monocytic
cells had been isolated using the Dynabeads coated with anti-CD4 antibodies.
The cells analysed resulted in a strange pattern of specificity. Lymphocytes
separated by anti-CD4 specific antibodies should only fluoresce with CD4
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specific conjugated antibodies. Although fluorescence was highest with the
CD4 specific conjugated antibody (23.9%), the anti-CD8 antibody labelling
was relatively high as well (16.7%). Dynabeads are marketed as being coated
with highly specific monoclonal antibodies, and are reported to permit the
separation of very pure samples of peripheral mononuclear cell subsets
(Gaudernack et at., 1986). Since lymphocytic cells, and in particular CD4+
lymphocytes, do not express Fc receptors on their cell surface, the high level
of non-specific labelling detected is difficult to explain.
Once separated, the cells are permanently attached to the Dynabeads, and so
it is possible that the Dynabeads interfered with the subsequent reactions.
Firstly, the nature of the binding may result in the formation of clumps of
beads and cells. This would block the delivery tube of the EPICS machine
resulting in the absence of events to analyse (as seen with some fractions
separated by anti-CD8, 14 and 19 separated cells, data not shown). Secondly,
the Dynabeads may give rise to non-specific binding of conjugated antibodies
if they were not sufficiently blocked prior to labelling.
8.1.2 Fluorescent antibody staining of negative blood donor cells.
Due to these results obtained with cells separated by Dynabeads, it was
decided to test the labelling procedure on PBMCs from a normal blood donor.
PBMCs from an HIV-1 negative donor were separated on Lympho-paque, and
split into 5 equal fractions. Each fraction was incubated with 1 of the 4
conjugated antibodies (anti-CD4, anti-CD8, anti-CD14, and anti-CD19) and
the final fraction used as a negative control. The labelled fractions were
analysed for staining of monocytic and lymphocytic cells. Antibody coated
Dynabeads were also incubated with each of the labelled antibodies to
determine the extent of non-specific labelling associated with them.
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The Dynabeads gave levels of fluorescence ranging from 1.2 to 1.4%,
indicating a very small and consistent level above background for each
antibody tested (Table 24).
The PBMCs were analysed for lymphocytic and monocytic cells as before.
CD4 antigens were observed in 74% of monocytes, and 35% of lymphocytes;
CD8 antigens on 81% of monocytes, and 18% of lymphocytes; CD14 antigens
on 91% of monocytes, and 0.6% of lymphocytes; and CD19 antigens on 20%
of monocytes, and 1% of lymphocytes (Table 24).
The total labelling of monocytic cells was greater than 100% (74% with anti-
CD4; 81% with anti-CD8; 91% with anti-CD14; and 20% with anti-CD19). The
results are, therefore, unlikely to be due to contaminating lymphocytic cells,
but due to cross reactivity of monocytic cells with non-specific antibodies via
Fc receptor molecules on the cell surface.
In contrast, the lymphocytic cells analysed gave an overall labelling of
approximately 55% (35% with anti-CD4; 18% with anti-CD8; 0.6% with anti-
CD14; and 1% with anti-CD19). Although the total CD4 and CD8 positive cells
should have been approximately 90% (actual 53%), the ratio of CD4:CD8
positive cells (1.9:1) was in accordance with the expected ratio of 2:1. This is
suggestive of inefficient labelling with the conjugated antibodies. Similarly, the
percentage of cells labelled with B lymphocytic specific antibodies (anti-CD19)
was considerably lower than the expected 10% (actual 1%). It is possible that
some of the cells present in this fraction were not lymphocytes, however, they
were also not CD4+ monocytic cells (0.6% labelling) and so it is more likely
that the cells were poorly labelled.
In general, the labelling reaction was as described by the manufacturer of the
conjugated antibodies (Serotec). It is, therefore, possible that further
optimisation of the method could have resulted in lower non-specific binding,
and a higher specific interaction with cellular surface antigens.
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Table 24. Staining of peripheral blood mononuclear cells (PBMCs) with
fluorescein isothiocyanate conjugated antibodies to CD4, CD8, CD14,
and CD19 surface antigens.
Antibody to

















Percentages refer to the fraction of each cell type which stained with each
conjugated antibody specific for cellular surface antigens. CD4 is expressed
on T-helper/inducer cells, monocytes, and macrophages; CD8 on T-
cytotoxic/suppressor cells; CD 14 on monocytes, macrophages, and some
granulocytes; and CD19 on B-cells (Serotec).
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8.2 HIV-1 DNA detection in monocytic cells by PCR.
Adherent cells were isolated from a total of 12 samples from 11 patients.
Eleven samples were isolated by adherence to T25 flasks, and 1 sample was
prepared by selective extraction of CD14+ cells by magnetic Dynabeads
coated with anti-CD14 antibodies. DNA from adherent cells was extracted and
amplified for detection of HIV-1 DNA using po/and env primers. Six samples
were positive for HIV-1 DNA and 6 were negative (Table 25). The cells were
not quantified due to the small numbers of PBMCs used for the isolation.
Comparisons were made with CDC group, plasma antigen detection, virus
isolation, CD4 cell count, and detection of CUVD. No patterns of association
were observed, although this may be due to the small sample size available.
Interestingly, monocytic cells were separated from 2 consecutive samples
from patient 20 (P20b and P20c). Sample P20b was separated by adherence,
and sample P20c (received 9 months later) using anti-CD14 antibody coated
Dynabeads. Monocytic cells from both samples were found to be positive for
HIV-1 DNA after a nested amplification for the pol sequence.
Although both methods of isolating adherent cells suffer from problems of
contamination with cells from other sub-populations, both samples from P20
were positive, lending support to the argument that HIV DNA is present in
adherent/monocyte or macrophage cells in the peripheral blood (Gartner et
a!., 1986).
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Table 25. HIV-1 DNA detection in monocyte/adherent cells isolated from
patient PBMC samples by adhesion to culture flasks or by specific
binding to anti-CD14 antibody-coated Dynabeads. The PCR results were
compared with other laboratory markers of infection.
Markers
Patient No. DNA p24 Ag CDC AZT VI CD4+
P3b + _ II no 280
P4a + + II no - 180
P5 - - III no - 190
P10 + - III no - 468
P11 b - - III yes + 176
P16 - - III no - 360
P19a - - III no + 560
P20b + - III no + 350
P20c* + - III no - nd
P25a + - III no - 470
P28c - nd IV no nd nd
P31 - - II no - 280
negative; +, positive; DNA, detection of HIV-1 DNA by PCR using a nested
PCR with primers for the po/and env gene sequences (Samples were scored
HIV DNA positive if either gene sequence was detected); p24 Ag, p24 plasma
antigen detection; CDC, CDC group; AZT, use of antiviral therapy; VI, virus
isolation; CD4+, CD4 surface antigen positive ceils per millilitre of blood; nd,
not done; *, cells separated by anti-CD14 coated Dynabeads. All other
samples were separated by adhesion to plastic flasks over a period of 3 days.
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CHAPTER 9: DETECTION OF HIV-1 RNA.
Although the detection of HIV-1 viral DNA sequences is accepted as evidence
of infection, it is not directly comparable to detection of free virus or viral
activity. In contrast, the detection of HIV-1 RNA in clinical samples is
indicative of replicative and free virus.
The initial aim of this study was to detect viral RNA sequences in clinical
samples using a 2 step amplification (reverse transcription (RT)-PCR). This
method was applied to RNA from whole virus extracts obtained using beads
coated with antibodies to HIV-1 viral surface glycoproteins. In this way, it was
hoped to correlate the detection of viral RNA to infectivity, and analyse its
detection in relation to other markers of infection.
9.1 Optimisation of antibody coated bead extraction of HIV-1.
9.1.1 Determination of protein concentration by Bradford's Coomassie
Blue assay.
The standard protein (BSA) concentrations (100ng to 1mg/ml) were plotted
against their optical density value (OD at 595nm) to give a standard curve
(Table 26 and Figure 25). The concentrations of test proteins (monoclonal
antibodies ADP 335, 361 and 362; polyclonal antibodies ADP 403; and
recombinant gp120 ADP 604, Appendix II) were determined from the standard
curve by reading off the corresponding concentration for their optical densities
(Table 27). The concentrations obtained in this way were used in later
experiments.
9.1.2 lodination of recombinant gp120 protein.
The iodinated protein was separated from free iodide by gel-filtration on a
Sephadex G-100 column with excess buffer (0.2% potassium iodide in RIP).
Fractions (1ml) were collected, diluted (1 in 10) and analysed for gamma
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Table 26. Bradford's Coomassie Brilliant Blue Protein assay.
Determination of the standard values using dilutions of BSA.
Conc./ml of BSA 1mg 100g 10 g 1g 100ng
Optical density 1.259 0.539 0.408 0.387 0.382
The standard protein (BSA) was diluted to give a range of concentrations from
100ng to 1mg/ml. The optical density was determined at 595nm by the
method of Bradford, (1976) and plotted against the known protein
concentration (Figure 25).
Table 27. Determination of the test protein concentrations from
Bradford's Coomassie Brilliant Blue Protein assay standard curve
(Figure 25).
MRC ADP No. 335 361 362 403 604
Optical density 0.773 0.887 0.915 0.953 0.612
Conc./ml 300 g 450 g 500 g 550 g 100 g
The concentration of each protein was determined by reading the
corresponding concentration to their OD value at 595nm from the standard
curve (Figure 25). Conc./ml, concentration per ml; MRC ADP No., Medical
Research Council AIDS Directed Program number (Appendix II).
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Figure 25. Bradford's Coomassie Brilliant Blue Protein assay.
[Determination of the standard value using dilutions of BSA.
The standard protein (BSA) was diluted to give a range of concentrations from
10Ong to 1 mg/ml. The optical density was determined at 595nm by the
method of Bradford, (1976) and plotted against the known protein concentration
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irradiation over a period of 60 seconds. The results showed 2 peaks of
activity, one corresponding to protein-bound Iodine, and the other to free
Iodide (Figure 26).
Radioiodine interacts with proteins by substituting the side chains of tyrosine,
and to a lesser extent histidine residues (Greenwood et al., 1963; Bolton &
Hunter, (1973); McConahey & Dixon, (1980)). From sequence data (kindly
provided by Dr G. Clements of Celltech Research, Slough) the recombinant
protein (gp120) was shown to contain 11 tyrosine and 7 histidine residues per
molecule, representing 3.8% of the total amino acid content (Appendix VI).
Assuming that all the available Iodide passed through the column, 57% was
substituted into amino acid residues of rgp120 glycoprotein. However,
assuming a loss of 5-10% of Iodide activity through adsorption to the column,
up to 63% was incorporated (Table 28).
Dilutions of the peak fraction (fraction 5) were utilised for analysis of the
specificity and sensitivity of the antibody coating procedure for polystyrene
beads.
9.1.3 Optimisation of antibody coating of polystyrene beads.
Beads were coated at varying dilutions of antibodies, and their ability to bind
iodinated recombinant gp120 protein was assessed in triplicate. The average
return of counts at each antibody dilution was expressed as a percentage of
the total counts available (Table 29).
The percentage return of counts ranged from 0.61% to 13.93%. Antibodies
ADP335 and 403 gave very low returns with a maximum percentage return of
1.78 and 1.27 respectively. Their peak returns were however at the maximum
dilution, and so it was decided to dilute these antibodies further (1 in 400, 1 in
500, 1 in 600, 1 in 800, and 1 in 1000). The use of BSA as a post-antibody
coating blocking agent was also tested on these further dilutions (Table 30).
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Figure 26. Separation of iodinated rgpl 20 glycoprotein
from free iodine on Sephadex G-100.
The separation was carried out by gel-filtration of the iodination mixture
containing125l-labelled rgp120 (2pg of approximately 140-160pCi/pg),
sodium metabisulphite (60pg), cloramine-T (25pg), and approximately
185-215pCi of 125l (iodine) diluted in 0.2% ptassium iodide in RIP buffer
to a total volume of 250-300/vl. The column was run with excess buffer
(0.2% Kl in RIP), and 1 ml fractions were collected. The fractions were
diluted 1 in 10, analysed for gamma irradiation over 60s, and the results
plotted. The unretarded iodinated protein was eluted first (fractions 4-6),
followed by a smaller peak of free iodine (fractions 11 -13).
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Table 28. Gamma irradiation activity of fractions of iodinated rgp120
collected from the Sephadex G-100 column.
Fraction 1 2 3 4 5
cpm 14 23 5 23492 286325
Fraction 6 7 8 9 10
cpm 21189 9447 4268 173 6276
Fraction 11 12 13 14 15
cpm 35071 150494 38460 5160 550
Fraction 16 17 18 19 20
cpm 204 147 92 127 94
Fraction 21 22 23 24 25
cpm 45 100 60 45 54
Fraction 26 27
cpm 52 77
Fraction, sequential fractions of 1ml collected from Sephadex G-100 column
loaded with iodinated recombinant gp120 and washed through with 0.2%
potassium iodide in RIP buffer; cpm, counts per minute. The cpm were plotted
against the fraction number to see the peak counts responding to iodinated
protein and free iodine (Figure 26). The percentage of free iodine incorporated
into the recombinant protein was calculated from the total counts in the protein
peak fractions (4-6) out of the total counts for the 27 fractions collected. From
this it was calculated that 57-63% of the available iodine had been
incorporated into the tyrosine and histidine residues of gp120.
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Table 29. Determination of the specificity and efficiency of antibody
coating of polystyrene beads with antibodies to HIV-1 surface
glycoproteins, using iodinated recombinant gp120.
Dilution Counts ADP335 ADP361 ADP362 ADP403
1 in 50 20000 1.02% 7.19% 7.18% 0.98%
50000 1.30% 13.93% 12.16% 0.61%
1 in 100 20000 0.84% 7.73% 4.91% 1.07%
50000 0.86% 10.75% 8.47% 0.61%
1 in 200 20000 1.35% 5.45% 4.14% 0.98%
50000 1.5% 8.46% 4.98% 1.00%
1 in 400 20000 1.78% 4.89% 3.48% 1.27%
50000 1.70% 5.24% 4.73% 0.86%
Each incubation was carried out in triplicate and the results averaged,
lodinated rgp120 was used at 20000 and 50000cpm per incubation aliquot.
Dilution, antibody dilution used to coat the beads; Counts, total counts of
iodinated gp120 available to bind to antibody coated beads; %, the average
counts returned as a percentage of the total counts available. ADP numbers
refer to the MRC AIDS directed program (Appendix II).
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Table 30. Further analysis of antibodies ADP335 and 403 for bead
coating, with preliminary BSA blocking studies using recombinant
iodinated gp120 label.
Dilution Counts ADP335 ADP335 ADP403 ADP403
1 in 400 20000 1.67% 0.69% 0.67% 0.39%
50000 2.04% 0.76% 1.06% 0.52%
1 in 500 20000 1.81% 0.58% 1.14% 0.48%
50000 1.78% 0.68% 1.12% 0.39%
1 in 600 20000 1.25% 0.87% 0.88% 0.38%
50000 1.64% 0.69% 1.02% 0.05%
1 in 800 20000 1.70% 0.54% 0.88% 0.40%
50000 1.50% 0.57% 1.24% 0.40%
1 in 1000 20000 1.26% 0.38% 0.94% 0.29%
50000 1.18% 0.48% 1.40% 0.44%
Data in normal type was from the dilution studies, and data in bold from the
BSA bead blocking experiment. Beads were blocked with a 5% solution of
BSA in carbonate/bicarbonate buffer. Counts, total counts available; %,
average counts returned as a percentage of the total counts available
(dilutions were carried out in duplicate). ADP numbers refer to the MRC AIDS
directed program (Appendix II).
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No significant improvement was observed by further diluting the antibodies.
This may be explained by the nature of the 2 antibodies with respect to the
iodinated gp120 used to assay the coated beads. Antibody ADP335 was
raised against a yeast recombinant gp160 glycoprotein, and so was likely to
show stronger affinity for gp160 epitopes. The antibody ADP403, although
raised against rgp120 (ADP604), was polyclonal and so anti-gp120 specific
antibodies bound to the beads may be of a lower concentration than expected
with monoclonal antibodies.
Antibodies ADP361 and 362 were both raised against the recombinant gp120
protein used to assay the bead coating efficiency. This may explain why the
return of counts was significantly higher for these antibodies in comparison
with beads coated with antibodies ADP335 and 403.
In addition to the specificities of the antibodies tested, the conformation of the
recombinant glycoprotein may have been altered directly by the iodination
procedure or indirectly by chemicals involved in the reaction thereby reducing
its specificity for the antibodies (Greenwood et al., 1963; Bolton & Hunter,
1973). Unfortunately, the amino acids associated with the binding of
antibodies ADP335, 361, 362, and 403 were not known; if, however, tyrosine
or histidine residues were involved, the binding capacity of the glycoprotein
may have been altered by conformational changes induced by the iodination
of their side chains.
The effects of the iodination process could have been monitored by assaying
the iodinated glycoprotein in competition with the original (non-iodinated)
glycoprotein in an anti-gp120 specific radioimmunoassay. In this way, the
comparative specificities of the 2 glycoproteins could have been determined.
In view of these results, and in particular, the variation observed in env
sequences from different patient isolates, it was decided to test all antibodies
with patient samples. Beads for subsequent studies were coated with
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antibodies at the following dilutions: ADP335, 1 in 400; ADP361, 1 in 50;
ADP362, 1 in 50; and ADP403, 1 in 500.
The antibody coated beads blocked with a 5% BSA solution showed a
dramatic reduction in binding capacity for rgp120 (Table 30). This may have
been due to the BSA blocking binding sites of the antibodies, or to efficient
blocking of non-specific binding of iodinated rgp120. Due to the low return of
counts in these experiments it was decided to use antibody coated beads
without BSA treatment for further studies.
9.2 HIV-1 RNA detection by RT-PCR.
9.2.1 HIV-1 RNA detection in patient samples.
Total RNA was extracted, reverse transcribed, and amplified for HIV-1
sequences in 8 samples from 7 patients using a reverse transcription-PCR kit.
Six samples were of cells isolated by adherence from patient PBMCs, 1
sample of patient PBMCs, and 1 patient plasma sample. Samples were
amplified for both pol and env sequences by a nested PCR, and the results
tabulated (Table 31). Only 2 samples were PCR positive for viral sequences,
1 adherent sample (P4a) and the PBMC sample (P7). Both samples had viral
markers indicative of viral activity (P4a was p24 plasma Ag positive, and P7
was positive for both 1 and 2LTR CUVD forms in PBMCs). All other samples
were negative for viral RNA, p24 plasma Ag, and CUVD forms. All samples
amplified without the reverse transcriptase step, and all HIV negative control
samples were negative.
Unlike the detection of HIV-1 DNA, viral RNA is indicative of active viral
replication and may not be detectable in all patient samples (eg. latently
infected individuals, or those responding to chemotherapy). This may explain
why only 2 out of 8 (25%) of samples were HIV-1 RNA positive. In addition to
the lack of RNA in samples, the method of detection may require a threshold
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RNA was extracted from all adherent cells isolated, from 1 x 106 PBMCs, and
from 1ml of plasma. Extracts were scored HIV-1 RNA positive if either pol or
env nested amplifications were positive. p24 Ag, detection of p24 viral core
antigen in patients plasma; CUVD, detection of 1 and 2LTR circular
unintegrated viral DNA in patient PBMCs; and nd, not done. Further details of
patient samples can be found in Appendix V.
All HIV negative controls and non-reverse transcribed controls were negative
(data not included).
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level of RNA considerably higher than the required template concentration
necessary for DNA PCR detection. The RT step is considerably less efficient
than PCR, and so multiple copies of template RNA are required to synthesize
a cDNA template for amplification. It is quite possible that the level of RNA in
the patient samples was below this threshold, particularly in the adherent cell
samples where the number of cells extracted from was not known. The RNA
extracts were also split into 3 fractions (for pol and env amplifications, and for
a viral DNA control) reducing the RNA concentration in each vial and making
detection less likely.
9.2.2 Detection of whole virus RNA from patient PBMC coculture
supernate.
The supernates from positive PBMC cocultures of 2 patients were incubated
with antibody coated beads to assess the ability of the HIV-1 surface
glycoprotein specific antibodies to bind free virus. The beads were coated with
gp120 and gp160 specific antibodies ADP335, 361, 362, and 403 (Appendix
II), and the RNA extracts were processed for the detection of pol and env
sequences by RT-PCR (Table 32).
Samples P11 b and P20b were both PCR negative for viral RNA after
incubation with beads coated with antibodies ADP335, 362, and 403.
However, after incubation with beads coated with antibody ADP361, both
samples were positive for pol sequences, and sample P20b was also positive
for env sequences, demonstrating the antibody's specificity for the viral
surface gp120.
Antibody ADP361 was raised against the recombinant gp120 protein used to
optimise the antibody coating procedure, and so it was decided to concentrate
on developing a technique for extraction of whole virus from patient samples
with beads coated with antibody ADP361.
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Table 32. Detection of whole virus RNA in PBMC cocultures using an

























Details of the antibodies used are given in Appendix II. Antibodies were used
to coat polystyrene beads at dilutions of 1 in 100 for ADP335, 1 in 50 for
ADP361, 1 in 50 for ADP362, and 1 in 500 for ADP403. The beads were
incubated with PBMC culture supernate to bind whole virus, extracted from in
order to release viral RNA from bound virus, and the extracts were then
reverse transcribed and amplified to detect pol and env specific viral
sequences. +, positive; -, negative; antibody coating, specific antibody used to
coat polystyrene beads.
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9.2.3 Quantification of RNA detection by whole virus bead capture.
Anti-gp120 coated beads were used to capture whole virus from dilutions of
titrated viral supernate to determine the efficiency of the viral capture and RT-
PCR methods. The HIV-1RF viral supernate (TCID50 = 107-17/ml, Appendix
III) was assumed to contain in excess of 107 virions per ml (equating to more
than 2x107 RNA molecules per ml). The dilutions utilised represented a
minimum of 6x102 to 6x105 RNA copies per extraction volume (300ul). The
diluted aliquots of supernate were incubated with 2 dilutions of antibody
coated beads (ADP361 diluted 1 in 50 and 1 in 500). RNA was extracted from
the beads which had been incubated with the viral supernate, reverse
transcribed, and amplified for pol specific sequences (Table 33).
Viral RNA was detected at dilutions of 1 in 10 and 1 in 102 after incubations
with beads coated with antibody dilutions of 1 in 50 and 1 in 500 respectively.
All other samples and controls (RPMI and uninfected C8166 cell culture
supernate) were negative. The detection of viral RNA by RT-PCR after bead
capture required a minimum of 6x104 to 6x105 RNA templates.
The requirement for such a high RNA template concentration correlates with
the observation that the HIV-1 RNA concentration in patient samples may be
below the level of detection for this method. Further optimisation of the
technique may elicit an increase in sensitivity and, therefore, improve
detection of virion associated RNA sequences in patient samples.
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Table 33. Quantitation of whole virus capture by anti-gp120 antibody
















Supernate dilution, dilution of viral supernate (TCID50 of 107-17/ml) incubated
with antibody coated beads; RNA templates, number of genomic RNA
templates for reverse transcription based on the assumption that the viral
supernate contained approximately 107 viral particles per ml, and that each
viral particle contains 2 copies of viral RNA; PCR result, detection of viral
cDNA after reverse transcription of bead RNA extracts and amplification with
the pol specific primers (PCR results are given for extracts using beads
coated with antibody ADP361 (Appendix II) at dilutions of 1 in 50 and 1 in
500); +, positive; -, negative. Both RPMI and supernate of C8166 uninfected
cells gave negative results throughout (data not shown).
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CHAPTER 10: HEPATITIS B VIRUS.
The primary aim of this section was to compare the detection of viral antigens
and their corresponding antibodies to the detection of viral DNA in clinical
samples using the polymerase chain reaction. Samples which were HBV DNA
positive, and had been HBsAg subtyped by Mr S.H. Black using a
radioimmunoprecipitation assay (as detailed in materials and methods), were
then subtyped using selective primers for the S-gene determinants. Finally, an
antibody specific bead extraction method was developed to extract viral DNA
selectively from free virus and IgG and IgM complexed virus. A table
containing all the HBV data is given in Appendix I.
10.1 HBs and HBe status of patient serum samples.
Of the 115 patient serum samples included, 89 were HBsAg positive, 20 were
positive for anti-HBs antibodies, and 6 were negative for both markers. Fifty-
eight samples were positive for HBeAg, 37 for anti-HBe antibodies, and 20
were negative for both HBeAg and anti-HBe antibodies. The relationship
between HBeAg and HBsAg was confirmed, as expected from the sequence
of events presented in Figure 4. (Table 34). No statistical analysis was
possible due to the fact that 2 cells of the table were equal to zero.
All control sera were HBe antigen and HBs antigen negative, but were positive
for anti-HBs antibodies due to their vaccination history.
10.2 Detection of HBV DNA in patient serum using a nested PCR;
comparisons with HBe and HBs markers.
HBV DNA was detected in 72 of the 115 serum samples tested (Table 35).
Seventy were HBsAg positive and 2 were positive for anti-HBs antibodies.
When compared with the HBe status of patients, 58 (100%) HBeAg positive,
12 (32%) anti-HBe positive, and 2 (10%) HBe negative samples were positive
for HBV DNA by PCR.
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Table 34. Comparison of HBs and HBe status of patient serum samples.
HBe status
















Total 58 20 37 115
Ag, detection of viral antigen; Ab, detection of antibody specific to the viral
antigen; neg, absence of viral antigen and its corresponding antibody.
From the data it is clear that the presence of HBeAg is closely associated with
the presence of HBsAg, and not with its corresponding antibody. Statistical
analysis was not possible due to at least one cell of the table equating to zero.
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Table 35. Comparison of HBV DNA detection by a nested PCR, with HBs
and HBe status in patient serum samples.
HBe status HBs status
PCR















Total 58 20 37 89 6 20
Ag, antigen positive; Ab, antibody positive; neg, no detectable antigen or
corresponding antibody.
The detection of HBV DNA by PCR was compared to the HBs status of the
patient. Unfortunately, statistical analysis was not possible as not all cells of
the table were greater than zero. However, the data clearly shows that both
HBe and HBs antigens are closely associated with the detection of HBV DNA
in patients' sera.
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Although statistical analysis of the data was not possible, the detection of HBV
DNA was more closely associated with the presence of both HBe and HBs
antigens than with their corresponding antibodies.
10.3 Subtyping of the dand / determinants of HBsAg.
A total of 38 samples had previously been subtyped for the d and / HBsAg
determinants. These samples were then subtyped using a nested PCR, and
12 samples were further subtyped by restriction digest of the amplification
product with the enzyme Sau 3A (PCR-RD). The results of the 3 methods
were compared.
10.3.1 Development of the PCR subtyping method.
HBV DNA positive samples were subtyped for the d and / determinants using
the / specific primers (907E and 394J), and the d specific primer (029H) with
807C as the pairing primer in each reaction.
Preliminary studies showed that the primers 029H and 394J amplified both d
and / specific DNA efficiently (data not shown). The primer 029H had a T:C 3'
mismatch, and 394J a C:A mismatch with the opposite subtype DNA, and
were both able to amplify d and / subtypes of HBV DNA sufficiently for
visualisation on agarose gels. These results were in agreement with the work
by Kwok et a!., (1990) which showed T:C and C:A mismatches to be efficient
at amplifying the target DNA. In contrast, Kwok et at., (1990) demonstrated a
G:A mismatch to be most effective at reducing the amplification efficiency of a
primer. The / specific primer (907E) was selected with a 3' G:A mismatch with
additional mismatches at the second and third bases. The primer pairing of
907E/870C was, therefore, able to distinguish between subtypes d and / by
not amplifying d specific samples sufficiently for ethidium bromide
visualisation on agarose gels. Due to the lack of a d specific primer, d
subtyping was inferred on the basis of a negative result with the / specific
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primer pair. Subtype d samples were often found to have visible primary
amplification bands after the y specific nested amplification reaction. This was
most probably due to the inefficiency of the nested primer pair permitting the
primers transferred with the primary amplification product to continue
amplifying the template DNA. In view of this, negative samples with the y
specific primers were only accepted as true subtype d if the primary
amplification band was visible indicating the presence of amplified viral DNA
(Lane 3, Figure 27).
Due to these preliminary studies, all PCR subtyping reported used the nested
primer pair 870C/907E for the detection of y specific DNA, and d subtyping
was based on a negative result with these primers.
10.3.2 Comparison of HBsAg subtyping by RIPA and PCR.
A total of 38 HBV DNA positive samples had previously been subtyped by
RIPA. Eighteen samples were subtyped band 20 subtyped y. These samples
were then subtyped by PCR using the y specific primer pair 907E/807C for the
nested amplification step.
PCR subtyping of HBsAg was in agreement with 20 (100%) of the RIPA
subtype y samples and 15 (83.3%) of the RIPA subtype d samples (3 samples
(P65, P68, and P71) were subtyped d by RIPA, and y by PCR), giving an
overall correlation of 92.1% for the 38 samples tested (Table 36). To resolve
these discrepancies, it was decided to subtype the samples by a third and
conclusive method. The samples were, therefore, amplified by PCR then
digested by the restriction enzyme Sau 3A (PCR-RD).
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Figure 27. Detection and subtyping of HBV DNA by PCR and Sau 3A
digest.
LANES 12345678
Lanes 1 & 9, DNA VI molecular weight marker (2176, 1766, 1230, 1033, 653,
517, 453, 394, 298, 234/220, 154bp); lane 2, Sau 3A digest of P36 (subtype
d, 548, 431, 321, 227, 204, 117bp); lane 3, subtype specific amplification of
sample P36 a subtype d sample demonstrating the presence of the primary
amplification band (548bp); lane 4, Sau 3A digest of sample P39 (subtype y,
band lengths of 548, 321, and 227bp); lane 5, subtype specific amplification of
sample P39 (band of 350bp); lane 6, nested PCR (235bp), with primary band
showing; lane 7, nested PCR; lane 8, primary PCR band (548bp).
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Table 36. Comparison of hepatitis B surface antigen subtyping by
radioimmunoprecipitation assay (RIPA) and the polymerase chain
reaction (PCR).
Subtyping by PCR
Total No. Subtyping by
of samples RIPA d y
18 d 15 3
20 y 0 20
The 3 samples which were subtype d by RIPA and subtype y by PCR were
further analysed by restriction digest of the primary amplified band by Sau 3A
(PCR-RD), and are presented in Table 37.
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10.3.3 Subtyping of HBV DNA by Sau 3A restriction digest analysis of
PCR products (PCR-RD).
Twelve samples were subtyped by each of the 3 methods (RIPA, PCR, and
PCR-RD). Four of the samples (P36, P43, P46, and P60) consistently
subtyped d by RIPA and PCR, and were included as subtype d controls.
Samples P38, P44, P58, P59 and P73 were similarly included as subtype y
controls, and P65, P68 and P71 were included as test samples.
As predicted from the digest patterns obtained from the GenBank for Sau 3A,
subtype d samples resulted in a total of 6 bands (117, 205, 227, 321, 431, and
548bp), and subtype y samples in 3 bands (227, 321, and 548bp) (Figure 27,
Lanes 2 & 4 respectively). These restriction patterns result from 2 cuts for d
specific samples, and 1 cut for / specific samples (Figure 28).
The nine control samples gave identical results with the 3 subtyping methods,
confirming the predicted digest pattern of Sau 3A. Of the 3 samples with
conflicting results, one confirmed the PCR result (P65, PCR-RD subtype y),
while the other two samples (P68 and P71, both PCR-RD subtype d)
confirmed the RIPA result (Table 37).
10.4 Selective extraction of free virus, and antibody complexed HBV
using antibody coated polystyrene beads.
The method described for selective extraction of HBV DNA from serum was
designed to differentiate between viral DNA associated with free infectious
virus, immune complexed virus, and free viral DNA released from necrotic
hepatocytes. Beads coated with anti-HBs antibodies were used to isolate free
virus, while antibodies against human immunoglobulins G and M were used to
isolate complexed virus. Due to the lack of a suitable extraction method for
naked viral DNA, detection of this form of HBV DNA was dependent on
detection of viral DNA by DNA extraction from sera in conjunction with
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Figure 28. Sau 3A restriction digest patterns of the primary amplification
band of HBsAg DNA (PCR-RD).
d site d&ysite
1bp 117/118bp 321/322bp 548bp
Primary product band
Band length and







The double amplification of HBV DNA with the primary primers (058C/869C)
resulted in the above band of 548bp. The concentration of template DNA was
sufficiently high to prevent complete digestion by Sau 3A, and so the patterns
represent a partial digest. The subtype d specific band resulted in a total of 6
bands (117, 205, 227, 321, 431, and 548bp), and y specific band in 3 bands
(227, 321, and 548bp).
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Table 37. Comparison of hepatitis B surface antigen subtyping by
radioimmunoprecipitation assay (RIPA), the polymerase chain reaction
(PCR), and Sau 3A restriction digest of PCR amplified HBsAg DNA
(PCR-RD).
Subtype determined by:
Patient No. RIPA PCR PCR-RD
P36 d d d
P43 d d d
P46 d d d
P60 d d d
P65 d y y
P68 d y d
P71 d y d
P73 y y y
P38 y y y
P44 y y y
P58 y y y
P59 y y y
PCR subtyping, HBsAg DNA was subtyped by a nested PCR which
selectively amplified DNA of subtype / specificity; PCR-RD, Sau 3A restriction
enzyme digest of HBsAg DNA amplified for 2x25 cycles with the primary
amplification primer pair (058C/869C); RIPA subtyping, the use of subtype
specific antibodies to detect conformational determinants of HBsAg
(Nicholson eta!., 1992).
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negative HBV DNA results from the antibody coated bead extractions
described.
10.4.1 Optimisation of antibody coating of polystyrene beads.
The antibody to HBsAg was initially diluted 1 in 10 to 1 in 100, and incubated
at each dilution with a negative control, 2 concentrations of HBsAg positive
control, and detected by incubation with iodinated anti-HBs antibodies. The
counts returned were very low, and the low level positive control was negative
for all dilutions except 1 in 100 (Table 38).
The antibody was further diluted 1 in 150 to 1 in 600, incubated in duplicate
with iodinated HBsAg (approximately 150,000cpm/ml), and the return of
counts expressed as a percentage of the total available counts (Table 39).
The peak return of counts from the combined results (Tables 38 and 39)
indicated that an antibody dilution of 1 in 150 was optimum.
Anti-human IgG and IgM antibodies were similarly optimised. The antibodies
were assayed directly using iodinated anti-HBc purified from a patient serum
sample. The return of counts were also very low, but indicated that a dilution
of 1 in 150 was optimum for anti-human IgG, and 1 in 500 for anti-human IgM.
10.4.2 Selective extraction of HBV DNA associated with free virus, and
IgG and IgM complexed virus.
To determine the form of HBV DNA present in patient serum, 14 samples
were selected which had tested positive for HBsAg DNA by PCR. Nine
samples were positive for anti-HBe antibodies (P68, P69, P71, P73, P116,
P117, P118, P148, and P149), 4 samples had detectable levels of HBeAg
(P144, P145, P146, and P147), and sample P97 was negative for both viral
markers. All samples were HBsAg positive except for P116 and P117 which
had detectable levels of anti-HBs antibodies.
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Table 38. Determination of the optimum antibody concentration for anti-
HBs antibody coating of beads detected by incubation with 2
concentrations of HBsAg and subsequent detection with iodinated anti-
HBs antibody.
Dilution of Percentage
anti-HBs Counts of counts Result
antibody Sample returned returned
1 in 10 N 51.724 0.2% -
P1 95.232 0.3% +
P2 56.750 0.2% -
1 in 20 N 33.683 0.1% -
P1 183.239 0.6% +
P2 76.570 0.3% +
1 in 40 N 37.207 0.1% .
P1 226.709 0.8% +
P2 70.731 0.2% -
1 in 100 N 30.021 0.1% _
P1 406.979 1.4% +
P2 90.044 0.3% +
N, negative serum control; P1, positive HBsAg control (1ng/ml); P2, positive
HBsAg control (4ng/ml); +, positive; negative. All beads were incubated with
a total of 30000cpm of iodinated anti-HBs antibody (HBsAg positive and
negative controls, and iodinated anti-HBs antibody were supplied as part of a
RIA kit for HBsAg detection, from BPL, Elstree). The cut off was determined
by multiplying the negative mean by 2 (Cut off = 76.318).
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Table 39. Determination of the optimum antibody concentration for bead
coating with anti-HBs antibodies by direct detection with iodinated
HBsAg.
Dilution Counts returned* Result
1 in 150 75% +
1 in 200 57% +
1 in 300 28% +
1 in 400 54% +
1 in 600 21% +
* Two beads were incubated at each antibody dilution and the average counts
returned calculated as a percentage of the total available counts. The cut off
was calculated as described in Table 38; +, positive.
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The 4 HBeAg positive samples each tested positive for free virus and IgM and
IgG complexed virus. This was as expected considering the well documented
association of HBeAg and infectivity. However, 2 samples (P68 and P148)
with antibodies to HBeAg were also positive for each form of HBV DNA,
suggesting that patients can still be infectious despite seroconversion from
HBeAg to anti-HBe.
In total, 9 samples tested positive for whole virus (all HBsAg positive; 4
HBeAg and 5 anti-HBe antibody positive), 8 were IgM complexed virus
positive (all HBsAg positive; 4 HBeAg and 4 anti-HBe antibody positive), and
7 were IgG complexed virus positive (all HBsAg positive; 4 HBeAg and 3 anti-
HBe antibody positive). The 2 anti-HBs/DNA positive samples (P116 and
P117) were negative for each form of virus, suggesting that their HBV DNA
positivity may arise from naked viral DNA released from necrotic hepatocytes.
The results are presented in Table 40.
An example of the results obtained in this way is given in Figure 29. HBV DNA
was extracted from serum samples by incubation with anti-human IgM coated
beads, and detected by PCR (Gel A, Figure 29). The results were then
compared with HBV DNA detection in neat serum extracts (Gel B, Figure 29).
Each patient sample was PCR positive for HBV DNA, but samples 69 and 73
were negative after the anti-human IgM bead extraction (Lanes 2 and 7
respectively, Figure 29). Numerous negative controls were included in each
batch.
10.4.3 Determination of the specificity of antibody coated beads.
The polystyrene beads were designed to bind proteins, and so it was
expected that beads insufficiently blocked would bind non-specifically, giving
rise to false-positive results. To demonstrate this, HBV DNA positive sera from
5 patients (P68, P71, P73, P146, and P147) were incubated with blank beads
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Table 40. HBV DNA amplification results for selective DNA extractions
from patients sera using beads coated with antibodies to HBsAg, and
human IgM and IgG antibodies.
Beads coated with Viral markers
antibodies to in serum
Sample HBsAg human IgM human IgG HBe HBs
P144 + + + Ag Ag
P145 + + + Ag Ag
P146 + + + Ag Ag
P147 + + + Ag Ag
P97 - - - neg Ag
P148 + + + Ab Ag
P68 + + + Ab Ag
P69 + - + Ab Ag
P149 + + - Ab Ag
P71 - + - Ab Ag
P73 + - - Ab Ag
P118 - - - Ab Ag
P116 - - - Ab Ab
P117 - - - Ab Ab
+, positive; negative; HBe and HBs markers of infection; Ag, antigen
positive sample; Ab, antibody positive; neg, no detectable antigen or antibody.
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Figure 29. Detection of HBV DNA by extraction with anti-human IgM
antibody coated beads.
Gel A: HBV PCR results of DNA extracted with anti-human IgM antibody
coated beads.
Gel B: PCR results on total DNA extracted from serum samples.
LANES 1 2 3 4 5 6 7 8 9 10 11 12
Lanes 1 & 12, DNA VI molecular weight marker (2176, 1766, 1230, 1033,
653, 517, 453, 394, 298, 234/220, 154); lanes 4, 6, 8, & 10, negative controls;
lane 2, P69; lane 3, P145, lane 5, P144, lane 7, P73; lane 9, P71; lane 11,
P68.
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and beads coated with: buffer, 5% BSA, and anti-HBs, anti-human IgG, and
anti-human IgM antibodies. The amplification results of these extracts are
presented in Table 41.
False-positive results arising from non-specific binding were demonstrated in
3 of the 5 samples tested (P68, P146, and P147). Although the false-positive
results obtained with blank and buffer coated beads were expected, BSA is a
known blocking agent (eg. hybridization assays) and so the false-positive
results obtained with samples from P68, P146, and P147 raised doubts as to
the specificity of the antibody coated extractions.
To determine the efficiency of the antibodies in blocking non-specific binding,
beads were coated with 2 anti-HIV antibodies (ADP361 and ADP403,
Appendix II), and incubated with sera from patient P68. The amplification
results from these extracts were positive for HBV DNA, indicating that the
antibody coating was not sufficient to block non-specific attachment of
proteins.
Although all 5 serum samples tested were HBV DNA positive, samples from
P71 and P73 were PCR negative after 5 of the 6 bead extracts. If it is
assumed that the antibody coated beads were specific, a possible role of
human IgG in the non-specific interactions observed with other sera might be
suggested, as both P71 and P73 sera were PCR negative for HBV DNA after
anti-human IgG bead extracts. However, if the antibody coatings are assumed
to permit non-specific binding, the results obtained may relate to a
concentration effect.
The non-specific binding observed clearly raises doubts over the specificity of
the antibody coated bead extractions, however, repeated extractions of any
patient's serum gave consistent results irrespective of the pattern of positivity
(at least 10 results in Table 40 were carried out in duplicate or triplicate with
identical results).
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Table 41. Amplification results for HBV DNA extractions with blank
beads, and beads coated with BSA, buffer, and anti-HBs, anti-human
IgG, and anti-human IgM antibodies.
Bead coating
Patient
No. 5% BSA Buffer Blank anti-HBs anti-IgM anti-IgG
P68 + + + + + +
P146 + + + + + +
P147 + + + + + +
P71 - - - - + -
P73 +
The polystyrene beads were coated at room temperature in
carbonate/bicarbonate buffer (pH 9.4), with 5% BSA (fraction V, Sigma),
buffer only, anti-HBs (1 in 150 dilution), anti-human IgM (1 in 500 dilution),




The primary aim of this thesis was to develop the relatively new technique of nucleic
acid amplification, known as the polymerase chain reaction, for the detection of
human immunodeficiency virus and hepatitis B virus in clinical samples. Although
this was already achieved for HIV (Saiki et al., 1985), the application of PCR to HBV
DNA detection was still to be described.
The study progressed to characterise the viral DNA of these viruses and , therefore,
focused on qualitative analysis. No quantitative analysis was attempted due to the
complexities involved. Primers were selected to determine the overall structure of
HIV DNA, including unintegrated linear and covalently closed circular forms, and a y-
specific primer was used to subtype the HBsAg DNA of HBV.
The data from these experiments are discussed in chapters 11 and 12.
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CHAPTER 11: HUMAN IMMUNODEFICIENCY VIRUS.
11.1 HIV-1 isolation by cocultivation of patient PBMCs.
The laboratory diagnosis of HIV is based on the detection of antibodies to core and
envelope proteins by ELISA, and confirmation by alternative ELISAs or Western blot
(Davey & Lane, 1990). Although highly indicative of infection, the detection of viral-
specific antibodies can be misleading. This is most apparent in babies born to
seropositive mothers, where the passive transfer of maternal IgG antibodies gives
rise to false-positive antibody results for the first 12-15 months of the infants life (Mok
et al., 1987; de Rossi et al., 1988; Laure et at., 1988). It has also been claimed that
haemophiliacs may give false-positive results due to the presence of HIV specific
antibodies arising from exposure to inactivated virus in blood products (Schneweis et
al., 1989). Clearly, the detection of antibodies in these 2 groups is insufficient for the
laboratory diagnosis of infection. Also, immunoassays are inappropriate for the
diagnosis of infected individuals in the window period prior to seroconversion, and in
cases where loss of antibody has been reported (Borkowsky et al., 1987; Imagawa et
al., 1989; Wolinsky et al., 1989; Clark et al., 1991; Daar et al., 1991). In these
situations, the direct detection of virus is important to confirm HIV infection.
11.1.1 Isolation from PBMCs.
Virus isolation from PBMCs is a method of direct viral detection from patient blood
but requires considerable time, materials, and expertise (Davey & Lane, 1990;
Coutlee et al., 1991). The standard procedure is to cocultivate patient PBMCs with
stimulated donor PBMCs. The culture supernate is then assayed for the presence of
viral p24 antigen, and/or, reverse transcriptase activity over a period of 28 days
(Ulrich et al., 1988; Nicholson et al., 1989; Stoeckl et al., 1989). The efficiency of
isolation is related to many factors, and so the technique requires careful
optimisation. This is apparent in the range of published isolation rates from 25% to
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100% (Ho etal., 1989; Nielsen et al., 1989).
HWB was processed on a Ficoll-hypaque gradient to recover PBMCs within hours of
sampling. The cells were then cocultivated with 3-7 day old PHA stimulated donor
PBMCs in the presence of IL-2. The cultures were assayed weekly for p24 antigen
production, and all new positives were neutralised for confirmation. The isolation rate
obtained in this way (59%), was comparable with other studies (Stoeckl et al., 1989;
Escaich et al., 1991) although poor in relation to Ho et al., (1989). A number of
factors may have contributed to this. Firstly, cells were not separated on the Ficoll
gradient exactly as recommended by the manufacturer. The heparinised whole blood
was separated without prior dilution so as to facilitate the recovery of neat plasma for
p24 antigen analysis. This may have contributed to a reduced lymphocyte recovery.
Secondly, amphotericin-B was included in the culture medium to control fungal
growth. This has been shown to bind to the steroid component of lipid envelopes and
alter membrane permeability and function, resulting in a loss of infectivity for
enveloped viruses including HIV (Schaffner etal., 1986; Nielsen et al., 1991). Thirdly,
the cell mitogen phytohaemagglutinin (PHA) was used to stimulate both patient and
donor cells (Davey & Lane, 1990). PHA is, however, toxic to cells and is generally
removed from cultures after 1-3 days (Stoeckl et al., 1989). Although PHA was
removed from donor cell cultures prior to cocultivation, patient cells were cultured in
its presence throughout. Each of these factors may have contributed to the sub-
optimal isolation rate observed. Despite these considerations, the technique was
confirmed by neutralisation in 20 out of 34 samples (59%).
Cocultivation of patient PBMCs was used to confirm the infection, and no attempt
was made to quantify the viral load. Patients in the study were, however, confirmed
HIV-seropositives on previous virus isolation, antibody and antigen detection and
clinical presentation. It was, therefore, decided to stop virus isolation by cocultivation
of patient PBMCs as it was an unnecessary usage of patient cells which could
otherwise be utilised for PCR analysis.
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11.1.2 HIV-1 isolation from plasma and heparinised whole blood (HWB).
More recently, isolation methods have been developed for small volumes of plasma
(Coombs et a/., 1989; Ho et al., 1989), and HWB (Bayliss et al., 1989; Fiore et al.,
1990a & b). These methods were attractive due to the small volume of material
utilised for each culture, and in particular to the minimal processing of blood required
for isolation from HWB.
Plasma cultures were set up basically as described by Ho et al., (1989) although
plasma was not ultracentrifuged prior to culture. In addition to this, the exact IL-2
concentration utilised by Ho et al., (1989) was not stated and so IL-2 stimulation was
not necessarily identical. Despite the similarities of the 2 methods the isolation rates
obtained differed considerably (38% in this study, and 100% in Ho et al., (1989).
Although the patients in both studies were from all stages of the disease, patients in
the cohort of Ho et al., (1989) were not receiving anti-viral therapy. In this study, 4
patients were receiving AZT treatment and 4 were not. The 3 patients from whom
virus was isolated were not receiving anti-viral therapy. Although a very small study,
the exclusion of patients on anti-viral therapy would improve the isolation rate to
75%. Coombs et al., (1989) also isolated from plasma at all stages of infection with
an overall success rate of 56%. As with Ho et al., (1989), the study consisted of
individuals not receiving AZT therapy. The main difference in the 2 studies, which
may have contributed to the difference in isolation rates, was that Ho et al., (1989)
isolated virus in small volumes and Coombs et al., (1989) in large volumes. Coombs
et al., (1989) were, therefore, diluting plasma 1 in 6 in comparison with Ho et al., who
diluted from 1 in 1.5 to 1 in 750. In this study, dilutions of 1 in 3 and 1 in 6 were used
in small volumes. It is possible that plasma components are toxic to virus isolation
and that a balance must be achieved between plasma concentration and virus titre.
The isolation rate may, therefore, be enhanced by multiple dilutions and the use of
small volumes which is reflected in the isolation rates of 56% (Coombs et al., 1989),
75% (this study), and 100% (Ho et al., 1989) for patients not receiving AZT therapy.
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Similarly with HWB isolations, published studies either excluded patients on AZT
therapy, or did not comment on its usage within their cohorts (Bayliss et al., 1989;
Fiore et al., 1990a & b). Despite this, Fiore et al., (1990b) demonstrated isolation
from FIWB to be more successful than PBMC cocultivation, particularly in
asymptomatic patients. Although only 1 sample was positive for HWB isolation in this
study, 4 of the other 5 samples were from patients receiving anti-viral therapy at the
time of sampling. This may have contributed significantly to the isolation rate as the
drug will have been present in the sample with potential to inhibit reverse
transcription of the viral genome, and prevent viral replication. Interestingly, both
plasma and HWB results were identical for the 6 samples compared.
Virus isolation techniques have progressed considerably from the initial attempts in
the early 1980s (Barre-Sinoussi et al., 1983; Gallo et al., 1984; Klatzman et al.,
1984a; Levy et al., 1984; Popovic et al., 1984). Modifications to the method showed
that isolation rates from patient PBMCs correlated to disease stage (Stoeckl et al.,
1989; Burke et al., 1990; Davey & Lane, 1990; Ferre et al., 1992). This is in
agreement with the isolation rate obtained in this study, which showed a significant
increase in isolation with disease stage (0.01>P>0.001, Table 10). Subsequent
improvements in PBMC isolation techniques have shown that virus can be isolated
from all groups of patients under the appropriate conditions (Ho et al., 1989). A
similar pattern has now emerged for plasma isolation, where lower isolation rates
appear to reflect the clinical stage (Coombs eta!., 1989; Venet eta!., 1991), while Ho
et al., (1989) have again obtained maximum isolation rates at all stages of infection.
It is, therefore, possible that infected individuals are continually viraemic, varying only
in titre at critical stages. This would be in agreement with PBMC titre results obtained
by Nicholson et al., (1989), which showed viral titres to be greater in individuals who
progressed clinically during the study, while non-progressors had lower and more
stable titres.
The detection of p24 plasma antigen, although insensitive, is thought to be indicative
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of viral activity and to correlate with disease stage (Goudsmit eta/., 1986; Paul etal.,
1987; Borkowsky etal, 1989; Davey & Lane, 1990). When compared with published
isolation rates, the antigen was detected in the plasma of 16% (Stoeckl et al, 1989),
45% (Coombs et al., 1989), and 74% (Ho et al., 1989) of PBMC coculture positive
patients which correlated with virus isolation rates of 45%, 97%, and 100%
respectively. In this study, plasma p24 antigen was detected in 10 out of 41
cocultivated patient samples, 7 of which were isolation positive. This was not
significant when analysed by the Chi-square test (0.50>P>0.10, Table 7). The
apparently low detection rates of p24 Ag could be due to the insensitivity of the
assay, and/or the presence of blocking antibody. The use of the newly developed
immune complex dissociating p24 antigen kits may answer this. Alternatively, it is
possible that antigen detection reflects the in vivo situation more accurately than
patient PBMCs cocultured in vitro.
The ability to isolate virus from PBMCs of all groups of patients raises an interesting
question about the state of the virus in vivo. The isolation of virus in vitro from
asymptomatic patients with no other markers of replication may result from the
successful stimulation of quiescent infected cells, as opposed to enhancement of
existing replicating cells. To demonstrate that viral sequences were present in
isolation negative samples, DNA extracts from 10 cocultures were amplified by PCR
for HIV-1 DNA (Table 11). Three of the samples were culture positive and 7 culture
negative (including a high risk seronegative control). The results indicated that the 9
seropositive samples were HIV-1 DNA positive, suggesting that infected cells had
failed to be stimulated into viral production in the 6 isolation negative samples. A
study by Mathez et al., (1990) addressed this problem by irradiating cells prior to
cocultivation. Gamma irradiation arrests cell division leading to cell death within 3
days. Such cells can continue RNA and protein synthesis, but cannot initiate
synthesis. Therefore, cells actively producing virus in vivo will continue to do so in
vitro, but quiescent cells will fail to be stimulated. Their comparative study revealed a
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5 to 500-fold reduction in virus production from cells irradiated prior to coculture. The
production of HIV in irradiated cells correlated to p24 plasma antigen levels
(P<0.001), demonstrating a correlation with plasma antigen levels and active viral
replication in vivo. The complications of this argument arise when plasma isolation
results are compared. Ho et a!., (1989) isolated virus from 100% of plasma samples
of which only 74% were also p24 Ag positive. Although Ho et at., (1989) do not
describe the vessels utilised in their study, the handling of small volumes for isolation
is most readily achieved by the use of 24 well plates. The use of culture plates,
however, removes the containment offered by individual flasks, and raises doubts
over the possibility of cross-contamination. The incubation of such cultures results in
considerable evaporation and inevitable condensation on the plate lid. It is, therefore,
not possible to guarantee that during the sampling and feeding of such cultures that
the condensation does not cross-contaminate the wells. This hazard requires the
processing of large numbers of negative controls interspersed between patient
samples, a critical step not described in publications of isolation results obtained in
this way (Ho et at., 1989; Fiore etal., 1990a, 1990b).
The disparity in p24 Ag and plasma isolation rates observed by Ho et al., (1989)
may, alternatively, be due to the presence of anti-p24 antibodies blocking detection
of the antigen. Combined analysis of plasma isolation rates, p24 antigen and
antibody titres in a group of patients may resolve this problem.
In conclusion, the isolation of HIV from patient PBMCs does not reflect the replicative
state of the virus in vivo as cells are stimulated in vitro. In contrast, plasma isolation
results from the infection of susceptible donor cells by free virus produced in vivo,
mirroring the in vivo replicative state. The isolation of virus from HWB combines both
cell free virus and the stimulation of cell-associated virus and should, therefore, offer
the most sensitive method. The use of small volumes of HWB not only offers 2
sources of virus, but also requires minimum handling of blood after collection making
virus isolation less time consuming. The only apparent drawback of this method is
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the potential inhibitory effects of toxic cellular components released from lysed cells.
It may, therefore, be the isolation technique of the future for diagnosis, particularly
when only small volumes of blood are available.
Despite the recent advances in virus isolation techniques, the conventional method
remains a time-consuming and costly technique for HIV diagnosis requiring special
laboratory conditions. Unless such methods as HWB and plasma isolation are
streamlined and made cheaper, it is likely that alternative methods will be developed
to overcome these problems for HIV confirmation.
11.2 HIV-1 infection of susceptible cell lines.
The use of established cell lines offers a pure population of susceptible cells for in
vitro analysis of HIV-1 infection. Cell lines have been used to characterise tropism
and growth patterns of clinical isolates (Schuitemaker et al., 1992) and in studies of
the life cycle of HIV-1 (Goto et al., 1988, 1990; Gelderblom et al., 1989; Robinson &
Zinkus, 1990; Stevenson et al., 1990a & b; Stieger et al., 1991; Tang et al., 1992).
In this study, 10 cell lines were infected with the well characterised Haitian and USA
isolates of HIV-1 (RF and NIB respectively). These infections were then used for
electron microscopy studies and analysis of HIV-1 DNA synthesis.
11.2.1 Electron microscopy studies of HIV-1RF viral uptake and release in vitro.
After random collision between a virus and a cell there are 2 main phases in the
uptake of virus; firstly, recognition and attachment of the virus to susceptible cells
and secondly, penetration and uncoating of the virus. HIV-1 recognises cells
expressing the CD4 antigen and attaches via its surface glycoprotein gp120
(Dalgleish et al., 1984; Klatzmann et al., 1984; Lifson et al., 1986). At least one other
mechanism has been proposed in which HIV, complexed with specific antibodies,
attaches via cell surface Fc receptors (Homsy et al., 1989; Jouault et al., 1989;
Laurence et al., 1990; McKeating et al., 1990). Penetration of cells and uncoating of
the virus have been demonstrated to occur in vitro by both the pH-independent
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mechanism of direct fusion between viral envelope and cell plasma membrane (Stein
et al., 1987; Goto eta!., 1988; McClure et al., 1988; Sinangil et al., 1988; Grewe et
al., 1990), and by a pH-dependent mechanism of membrane fusion following
receptor-mediated endocytosis (Goto et al., 1988; Pauza & Price, 1988; Grewe et al.,
1990). Both methods are reported to occur within 10 minutes of incubation at 37°C,
and it has been proposed that the surface glycoprotein gp41 plays a role in the
fusion process (Kowalski et al., 1987; Goto et al., 1988; Grewe etal., 1990).
It was decided to observe the early and late virus:cell interactions using ultra-thin
stained sections of infected cells viewed by transmission electron microscopy.
C8166 cells were inoculated with HIV-1RF at 4°C to allow recognition and attachment
to occur. The temperature was then raised to 37°C to permit viral penetration, and
cells were harvested over 60min to observe the budding process.
Pits and vesicles were observed on micrographs of the early cell sections (Figures
10 & 11). Although these resembled those reported by Goto et al., (1988) and Grewe
et al., (1990), they were not associated with virus and were also present in cell
controls. As the cells were growing in culture at the time of sampling, the pits and
vesicles were most likely involved in nutrient transport (Goldstein et al., 1979).
Due to the lack of evidence for receptor-mediated endocytosis, it may be assumed
that the mechanism of uptake in C8166 cells infected with HIV-1RF was by direct
fusion at the cell surface. However, to synchronise the infection and achieve
maximum viral attachment, the adsorption period was overnight at 4°C. Although this
is thought to inhibit membrane mobility, HIVlav uptake, by direct fusion, has been
reported at 4°C in a T lymphoblastic cell line (Stein et al., 1987). Therefore, due to
the long incubation at 4°C, and the processing time involved to fix the cells, it is
possible that the majority of early virus:cell interactions had occurred and were
consequently not observed.
The mechanism of lentiviral budding has been well studied and documented to the
extent that it is used in the classification of retroviruses (Gelderblom et al., 1989).
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Electron micrographs of infected cells harvested on days 3 to 8 confirmed this
process for HIVRF infection of C8166 cells (Figures 12 to 15). Virus was seen to
assemble at the cell surface. This was associated with a thickening of the cell
membrane, progressing to a horseshoe-like protrusion which eventually closed
releasing the virion. As with Gelderblom, (1991), Gelderblom et al., (1989) and
Katsumoto et ai, (1987), maturation of the cone-like core structure was observed
after budding, however, this has been contradicted by studies of viral mutants which
suggested that core maturation occurred prior to virion release (Goto et at., 1990).
Cells were first viewed for budding virus on day 3, by which time the majority of cells
showed stages of the budding process, suggesting that it started earlier. As cells
were not viewed between 1 hour and day 3, the time at which budding commenced
is unknown.
Direct comparisons of electron microscopy and viral DNA detection results for
infected C8166 cells were hindered by the fact that the cells were inoculated at
different temperatures. However, comparison established that viral penetration and
uncoating had occurred within 2 hours of infection due to the detection of viral DNA.
This supports studies which demonstrated viral penetration to be very rapid at 37°C
(Goto et at., 1988; Grewe et a!., 1990).
11.2.2 HIV-1 cytopathic effects (CPE).
Infection of susceptible cells with HIV-1 can lead to cell death by single cell lysis or
cell fusion (Fauci et at., 1988; Garry, 1989). Single cell lysis may result from excess
budding of virus from the cell membrane, and cell fusion from the interaction of
gp120 and CD4 molecules on the cell surface (Lifson et at., 1986; Sodroski et at.,
1986a; Fisher et al., 1988; Hussey etal., 1988; Dedera & Ratner, 1991).
In this study, cells infected with HIV-1 RF and NIB laboratory strains were observed
daily for the production of syncytia. The initial observation in the IIIB study was that
syncytium formation only occurred in T cell lines in agreement with Shepherd et al.,
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(1992). This led to the total destruction of C8166 and MT4 cultures by day 8. In
contrast, C8166 cells similarly infected with HIV-1RF were not completely destroyed
during the 14 day study, suggesting differences in the cytopathogenic properties of
the viral strains which may be attributable to the envelope region associated with
cellular tropism and syncytium-inducing (SI) capacity (Tersmette et a/., 1988;
Cordonnier et al., 1989; Liu et at., 1990; Westervelt et al., 1991). Of the 6 remaining
syncytia-negative cell lines, 4 were later shown to be HIV-1 DNA positive indicating
the establishment of an infection. These cells were, therefore, infected by HIV-1 mB
but did not produce a visible CPE. This suggests that the virus itself is not solely
responsible for syncytium formation, and indicates a potential role for cellular factors.
Cells grown in serum-free medium are deprived of important growth factors and are
generally retarded in their growth, although the degree to which growth is affected
differs with the cell type. Some cells are completely arrested in the G0 phase of cell
division while others can adapt to divide normally (Chen & Temin, 1982; Yahi et al.,
1991). C8166 cells used in the study were grown in serum-free medium during the
experiment and 3 days prior to inoculation. The effects on cell division were not
determined; however, in contrast to C8166 cells grown in complete medium, serum-
free cells did not form syncytia when infected with HIV-1 RF. This supports the earlier
findings in HIV-1 |NB infected cell lines (this study), and transfection studies using
HXB-2 clones in SupT1 cells (de Jong et al., 1992) which demonstrated that cellular
factors may contribute to the cytopathology of the infection.
11.3 Viral DNA detection in cell lines.
Since the advent of PCR (Saiki et al., 1985) the technique has rapidly become
established as the most sensitive method of detecting HIV-1 infections. To ensure
the detection of multiple isolates, the primers used in the reaction must hybridize to
highly conserved sequences of the genome. The polymerase gene of HIV-1 is used
in such studies (Laure et al., 1988; Simmonds et al., 1990a). We used 4 primers, in a
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nested PCR, for the detection of pol sequences (Appendix IV). These primers had
been extensively used by Simmonds et al., (1990a) to establish their efficacy. The
use of a nested PCR increased the sensitivity of the reaction, and improved its
specificity by requiring the correct hybridization of 4 oligonucleotides to the target
sequence. This method has been shown to detect single copy templates (Simmonds
et a!., 1990a) and has since been applied to clinical quantification studies (Bell et a!.,
1993). The pol primers were, therefore, applied to the detection of total HIV-1 DNA in
sequential crude extracts of infected cell lines.
The detection of HIV-1 DNA by amplification of the pol gene detects all forms of viral
DNA with an intact pol gene (Figure 16), and requires a minimum reverse
transcription of 55% of the RNA genome. Therefore, the earliest time point at which
this amplification was positive for each cell line probably relates to the initial reverse
transcription of the genome, after uncoating, prior to completion of the LUVD
molecule.
Of the 10 cell lines studies 7 were naturally susceptible to infection with HIV-1 (4 T
cell lines & 3 monocytic lines) and 3 had been modified to become susceptible. The
T lymphocyte and monocyte cell lines were all HIV-1 DNA positive for pol sequences
2h post-infection with HIV-1 RF and HIV-1 mB. The other 2 cell lines which became
infected (HB1 and LC5) did not become DNA positive until 8 and 12h post infection
respectively. Therefore, cells which were naturally susceptible to infection started to
replicate virus more rapidly than cells which had been modified to become
susceptible. This may reflect differences in the tropism of the viral strains for different
cell lines, as cellular tropism of HIV-1, related to the env gene, has been associated
with the rate and efficiency of the early stages of viral penetration (Kim et al., 1990;
Srivastava et al., 1991).
The donor PBMCs infected in vitro with HIV-1 RF were first positive for HIV-1 DNA at
2h post-infection. This supports the theory of more rapid viral replication in naturally
susceptible cells. However, HIV-1 DNA detection was not consistently positive in cell
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aliquots until day 2 (Table 15). The percentage of susceptible cells present in donor
PBMCs may be responsible for this result. In the PBMC culture, approximately 40-
70% of the cells were lymphocytes of which only 60% are CD4+. This gives a total of
24-42% of cells susceptible to infection by HIV-1, excluding CD4+ monocytes.
Therefore, with less than half the cells, and possibly as low as a quarter of the cells,
present being susceptible to HIV-1, it will take longer for the virus to infect the
equivalent number of cells observed in T cell line cultures. It is possible that during
the initial harvested aliquots, very few donor PBMCs were infected, and
consequently, not all cell aliquots removed for DNA extraction contained infected
cells. This is supported by the findings of Kim et al., (1989) where HIV-1 infection of
H9 and CD4+ enriched T helper cells showed that full length LUVD was detectable at
4 and 5h post-infection respectively. This showed that the purified cells were infected
at a similar rate to the established cell line.
HIV-1 DNA was detected by 2h post-infection in RF infected C8166 cells grown in
complete and serum-free medium, demonstrating that the initial steps of viral
replication are independent of the state of the host cell. This is in agreement with in
vitro studies with quiescent and stimulated T cells which showed that initiation of
HIV-1 replication occurred at the same time in the 2 cell populations, but that
replication was arrested prior to integration in quiescent cells (Stevenson et al.,
1990b; Zack et al., 1990, 1992).
Comparison of HIV replication in quiescent and replicating cells may elicit
mechanisms by which integration of the provirus can be prevented. This could prove
to be advantageous in the development of therapeutic agents to prevent integration
of UVD in quiescent T cells which are thought to be an inducible reservoir of
infection.
11.3.1 Detection of linear unintegrated viral DNA (LUVD).
Upon entry to the host cell, HIV-1 initiates replication by reverse transcribing its RNA
190
genome to a double stranded DNA molecule. The detection of LUVD is, therefore, an
early indicator of viral infection. The LUVD molecule has successfully been detected
by Southern blot analysis (Pauza & Galindo, 1989; Pauza et al., 1990; Robinson &
Zinkus, 1990; Tang et al., 1992; Titti et at., 1992), however, this lacks the sensitivity
offered by PCR.
To ensure that the DNA detected by PCR is LUVD requires the use of a unique
characteristic of the template molecule. LUVD has no defining sequences or junction
sites, but is unique in that the viral LTRs have free ends (Figure 16b). The molecule
can, therefore, be detected by ligation of a small sequence and amplification from
this sequence to an internal site giving a band of known length (Figure 17b).
This method was developed on early extracts from infected cell lines. Each time
point was amplified in triplicate; one vial containing all reagents, a second vial lacking
the ligase enzyme, and the third vial lacking the ligation sequence. In all samples,
the 2 control vials were negative. Uninfected cell extracts were similarly amplified to
ensure that cellular sequences could not give rise to false-positives. After extensive
replicates of this work it was established that the ligation and amplification method
was specific to the detection of HIV-1 LUVD.
The presence of unintegrated viral DNA (UVD) in non-human retroviral infections has
been found to correlate with cytopathology in vitro and in vivo (Keshet & Tern in,
1979; Temin et al., 1979; Weller et al., 1980; Robinson & Miles, 1985; Mullins et al.,
1986; Hoover et al., 1987). There is now increasing evidence that these forms of viral
DNA are present in HIV-1 infections in vivo. Both linear and circular UVD forms were
first described in the tissue of AIDS and ARC patients (Shaw et al., 1984). More
recently, HIV UVD forms have been detected in patient samples from the brain and
PBMCs, using PCR to amplify from or across unique sequences (Pang et al., 1990;
Bukrinsky et al., 1991; Li et al., 1991; Poznansky et al., 1991; Dickover et al., 1992;
Juriaans et al., 1992). As in other retroviral infections, the presence of UVD has been
associated with secondary infections, or superinfections (Bergeron & Sodroski,
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1992). However, as a maximum of 1% of PBMCs are thought to be infected with HIV,
superinfection of these cells is statistically unlikely, although possible (Bukrinsky et
al., 1991).
To observe the effects of HIV-1 UVD forms on cytopathology, a variety of cell lines
were infected with a known inoculum, and aliquots removed and analysed for
detection and characterization of HIV-1 DNA forms. Four T-cell lines (C8166, Hut 78,
MT4 and Sup-T1) and 6 non-T cell-lines (HB1, HeLa T8+, LC5, THP1, U138MG and
U937) were inoculated with HIV-1 mB to determine the role of cellular factors in the
development of the infection. C8166 cells, in complete and serum-free medium, were
also inoculated with HIV-1 RF to observe differences associated with the viral strain,
and to demonstrate the importance of cellular activation in viral replication and
cytopathology of HIV-1 infection of T cells. HIV seronegative donor PBMCs were
infected with HIV-1 RF for comparison with C8166 cells, and also in view of the
interest in applying the techniques to seropositive patient samples.
The detection of LUVD, particularly in T-cell derived lines, gave an interesting pattern
of detection. The primers used for LUVD detection were specific to the e/ivtermini of
the viral genome. This end of the genome is copied first (Varmus & Swanstrom,
1982), and so as little as 10% of the viral genome was required to be reverse
transcribed for a positive detection by the ligation mediated-PCR. In view of this,
positive results by this method did not relate to the completion of LUVD synthesis,
but gave an indication that the process had started.
The application of this method to sequential extracts of HIV-1 mB infected cell lines
detected viral DNA sequences within hours of infection. In all infected cell lines,
except C8166, LUVD was detected before or at the same time point as total viral
DNA. Although neither method of detection required a completed HIV DNA strand,
the pot primers required 55%, and the ligation mediated-PCR approximately 10% of
the genome to be reverse transcribed. Therefore, LUVD was expected to be
detected before total HIV DNA. The reversal of this in IIIB infected C8166 cells was
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most probably due to the efficiencies of the 2 amplification reactions. PCR is a highly
specific and sensitive detection method, however, the detection of LUVD is limited by
the ligation reaction which is non-specific and consequently inefficient. The detection
of total HIV DNA is, therefore, more sensitive than the ligation dependent-PCR for
LUVD detection.
The appearance and disappearance of detectable LUVD in T cell lines (Table 13)
may have been attributable to a concentration effect taking the level below that
required for the ligation mediated-PCR. Alternatively, the structure of the linear
molecule may be rapidly altered upon completion, preventing detection by this
method. Firstly, the free ends may be modified in preparation for integration. This is
known to involve the removal of 2bp from either end (Pauza et a!., 1990; Vink et at.,
1990; Whitcomb et al., 1990; Hong et at., 1991) and would prevent hybridization of
the ligation and viral specific primer. Secondly, the LUVD may be rapidly circularized
in the absence of integration, preventing ligation and subsequent detection. A third
possibility is that the appearance and disappearance of LUVD represents sequential
rounds of viral infection. This is, however, highly unlikely due to the small time scale
involved. For example, LUVD was first detected 1h post-infection in MT4 cells. The
following time-point at 2h was negative, however, LUVD was again detected at 4h.
This would suggest that HIV-1 had infected and replicated in MT4 cells with a life
cycle of less than 4 hours. The pattern was also not due to sequential infections of
cells with input virus as the cells were washed after the initial 1h incubation. The
pattern of detection in non-T cell lines was much more suggestive of a low efficiency
of detection (Table 14). Only THP1 cells were positive for LUVD on day 1, however,
THP1, U937 and HB1 cells were all strongly positive later when progeny virions had
been produced and were then able to infect more cells.
As expected, the overall data suggested that ligation mediated-PCR was less
sensitive than the standard nested PCR used for total HIV DNA detection. However,
the results from T cell lines also indicated that the initial LUVD molecule is rapidly
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modified upon completion, resulting in the failure to detect it by our ligation mediated-
PCR method. It is unlikely that this is due to instability of the molecule, as dsDNA is
known to be relatively resistant to cellular nucleases (Nandi & Banerjee, 1993).
The detection of LUVD forms in HIV-1RF infected cells differed considerably from the
HIV-1 |||B study. Only C8166 cells in complete medium (on day 14) were positive for
LUVD. Samples from all other time points were negative despite the detection of
LUVD in HIV-1 |NB infected cell extracts used as positive controls. The concentration
of LUVD present in the 2 studies may have differed considerably. This could have
been due to the viral strain, or to the DNA extraction method used. Cells infected
with HIV-1 me were crudely extracted prior to amplification so that PCR aliquots
contained cell debris and culture medium. Cells infected by HIV-1 RF were digested
by proteinase K and N-lauroylsarcosine prior to repeated phenokchloroform
extractions and alcohol precipitation. Therefore, the RF extractions were
considerably purer than those of NIB, although both the extraction and precipitation
steps will have led to the loss of DNA. It is possible that by purifying the DNA extract,
LUVD has been lost, effectively resulting in false-negative results. In view of this, the
apparent differences in detection of LUVD may be due to the viral strain, the
extraction method, or a combination of both.
The primer used to amplify across the ligation and viral sequence junction was
specific to the envelope LTR of the proviral copy of HIV-1. As this end of the genome
is copied first, its detection represents the initiation of reverse transcription. As the
ligation sequence was known to be non-specific, it was decided to amplify the gag-
LTR terminus of the genome in a similar reaction, in an attempt to ascertain the time
point at which LUVD synthesis was completed. The LUVD molecule is known to lose
2bp from either end prior to integration (Bushman et al., 1990; Kulkosky et al., 1990;
Pauza, 1990; Whitcomb et al., 1990; Hong et al., 1991; Lee & Coffin, 1991). It was,
therefore, decided to use 2 primers for the detection of full-length LUVD and the
integration precursor with 2 bases deleted. This method was repeatedly applied to
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extraction aliquots from HIV-1mB infected cell lines. Despite the detection of early
synthesis of LUVD in many of these extracts, the full-length and integration precursor
linear molecules were not detected. Since the method was never shown to detect
completed LUVD it is possible that it failed to detect template present in the extracts
tested. However, the method was a direct copy of that used to detect env-LTR
sequences and should, therefore, have worked similarly. If it is assumed that the
method could detect LUVD, the results indicate that the completed form of LUVD
may be very unstable. This is in keeping with the pattern of detection of LUVD
synthesis observed in T cell lines, where it was proposed that the molecule was
rapidly integrated or circularized upon completion.
Zack et al., (1990) showed that many transcripts in quiescent cells did not complete
synthesis. The observation may reflect the instability of full-length transcripts and
explain why our method failed to detect these forms. However, the failure to detect
these forms in stimulated cells favours the theory that the confirmation of these forms
is rapidly changed, effectively escaping our method of detection.
The use of a variety of primer pairings may have been more useful in monitoring the
rate of LUVD synthesis. This was used by Zack et al., (1990) to measure the extent
of reverse transcription in quiescent T cells. The primers were selected to amplify
progressively later transcript sequences, based on the replication model described
by Varmus and Swanstrom, (1984). The use of such primers would have increased
the sensitivity of detection of LUVD forms by negating the need for the ligation
sequence, and would have given more information as to the rate of progression of
DNA synthesis. This development was, however, not possible due to both time and
financial constraints.
11.3.2 The detection of circular unintegrated viral DNA forms (CUVD).
Early studies on the life cycle of retroviruses proposed that the integration precursor
was a covalently closed circular DNA copy of the RNA genome (Varmus et al.,
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1974a & b; Guntaka et al., 1975; Kakefuda et al., 1977; Shank et al., 1978a & b). It is
now known that the linear reverse transcript is the precursor to integration (Brown et
al., 1987, 1989; Fujiwara & Mizuuchi, 1988; Lee & Coffin, 1991) and so an alternative
role for CUVD was sought.
Analysis of avian retroviral infections elicited a biphasic infection in vitro. The acute
phase was associated with cell lysis followed by chronicity, with little or no cell death
(Battula & Temin, 1978; Keshet & Temin, 1978). Further analysis of these infections
associated the lytic phase with the presence of UVD (Keshet & Temin, 1979; Temin
et al., 1979; Weller et al., 1980). However, despite extensive research of UVD forms,
no direct role in the retroviral life cycle has been determined.
More recently, a link with clinical disease has been demonstrated in vivo. UVD has
been correlated with osteopetrosis in chickens infected with ALV (Robinson & Miles,
1985) but more importantly, it has been implicated in the cytopathogenicity observed
in cats suffering from feline AIDS (Mullins et al., 1986; Hoover et al., 1987). It was,
therefore, decided to develop a method to detect CUVD in infected cells, to
determine if these viral DNA forms play a role in HIV-1 infections in vivo.
The presence of CUVD in HIV-1 infections in vitro was initially described using
Southern blotting techniques (Pauza & Galindo, 1989; Masuda & Harada, 1990;
Pauza et al., 1990; Robinson & Zinkus, 1990). Due to the sensitivity known to be
required for in vivo HIV DNA detection (Simmonds et al., 1990a; Ferre et al., 1992;
Wood et al., 1993) it was decided to develop PCR as a method of detecting both 1
and 2LTR CUVD forms.
HIV-1 has 2 main forms of CUVD which are thought to be products of the linear
transcript. The smaller molecule contains 1 LTR sequence and is formed by
recombination of the 2 LTR sequences, while the larger form contains 2 LTR
sequences and is the product of autointegration (Farnet & Haseltine, 1991). A minor
population of circular forms include defective genomes with internal deletions and
insertions, rearrangements and inversions (Li et al., 1991; Juriaans eta!., 1992).
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The detection of CUVD by PCR was first described in 1990 (Pang et al., 1990;
Pauza, 1990). Primers were used which amplified across the junction sequence of
the circular molecules. Although both studies were able to detect CUVD neither
study was able to discriminate fully between 1 and 2LTR forms.
In an attempt to develop a rapid and highly specific method of HIV-1 CUVD
detection, it was decided to select pairs of primers which were not only specific to
CUVD, but were also able to discriminate between 1 and 2LTR forms. The
development of this method is described in detail in section 7.2.
The detection of 1 and 2LTR forms was complicated by a number of issues. The
primers selected to amplify both 1 and 2LTR forms were largely specific to LTR
sequences. Upon amplification, it was found that these oligonucleotides were priming
cellular in preference to viral sequences, resulting in non-specific amplification bands
(Figure 18). This was due to the universal presence of control sequences in the viral
LTRs and cellular nucleic acid (Starcich et al., 1985). The successful amplification of
cellular sequences may have been due to the abundance of cellular DNA present in
comparison to viral DNA and/or to the resistance of covalently closed circular DNA to
denaturation (Pang et al., 1990; Linz et al., 1990). The amplification specificity was
directed towards viral DNA by increasing the amplification to 3 reactions of 25 cycles,
and by using non-LTR specific primers in the first 2 reactions to bulk-up the
concentration of viral sequences (Figures 20a, b & c). Although tertiary amplifications
increase the risk of cross-contamination, samples were screened for 1 and 2LTR
CUVD forms by this method. The reliability of the data generated was supported by
the lack of contamination in numerous negative controls incorporated.
Despite the efficiency of the method for CUVD detection, the primer selection was
only able to definitively detect 2LTR CUVD forms. The band observed with the 1LTR
specific primers was also generated by 2LTR forms. To overcome this problem, DNA
extracts were re-amplified with alternative primers which hybridized to the gag and
env genes only. In this way, the primers were able to distinguish between 1 and 2
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LTR forms by amplifying the entire LTR sequences of the form resulting in a
significant band length difference for the 2 forms. As the primers detected both forms
in the same reaction it was feared that the primers would preferentially amplify the
shorter sequence. This was not found in practice, suggesting that the nested PCR
may also be an indicator of the proportion of each form present in the given
population (Figure 21).
The technique was initially applied to DNA extracts of cell lines infected with HIV-1
NIB and RF to establish the sequence of events in HIV-1 DNA synthesis, and was
then used to detect the prevalence of CUVD forms in clinical samples.
The detection of CUVD in both 1MB and RF studies was invariably after overall viral
DNA detection, although the time delay differed with the cell line studied. The delay
in T cell lines infected with HIV-1 mB ranged from 1 to 11 hours, whereas some non-T
-cell lines did not have detectable levels of CUVD until day 3, up to 64 hours after
initial HIV-1 DNA detection. This is in agreement with Farnet & Haseltine, (1990) who
■showed that LUVD was detectable by 2h and that CUVD forms were not present until
10h post-infection. The appearance of 1 and 2 LTR CUVD did not follow any obvious
-pattern, but in all but 1 cell line (U937) they were detected within 1 time point of each
ether. A greater delay was observed in the detection of CUVD in RF infected cells,
-although both cultures (complete and serum-free medium) were positive within 1 day
ef each other. This suggests that viral activity was retarded in serum-free cells,
although CUVD forms were synthesized. Careful analysis is required to ensure that
^erum starvation is sufficient to arrest cells completely. This was not carried out, and
-so although slowed down, it is possible that C8166 cells maintain cellular activity
■despite these restrictions. However, the results show that the cells were sufficiently
effected, by serum-starvation, to prevent the formation of syncytia. An interesting
addition to this study would have been to change to complete medium during the
-study to see if the ability to form syncytia was returned.
-n all cell lines, once CUVD forms had been detected they remained present
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throughout the experiment. CUVD was, therefore, either synthesized continuously or
was stable in the cell cultures.
Donor PBMCs were negative for both forms of CUVD until day 14 when, as with all
cultures of RF, both 1 and 2LTR forms were detected simultaneously. The delay in
detection may be due to the small number of infected cells and, therefore, excludes a
direct comparison with C8166 infected cells. A more appropriate comparison would
have been C8166 cells with a purified CD4+ T helper lymphocytes population
(Nielsen etai, 1991).
The appearance of CUVD forms has been associated with cytopathic effects in other
retroviral infections (Keshet & Temin, 1979; Temin etai, 1979; Weller et al., 1980).
The accumulation of CUVD was efficiently blocked by the addition of neutralising
antibody, demonstrating that the build up of CUVD forms was due to secondary or
super-infections (Temin et al., 1979; Weller & Temin, 1981; Chen & Temin, 1982;
Robinson & Zinkus, 1990). The results with cell lines in this study are not in
agreement with the published data, as detection of CUVD did not always correlate
with syncytium formation. Also, cells were infected at a low multiplicity of infection for
1 hour and were then washed to remove free virus. It is unlikely, due to the ratio of
virus:cells and to the time of exposure, that cells would have been infected by more
than one virion. The presence of CUVD, therefore, appears to be attributable to
single infections of susceptible cells. Further experimentation using anti-CD4
antibodies to block cell-to-cell and free virus infection may have supported this
observation. The discrepancies with published studies on other retroviruses may be
due to the insensitivity of their detection methods. Previously, CUVD forms have
been detected by Southern hybridization requiring substantial copy numbers for
detection (Keshet & Temin, 1979; Temin et al., 1979; Weller et al., 1980). In this
study, CUVD forms were detected by sequential amplification with 3 sets of primers,
each round potentially increasing the template concentration by more than 105 (Ou
etai., 1988; Saiki et al., 1988).
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Whether CUVD forms are the product of single or multiple infection events, the
source of viral DNA is of interest. Upon entry to susceptible cells the virus initiates
reverse transcription of its genome which results in the degradation of the RNA
template (Varmus & Swanstrom, 1982) Therefore, for each virion, a maximum of 2
copies of LUVD can be synthesized. Since CUVD exists as 2 forms (1 & 2LTR), and
is most probably present as multiple copies per cell, infected cells must produce viral
DNA by some other mechanism. This could be mediated by cellular or viral DNA
polymerase activity, using LUVD or the integrated provirus as a template.
Viral DNA synthesis from the provirus would be in agreement with Farnet &
'Haseltine, (1990), who showed that CUVD was only detected in the nucleus of
infected cells. However, contradictory to this, CUVD has been detected prior to
integration in some cell line infections (Gowda et al., 1989; Kim et al., 1989). These
studies were based on Southern blot analysis of fractionated DNA extracts and may
disagree due to the difference in copy number and not, therefore, accurately reflect
the sequential synthesis of HIV-1 DNA forms.
The infection of resting T cells in vitro has contributed to the determination of the
source of CUVD forms. Such infections have been shown to result in partial reverse
-ranscripts and/or complete viral DNA forms which were unable to integrate (Gowda
al., 1989; Stevenson et al., 1990b; Zack et al., 1990). Although LUVD synthesis
■vas not affected, the accumulation of CUVD was inhibited (Li & Burrell, 1992). The
-ack of CUVD production in the presence of LUVD synthesis suggests a role for
cellular factors for which TNF-alpha has already been implicated in vitro (Kitamura et
ml., 1993).
■fowever, UVD is seen to accumulate if integration is prevented, suggesting that viral
)NA can be further synthesized from the initial linear DNA reverse transcript
=Stevenson et al., 1990b; Tang et al., 1992). This accumulation has been associated
—vith single cell lysis and the production of p24 antigen, indicating that the LUVD form
-an act as a template for transcription (Pauza et al., 1990; Stevenson et al., 1990a;
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Tang et a/., 1992). The unequivocal detection of integrated proviral DNA may have
helped determine the source of CUVD. However, largely due to the non-specific
integration of the DNA, a satisfactory method of detecting this form by PCR has not
been found.
This study was able to demonstrate the presence of at least 3 UVD forms in HIV-1
infection of a variety of cell lines. Although these forms were not quantified, the copy
number is known to vary among retroviruses and with respect to the host cell. SNV
infection of chicken cells leads to the production of up to 200 copies of UVD per cell
in contrast to infections in rat cells which results in approximately 2 copies per cell
(Keshet & Temin, 1979). Similarly, in vitro infection with HIV-1 produces 20 copies of
UVD in H9 cells, 50-100 copies in Hut78 cells and 80 copies per cell in C8166 cells
(Kim et al, 1989; Robinson & Zinkus, 1990; Li & Burrell, 1992). The differences
observed in detection of viral DNA forms suggests that the virus alone is not
responsible for the formation of UVD forms, or for the overall timing of the viral life
cycle. It would appear that the cell type plays an important role in these events, a
role which may be determined by cellular factors or by the interaction of cellular and
viral factors.
The variation observed may also reflect differences in the life cycles of the 2 viral
strains (IIIB and RF). Isolates have been shown to have different growth
characteristics determined by both the viral env sequence and the host cell
(Tersmette et al., 1988; de Jong et al., 1992; Kuiken et al., 1992; Fouchier et al.,
1992; Andeweg et al., 1993). The IIIB isolate of HIV-1 may be significantly more
adapted for rapid growth than the RF strain, resulting in a higher yield of viral DNA.
This is supported by the detection of CUVD within 2h of HIV-1 mB infection, in contrast
to RF which did not produce CUVD until day 3. Also, some C8166 cells infected with
RF were still viable on day 14, whereas IIIB infected cells died between days 5 to 8,
again suggesting that IIIB is a much more aggressive and cytopathic virus.
Using isolates from clinical samples, HIV-1 strains from patients with more advanced
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disease have shown more rapid and cytopathic infections in a wider range of cell
lines (Cheng-Mayer et al., 1988). These growth properties have been labelled
syncytium inducing (SI) and non-syncytium inducing (NSI) and have been shown to
be a phenotypic characteristic of the viral isolate (Tersmette et at., 1988). Mutational
analysis of viral strains has attributed some of these characteristics to the v/'f gene,
as mutants cause slow and non-cytopathic infections (Sakai et at., 1991). More
recent studies have shown that sequence variation in the V1-V2 and V3
hypervariable domains of the envelope gene can induce the SI phenotype in
transfection studies (Andeweg et al., 1992; Fouchier et al., 1992; Kuiken et at.,
1992).
Two of the susceptible non-T cell lines gave interesting HIV-1 DNA patterns. Firstly,
the glioblastoma cell line (U138MG) could not be infected with the IIIB strain of HIV-
1, demonstrating that not all viral isolates can infect all HIV-1 susceptible cell lines.
Gartner et al., (1986) also found the IIIB strain to be 10000-fold less able to infect
macrophage lines than T cell lines. Secondly, the embryonic lung fibroblast line
(LC5), although infected by HIV-1, failed to produce detectable levels of UVD
throughout the experiment. LC5 cells, therefore, appear to demonstrate true latency
in this experiment. An important continuation of this work would be to repeat the
study with other viral isolates, and look for patterns of UVD which may reflect viral or
cellular control factors. In this way, it may be possible to obtain more cell lines which,
like LC5, appear to become infected but are able to control the infection. It is
possible that careful analysis of the biochemistry of such cell lines could reveal
modulating factors which could be adopted therapeutically.
The progression of this work should include quantification studies to determine
whether or not these forms coexist in individual cells or are mutually exclusive forms
which are all derived from LUVD. If the latter was true, the induction of CUVD
formation may prove to be of therapeutic value in the prevention of proviral
integration. The build up of CUVD has been associated with TNF-alpha induction
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(Kitamura et al., 1993), however, in line with other retroviral infections it is more likely
that these viral DNA forms are cytopathogenic (Weller et a/., 1980; Weller & Temin,
1981; Chen & Temin, 1982; Mullins etal., 1986; Hoover et al., 1987).
However, despite some associations with persistent infections in vivo (Rasty et al.,
1990), the accumulation of UVD has largely been correlated to cytopathology in HIV
and other retroviral infections (Keshet & Temin, 1979; Temin et al., 1979; Pauza et
al., 1990; Bergeron & Sodroski, 1992). It was, therefore, postulated that infection of
quiescent T cells in vivo may lead to the accumulation of UVD as observed in vitro
(Stevenson et al., 1990b). A possible consequence of this is that all T cell stimulants
may potentially induce HIV DNA integration and viral production leading to an
increase in the number of infected cells and HIV-associated cell death.
In view of this, it was decided to determine the frequency of detection of CUVD forms
in patient PBMC samples, and to attempt to correlate these findings with clinical
markers of HIV infection.
11.4 Detection of HIV DNA in patient PBMC samples.
All patient samples were initially tested for the presence of HIV pol and env DNA
sequences using a nested PCR. In this section, PCR was initially developed to
confirm HIV-1 infection in seropositive patients diagnosed by ELISA and Western
blot. The technique allowed the rapid detection of viral DNA from PBMCs
demonstrating the presence of a product of viral replication.
The pol gene is highly conserved among HIV clinical isolates and is, therefore, the
preferred sequence for amplification to detect DNA in the majority of patient samples.
In contrast, the env gene contains variable regions which have been sequenced and
characterized using PCR (Hahn etal., 1986; Starcich et al., 1986; Saag etal., 1988;
Simmonds et al., 1990b; Wolfs et al., 1990). The primers used for pol and env
detection were those of Simmonds et al., (1990a).
HIV-1 DNA sequences were detected by pol and/or env amplification in all 32
203
seropositive patients, although 2 of the 61 samples from these patients gave a
negative result. The most plausible explanation for this is the absence of template in
the amplification aliquot. Amplifications were carried out on DNA aliquots ranging
from 7x103 to 1x106 cell equivalents. Published quantifications of HIV load indicate
that the limit of detection may be as high as 4 to 8x104 cells, it is possible, therefore,
that some of the aliquots used in this study were inadequate (Simmonds et al.,
1990a; Srugo et at., 1991).
11.4.1 Observation of variation in the envgene.
Analysis of sequence variation in the envelope gene was not studied, however, after
amplification with env-specific primers, band length variations were detected by
agarose gel electrophoresis. The band length varied by a minimum of 20-40 bases,
and variation was observed between patients, in sequential samples from individual
patients, and in nuclear and cytoplasmic extracts from single patient samples. This
was in agreement with published data on the env gene, which show considerable
sequence variation among and within patient samples (Meyerhans et al., 1989; Balfe
et al., 1990; Nowak et al., 1990; Pang et al., 1991; Simmonds et al., 1991). This
variation is thought to contribute to cellular tropism (Cheng-Mayer et al., 1990, 1991;
Liu et al., 1990; York-Higgins et al., 1990; Cann et al., 1992), the ability to infect cells
in different biological compartments of the body such as the blood and cerebrospinal
fluid (Liu et al., 1990; Pang et al., 1991; Steuler et al., 1992), and in viral uptake and
cytopathogenicity (Dalgleish et al., 1984; Klatzmann et al., 1984; Fauci, 1988; Garry,
1989). Some studies have shown a direct correlation between genetic diversity and
more progressed disease, whilst others have not (McNearney et al., 1990; Wolfs et
al., 1990).
Despite the extensive variation observed in the envelope gene, it is important to keep
a perspective on the significance of these results. PCR amplification will occur if the
primers bind, and cannot distinguish between infectious and non-infectious
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sequences. To analyse significant variation would, therefore, require a purification
step to isolate infectious sequences prior to amplification. This could be achieved by
total RNA extraction of filtered plasma, or by antibody mediated extraction of whole
virus RNA from clinical samples.
11.4.2 Detection of LUVD in seropositive patient PBMCs.
No linear UVD was detected in extracts of patient PBMCs. Since LUVD was not
detected in all cell line studies, and in particular in the synchronised infection of
donor PBMCs, the lack of detection in vivo was anticipated. Detection of LUVD in
vivo is unlikely, due to the lack of synchronizations of the infection, and the small
percentage of actively infected cells at any one time (Mathez et al., 1990). It has
been estimated that between 0.01 and 1% of patient PBMCs are infected with HIV
(Psallidopoulos et al., 1989; Schnittman et al., 1989). Additionally, only a small
fraction of the cells are actively producing virus at a given time (Harper et al., 1986).
The infected cells which are not transcriptionally active may be quiescent T cells
which are thought to require activation for viral production (Gowda et al., 1989;
Stevenson et al., 1990b; Tang et al., 1992). However, the detection of LUVD might
have been enhanced by increasing the amplification aliquot and by removing high
molecular weight DNA which may have reduced the efficiency of the reaction. The
lack of detection was, however, not due to technical difficulties as LUVD forms were
detected, by this method, in cocultivated cells of clinical isolates and extracts of
infected cell lines.
11.4.3 Detection of CUVD forms in seropositive patient PBMCs.
Due to the time constraints of this study, analysis of CUVD forms in clinical samples
was cross-sectional. CUVD forms were detected in 34 of the 52 samples tested,
relating to a total of 32 patients (15 positive for CUVD forms in sequential sample; 12
patients consistently negative; and 5 patients positive and negative in different
PBMC samples). One patient (samples P12a & P12b) was positive for both 1 and 2
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LTR forms over a period of 16 months. As found in infected cell lines in vitro, the
apparent persistence of CUVD forms may be attributable to prolonged synthesis or
to their stability in infected cells. One patient had detectable CUVD forms although
the 2 LTR CUVD amplification resulted in a strong positive band (approximately
400bp) slightly smaller than the expected band of 447bp. Although further analysis
was required, it was postulated that the band was due to aberrant forms of 2 LTR
CUVD as described in published findings (Li et al., 1991; Juriaans et al., 1992).
Longitudinal analysis was possible in some patients where samples had been
collected over a period of months. Sequential samples from 2 patients (P19 & P28)
converted from CUVD negative to positive over 8 and 3 months respectively, with
patient 28 still positive 5 months later. More interestingly, 2 patients lost detectable
levels of CUVD. Patient 23 was positive in sample P23a, but was negative 2 months
later (P23b). However, this may have been a false-negative result as the
amplification aliquot used was negative for env sequences despite the previous
sample (23a) being env positive. The second patient, (P17), was CUVD positive for 2
sequential samples 2 months apart (P17a & P17b) and was negative for the third
sample (P17c) 2 months later. The loss of CUVD forms is contradictory to their
continual synthesis and/or stability in PBMCs. Interestingly, the loss of CUVD forms
was associated with a drop in CD4+ cell counts from 240 to 100 cells per millilitre
over the 4 months. The loss of CUVD was, therefore, associated with cell death as
observed in retroviral infections of cell lines in vitro (Keshet & Temin, 1979; Temin et
al., 1979; Weller et al., 1980).
Although this study has clearly demonstrated an association between CUVD forms
and disease stage, an extensive longitudinal study is required to determine if these
viral DNA forms are related to disease progression. The study would ideally follow
patients over a period of 5-10 years, with sequential samples tested for viral DNA
and RNA populations as well as surrogate markers of viral replication and disease
progression. The study would also have to determine the effects of anti-retroviral
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therapy. Statistical analysis of the data reported here showed a correlation of AZT
therapy with the detection of CUVD forms. Published data on quantitative analysis of
UVD in patients on antiviral therapy showed a considerable reduction in UVD copy
number after therapy (Dickover et at., 1992). Although no discrimination was made
between linear and circular forms, this is contradictory to the findings of this study in
which a significant correlation between CUVD forms and AZT therapy was found.
This could be due to the common association of AZT therapy and CUVD forms with
more advanced disease, and/or to the lack of quantitation of the circular forms in this
study.
The decrease in UVD observed by Dickover et a!., (1992) was accompanied by an
increase in integrated viral DNA. From other studies (Gowda et at., 1989; Stevenson
et at., 1990b; Zack et at., 1990; Tang et a!., 1992), these results suggest that the
antiviral therapy may be stimulating infected quiescent T cells resulting in the
integration of UVD transcripts. Due to the requirement of integration for retroviral
replication, this is a highly undesirable action of an antiviral drug. Since most drugs
act on the viral polymerase, the increase in integrated copies will facilitate the
production of more infectious virus. This in turn may lead to infection of more
susceptible cells, and enhance the emergence of drug resistant virions.
All patients analysed for CUVD forms had received AZT therapy. The average time
of therapy for CUVD negative samples was 3 months (range 1-7) as opposed to
CUVD positive samples which had an average of 9 months (range 1-23). It is,
therefore, possible that fluctuations of CUVD levels did occur but were not detected
due to the lack of quantitation of these results. In vitro studies have also shown AZT
therapy to reduce the copy number of UVD in cells, although this was observed to be
a transient effect which returned to near baseline levels by 3 days post treatment
(Pauza et ai, 1990). Unfortunately, levels of integrated DNA were not monitored.
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11.4.4 Viral DNA forms in nuclear and cytoplasmic extracts of patient PBMCs.
In trying to ascertain a role for CUVD in the life cycle of HIV-1 replication, it is
important to determine the localization of these forms. Hybridization studies
established that both 1 and 2 LTR forms were only present in nuclear extracts of cell
lines (Kim et ai, 1989; Farnet & Haseltine, 1990). To investigate further, nuclear and
cytoplasmic extracts were prepared from patient PBMCs to determine the
localization of CUVD forms in vivo. The technique required gentle lysis of the cell
membrane, leaving the nucleus intact to allow separation of the nuclear and
cytoplasmic DNA extracts.
CUVD forms were detected in cytoplasmic extracts in 5 out of 7 patients tested, in
direct contrast to the findings of Farnet & Haseltine, (1990). Although great care was
taken to avoid disrupting nuclei prior to cytoplasmic separation, it was possible that
nuclei were lysed releasing UVD into the cytoplasmic extract. Although this
contamination would have been acceptable for hybridization analysis, it may have led
to the false detection of HIV-1 sequences, by PCR, in cytoplasmic extracts.
Both nuclear and cytoplasmic extracts of some patients were positive for viral DNA
but negative for CUVD forms. This could be due to the difference of amplification
efficiencies of the po/-and CUVD-specific primers. The po/primers have been shown
to be highly specific and efficient at amplifying viral sequences in both this study and
by Simmonds et a!., (1990a). In contrast, the primers for CUVD detection have
clearly been shown to be both viral and T-cell specific in this study, and so their
amplification efficiency for viral CUVD detection will be reduced. It is, therefore,
possible that CUVD forms were detected by the po/-specific primers and not by the
CUVD-specific primers. This would account for the absence of CUVD forms in HIV
DNA positive cytoplasmic extracts. Alternatively, the detection of viral DNA in the
cytoplasm may have been due to the presence of LUVD. Similarly, the detection of
viral DNA in nuclear extracts may have been due to the detection of linear or circular
forms, but will also have included the detection of integrated provirus. However, due
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to the lack of a discriminating method of integrated proviral detection, it was not
possible to prove this.
11.5 STATISTICAL ANALYSIS OF DATA.
11.5.1 Correlation of the detection of CUVD forms with other markers of
infection.
The detection of CUVD forms was analysed to correlate their presence with other
viral markers and the patient's disease stage. The study was cross-sectional due to
the small number of sequential samples from individual patients, and so the data
could only be used to correlate markers to disease stages and not to disease
progression which would have required a longitudinal study. Due to the slowly
progressive nature of HIV infection, such a study would have required data collected
over a period of 5-10 years which was clearly beyond the scope of this study.
The detection of CUVD was compared with virus isolation, p24 antigenaemia, total
CD4+ cell counts, AZT antiviral therapy, and the patients CDC grouping. Statistical
analysis was by the Chi-square test, and the Yates "correction for continuity" was
applied to compensate for the small number of samples (Swinscow, 1991).
The detection of CUVD forms was statistically significant in samples from patients
receiving antiviral therapy, and from patients with more advanced disease. The
interpretation of this data was difficult because of the known association of various
markers with disease stage. For example, it seemed unlikely that patients receiving
antiviral therapy would be more likely to have a build up of CUVD forms in the
peripheral blood when the action of the drug is to terminate reverse transcription of
the viral genome. In an attempt to clarify the situation, a similar comparison was
made between viral markers and CDC groups. Significant associations were
demonstrated with virus isolation, p24 antigenaemia, and the use of antiviral therapy.
Therefore, the association of AZT therapy with CUVD detection may be attributable
■to the fact that both these factors correlate with more advanced stages of the
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disease.
The lack of correlation between some markers may have been due to the small
sample sizes analysed. Sufficient data could not be generated in the time available,
and so it was decided to expand the data by multiplying by a factor of 2 or 3 to obtain
a minimum of 100 results. The analysis of this data was not intended to be used in
place of the genuine results, but merely as an indicator of the possible associations
had the raw data been more extensive.
Once re-analysed, significant correlations were established between CUVD detection
and CD4+ cell counts of less than or equal to 200, and p24 antigenaemia. Similarly,
a correlation was established between more advanced disease and p24
antigenaemia. Due to these associations with disease stage, it is difficult to
determine if CUVD detection is correlated to other markers of infection, or if the
associations observed are artifacts of the common association with a more advanced
disease stage.
Expansion of this data on more clinical isolates is required to substantiate the results.
However, from the data obtained, the significant association of CUVD forms and
more advanced disease stage suggests a potential role for these DNA forms in the
cytopathogenicity of HIV-1. This is in agreement with recent studies in feline AIDS,
which have shown UVD forms to be associated with clinical disease (Mullins et al.,
1986; Hoover etal., 1987).
11.6 DETECTION OF HIV-1 INFECTION IN PERIPHERAL BLOOD
MONONUCLEAR CELL SUBSETS.
T lymphocytes are known to be the primary site of infection in PBMCs, HIV-1
infection of these cells alone does not explain the complex immunodeficiency
observed in seropositive individuals with advanced clinical disease. To understand
the pathology of the disease, and also for the development of therapeutic strategies,
it is important to know which cell types are infected and subsequently affected by
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HIV-1 infection.
HIV infects T helper/inducer cells via the CD4 surface marker, and so other cells
expressing this antigen have been assayed in vitro for their susceptibility to infection.
Monocyte/macrophage cells express a low copy number of CD4 antigens on their
surface and so these adherent cells have been separated and inoculated with
laboratory strains of HIV-1 (Wood et al., 1983). In vitro studies showed that blood
monocyte/macrophage cells were susceptible to HIV, demonstrating a less
cytopathic and more persistent infection than seen in CD4+ T cells (Gartner et al.,
1986: Ho et al., 1986, 1992; Nicholson et al., 1986; Salahuddin et al., 1986;
Koyanagi et al., 1988; Kazazi et al., 1989). Further in vitro studies have shown that it
is possible to infect other antigen presenting cells such as alveolar and peritoneal
macrophages (Salahuddin et al., 1986; Olafsson et al., 1991), brain glial cells
(Cheng-Mayer et al., 1987; Christofinis et al., 1987; Dewhurst et al., 1987; Kunsch et
al., 1989) and dendritic cells (Patterson & Knight, 1987).
Cells deficient in CD4 antigen have also been infected via uptake mechanisms
involving Fc receptors and other undefined modes of entry. In this category are
epithelial cells, lung fibroblasts, chondrocyte cells, synovial cells, foreskin fibroblasts
(Ikeuchi et al., 1990), CD8+ T lymphocytes (de Maria et al., 1991), B cells (James et
al., 1990) and natural killer cells (Chehimi et al., 1991).
However, the ability to infect cells in vitro says little about the role they play in the
infection in vivo. Studies on visna-maedi lentiviral infections in sheep have
demonstrated viral tropism for monocyte and macrophage cells, and a source of
persistence in precursor cells in the bone marrow (Gendelman et al., 1985). This was
an important development to the understanding of the mode of viral persistence in
sheep, as differentiated macrophages were known to have a short life-span and
were, therefore, unlikely candidates for the long term maintenance of infection
(Gendelman et al., 1985; Potts et al., 1990; Spear et al., 1990). FIV sequences have
=also been detected in bone marrow tissue in naturally and experimentally infected
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cats (Beebe et al., 1992). A similar role in persistence may be found for human
macrophages in HIV-1 infections, as bone marrow progenitor cells have been
infected with HIV-1 in vitro (Folks et al., 1988; Steinberg et a!., 1991). It is important
to examine if these cell subsets are infected in vivo to establish their role in the
persistence and dissemination of the disease.
11.6.1 Separation of peripheral blood mononuclear cells into cellular subsets
for PCR analysis.
Monocytes and macrophages are well documented as being targets for persistent
HIV in vivo (Gartner et al., 1986; Ho et al., 1986; Koenig et al., 1986; Nicholson et al.,
1986; Tschachler et al., 1987). The viral tropism for cell subsets is determined by the
surface glycoproteins encoded for by the envgene, and is associated with the rate
and efficiency of the early stages of viral entry into the cell (Cordonnier et al., 1989;
Cheng-Mayer et al., 1990, 1991; Kim et al., 1990; Liu et al., 1990; York-Higgins et
al., 1990; Hwang et al., 1991; Srivastava et al., 1991; Westervelt et al., 1991). Viral
isolates have been recovered which show selective tropism for CD4+ lymphocytes
and monocytes. Monocytic isolates generally replicate more slowly with little cell
pathology, and T-cell tropic strains replicate rapidly and form syncytia (Tersmette et
al., 1988; von Briesen et al., 1990; Liu et al., 1990; Schuitemaker etai, 1991, 1992).
The monocytic, or non-syncytium inducing (NSI) isolates, are more frequently
isolated from asymptomatic patients, and SI isolates are more often recovered from
AIDS/ARC patients (Tersmette et al., 1988, 1989; Schuitemaker et al., 1991, 1992).
In a study by Gendelman et al., (1988) macrophage-tropic strains were isolated from
most patients, and up to 90% of cells demonstrated infection as determined by RNA
detection and electron microscopy. Despite this level of viral activity, budding was
rarely seen from the cell membrane (Dahlberg et al., 1981; Lairmore et al., 1987;
Orenstein et al., 1988). HIV infection of monocytic cells was also observed to differ
from lymphocytic cells in that viral surface glycoproteins were only observed in the
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cytoplasm of monocytes, but were detected in the cytoplasm and on the cell surface
of infected lymphocytes (Potts et al., 1990). This supports the theory that lentiviral
infections of monocytic cells can act as "Trojan horses", by avoiding immune
surveillance thereby contributing to the persistence and dissemination of the infection
(Gendelman et al., 1985; Haase, 1986; Potts etal., 1990).
To determine the extent of monocytic cell involvement in the in vivo infection, it was
decided to separate monocytic cells from patient PBMCs, and to analyse their viral
DNA content by PCR.
Preliminary studies separated the cells utilising the ability of monocytic cells to
adhere to plastic. PBMCs separated from HWB on a Lympho-paque gradient were
incubated for 3 days to allow adherence of cells. Although a short incubation of
45min would have been sufficient for attachment, cells were left for 3 days to allow
non-monocytic cells to detach.
Monocytes from 11 patient PBMC samples were separated by this method. The
samples represented patients from all stages of infection (3 from CDC II; 7 from CDC
III; and 1 from CDC IV) although the number of samples tested was insufficient for
detailed analysis. Samples from ten of the patients (all except P28) had been
amplified by PCR for HIV-1 DNA sequences in PBMC DNA extracts, and 9 were
positive for aliquots equating to 2-4x104 cells (Appendix IV). Patient 25 (sample
P25a) was negative for HIV-1 DNA in an aliquot of 4x104 PBMCs, although a sample
from the patient taken 9 months later was PCR positive (aliquot 2x105 cell
equivalents).
HIV-1 DNA was detected in adherent cell extracts in 5 of these patients. This
suggests that adherent cells of the peripheral blood are infected with HIV in some
patients. However, the detection of HIV-1 DNA may have been due to the presence
of contaminating CD4+ cells. Published studies of cell separation by adherence
alone claim purities in excess of 90% (Pennline et al., 1981). Although this can be
improved to >99% by the addition of 20-40% serum to the culture medium to reduce
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B cell contamination, and by removing contaminating lymphocytes by complement
mediated lysis, the separation is still based on non-specific selection (Gartner et al.,
1986; Spear et al., 1990). HIV has been detected in patient peripheral blood
monocyte/macrophage cells by isolation and by PCR detection of viral sequences
(Ho et al., 1986; Psallidopoulos et al., 1989; Schnittman et al., 1989; Spear et al.,
1990). In these studies, separation of the cells from PBMCs generally involved 2
purification steps. Adherence was most commonly used followed by complement
mediated lysis of residual contaminating cells resulting in purities of 96% to 99%
(Nicholson et al., 1986; Gendelman et al., 1988; Psallidopoulos et al., 1989;
Schnittman et al., 1989; von Briesen et al., 1990; Gendelman et al., 1990; Spear et
al., 1990). Despite these claims of high purities, any contamination by CD4+ T helper
cells may have resulted in false detection of viral sequences.
To improve the purity of cell preparation, and to expand its application to other cell
subsets, an alternative separation technique was sought, based on the detection of
surface antigens characteristic of the cell subsets. To achieve this, sets of
commercially available antibody-coated magnetic beads were used to capture
monocytic cells as well as T helper/inducer, T cytotoxic/suppressor and B
lymphocytes.
There were 2 main approaches available for the antibody-coated Dynabead
separation of patient PBMCs. Firstly, cells could have been fractioned into equal
aliquots and each incubated with a different specificity of Dynabead. However, this
method reduced the number of each cell type available for separation, and would
have resulted in CD4+ monocytes being removed with T helper/inducer cells. Patient
samples were, therefore, separated by the alternative method of sequential
incubations with the 4 different antibody coated Dynabeads. Cells were initially
incubated with anti-CD19 coated beads, as B cells were the least abundant cell type
to be removed. CD14+ cells were removed next, to reduce the contamination of the
CD4+ T cell subset with monocytes expressing the CD4 antigen and finally, CD8 and
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CD4 positive cells were removed. The main drawback of this method was that any
microspheres transferred with the remaining cells, could potentially contaminate the
next cell separation.
The microspheres were mixed with cells at a ratio selected to obtain maximum purity
by positive selection, and to reduce the possibility of complex rosette formation
between the cells and beads. The formation of rosettes would have resulted in a high
percentage of the target cells being removed, but would also have complicated
further analysis of the cells by inhibiting interactions with cell surface markers and by
physically blocking the delivery tip of the EPICS machine. However, this
phenomenon may have been observed with samples isolated by anti-CD8, anti-
CD14, and anti-CD19 coated beads.
The FACS analysis of the cells separated by Dynabeads proved very difficult to
interpret. The general fluorescence patterns observed for sorted cells depicted mixed
cell populations with low labelling efficiency. Analysis of the appropriate bead and
cell controls showed that the magnetic microspheres did not contribute to the non¬
specific binding, but did reveal the labelling procedure to be inefficient. Unfortunately,
due to time constraints, it was not possible to develop this method further.
However, from the data obtained from these preliminary studies, it was clear that
existing single-step separation techniques were inadequate for further analysis by
PCR. From the known sensitivity of PCR as a detection method, 100% purity is
required. Although a simple and rapid method was desirable, the application of a 2
step separation technique was required to obtain a higher purity for PCR analysis.
Monocytic cells could, therefore, be separated by adhesion over a short period of
time followed by antibody specific binding to Dynabeads. Pure samples of CD4+ and
CD8+ cells would be most readily achieved by separating T lymphocytes and
depleting the sample of all undesired subsets by complement mediated lysis.
The antibody-coated Dynabeads have been used for the separation of cell subsets in
■published studies. Brinchmann et al., (1988) claimed to have separated B and T cells
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to a similar degree by FACS and antibody-coated Dynabeads. However, the purity of
cells separated by the beads was not proven as the comparison was made on a
quantitative basis. The cells attached to the beads were gently lysed and the
released nuclei were subsequently counted and compared with the FACS data. In
contrast, Gaudernack et at., (1986) separated CD8 positive cells from PBMCs and
demonstrated a purity of 95-97% of CD8+ cells with 1-5% contamination with CD4+
cells, and Folks et al., (1989) separated CD34+ myeloid progenitor cells from bone
marrow with a purity of 99-100% as determined by immuno-staining and flow
cytometry. The use of commercially available Dynabeads can be a highly specific
and rapid method of cell separation. The purity of the product can be improved by
careful handling and by the specificity of the coating antibody. The separation of cell
subsets in this study was unsatisfactory due to the inability to demonstrate the purity
of the sample. This may have been due to the use of an inappropriate method of
analysis as the Dynabeads may have inhibited the attachment of labelled antibodies,
and also changed the properties of the cells as analysed by the EPICS machine.
However, despite the high purities achieved by other researchers (Gaudernack et al.,
1986; Folks et al., 1989), the method was not fully suitable for PCR analysis.
Despite doubts over the purity of samples obtained by immunomagnetic selection,
cell subsets were separated from PBMCs of patient 20 (sample P20c) using anti-
CD14 antibody coated Dynabeads. The DNA extract from the purified cells was
positive for HIV-1 DNA after PCR amplification, in agreement with the adhesion
separated cell results for a sample from the same patient taken 9 months earlier
(P20b). Although the purity of the cell preparations was not established, 6 of the 12
patient samples tested were PCR negative for HIV-1 DNA. These patients were all
positive for viral sequences in PBMC aliquots and, therefore, demonstrate the
selection of an HIV-1 negative cell subset. If the cell samples analysed are assumed
to be pure, the results clearly show that HIV infects monocytic cells in some, but not
all patients. This may relate to the pathology of the disease, to viral markers (eg. p24
plasma antigen, UVD), or to the clinical stage of the disease (CDC groups).
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Unfortunately, analysis of these associations was not possible due to the small
sample size.
Although cells were not quantified, it was clear that the total number of cells
separated from some patients was small. The negative results could, therefore, have
arisen from the absence of any infected cells due to inadequate sample size. The
importance of aliquot size was further illustrated by the detection of HIV-1 DNA in the
adherent cell extract of patient 25. This sample had previously been tested negative
for viral DNA in an extract equivalent to 4 x 104 PBMCs. Although this could have
ceen a quantitative effect, the patient may have harboured an NSI isolate which was
Dnly present in monocytic cells and was, therefore, below the level of detection in the
DBMC extract.
n addition to the evidence of infection of monocytic cells obtained by PCR, the
comparison of adherent cells from infected and uninfected individuals suggested that
he cells were affected by HIV-1 infection. The cells from negative controls were
observed to adhere rapidly and show a change in morphology over the following 3
days. Cells appeared to flatten and extend appendages over the surface of the
■clastic. In contrast, adherent cells from infected individuals showed no morphological
changes with reduced adherent properties and a greater tendency to detach over
ime in agreement with Lioy et al., (1993). These observations support the theory that
-nonocytic/adherent cells are affected by HIV-1 infection and may themselves
larbour the virus.
"his area of research is currently undergoing expansion. PCR is being used to
equence the NSI and SI isolates, demonstrating a genetic basis to their tropism and
ytopathogenicity (Fouchier et al., 1992). The work is also moving towards the in vivo
malysis of cell subsets which have been shown to support viral replication in vitro.
'his work may help explain the complex immunodeficiency observed in the later
=tages of HIV-1 infection, and may also open up areas for future targets of
-ntiretroviral therapy.
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11.7 Detection of viral RNA.
Although the detection of HIV DNA is indicative of an established infection, it does
not correlate to the replicative state or infectious nature of a sample. A more
informative method is where viral RNA is detected by PCR after a reverse
transcriptase step (RT-PCR). This can be used to demonstrate the presence of free
virus and/or transcriptionally active infected cells (Zhang et al., 1991; Bagnarelli et
al., 1991a).
In this study, RNA was extracted from PBMCs, adherent cells and plasma from a
small number of samples. In each extraction total RNA was recovered, in the
presence of RNase free DNase, and reverse transcribed prior to amplification. The
RNA may have been genomic and/or subgenomic transcripts. The samples used had
all been stored at -70°C over a period of months. The central aim was to establish a
method of RNA detection, but also to show that viral activity was occurring in patient
cells.
The plasma sample was included as a source of free virus. The patient was not
selected for any reason other than plasma was available on the day of the
experiment. Despite a positive virus isolation from PBMCs, the plasma sample was
negative for HIV RNA sequences. Although the majority of patients are now thought
to be viraemic (Ho et al., 1989; Ottmann et al., 1991) the concentration of RNA
present in this sample may have been below the level of detection, particularly as the
plasma was not ultracentrifuged prior to extraction.
PBMCs from sample 7a were isolation and HIV RNA positive. Although the patient
was p24 antigen negative at the time of sampling, virus isolation, HIV RNA and
CUVD detection are all indicative of viral activity.
RNA was extracted from a total of 6 adherent cell samples. Again these samples
were not selected specifically for this experiment, and consequently only 1 sample
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was from an antigenaemic patient. This sample was subsequently found to be the
only HIV RNA positive adherent cell extract.
Due to the small number of samples tested, it was not possible to comment on the
correlation of HIV-1 RNA detection with other viral markers. A larger study by
Bagnarelli et a/., (1991a) detected HIV RNA in 23 out of 37 PBMC samples, but
found no correlation with p24 antigenaemia. This is not particularly surprising as
cellular sequences may represent subgenomic length transcripts and not relate to
antigenaemia or viraemia. To detect HIV RNA from infectious virus would require an
initial purification step to isolate whole virus. Although it is known that defective viral
genomes can be enveloped, it was decided to develop a method of detecting
infectious viral RNA by extracting total RNA from captured HIV-1 particles (Ottman et
ah, 1991). This was achieved by coating polystyrene beads with anti-gp120
antibodies and incubating the beads with the patient samples.
Two PBMC coculture positive samples were used to develop this method.
Supernates, containing the clinical isolates, were incubated with beads coated with 1
of 4 anti-gp120/160 specific antibodies. Both isolates were captured using the anti-
gp120 specific monoclonal antibody (ADP361, Appendix II) and subsequently
detected after RT-PCR. Further attempts to capture virus by this method were
unsuccessful and so it was decided to use a viral supernatent of known TCID50 to
estimate the limit of detection. The method used was very crude but indicated that
the technique required in excess of 6 x 104 RNA templates for a positive result.
Although efficiencies differ due to assay conditions and oligomers utilised, a
quantitative RT-PCR study calculated the efficiency of the RT step to be 5% for a
sequence of 400-500bp (Zhang et at., 1991). In addition to the poor efficiency of the
RT method, the capture step will have decreased the efficiency even further. The
antibody used for this step was raised against HIV-1 mB and may not, therefore,
efficiently recognise other viral isolates. Alternative approaches to virion capture by
immunoselection have utilised mixtures of monoclonal and polyclonal antibodies to
219
overcome this problem (personal communication, C. Loveday). The insensitivity of
the RT-PCR method for whole virus capture may, therefore, be a combination of a
low specificity antibody and an inefficient RT step. Considerable optimisation of both
the virus capture and RT steps is required to validate this method of HIV genomic
RNA detection.
Published methods of HIV RNA detection have largely concentrated on the detection
of total plasma RNA which may be genomic or subgenomic transcripts released from
lysed cells (Ottman et al., 1991). Studies have detected viral RNA in the majority of
patients from all clinical stages with little or no correlation to p24 antigenaemia and
CD4+ cell counts (Bagnarelli et al., 1991b; Ottman et al., 1991; Zhang et al., 1991).
However, RT-PCR of neat serum by Holodniy et al., (1991) correlated HIV RNA
detection with p24 antigenaemia and CD4+ counts below 400/ml. The method
differed from the others in that RNA was extracted from neat sera as opposed to an
ultracentrifugation pellet. The difference in results may, therefore, be due to a
concentration effect.
Although the capture assay was relatively unsuccessful, the capture of infectious
particles is an important step for analysis of genomic RNA. The sensitivity of the
assay may be improved by using smaller beads, a cocktail of specific antibodies,
and/or by further optimising the antibody coating procedure. Alternatively, genomic
RNA may be captured by poly T tails bound to a solid phase in individual vials or
microtitre plates. The development of an assay to detect virion associated HIV RNA
would be extremely useful in sequence analysis, particularly in determining the
significant sequence variations; in the assessment of loss of sensitivity to therapeutic
agents; and in the quantification of plasma viraemia.
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CHAPTER 12: DETECTION OF HBV DNA IN HEPATITIS B SEROPOSITIVE
SERA.
The initial aim of the HBV study was to apply PCR to the detection of HBV DNA
sequences in the serum of a cohort of patients, and to correlate the results to the
presence of HBeAg.
The hepatitis B e antigen is present during the early stages of infection, with
seroconversion to anti-HBe positive being indicative of resolution of the acute
infection (Figure 4). The antigen has been well characterised as a marker of viral
replication, and has been closely associated with the detection of DNA polymerase
activity and HBV DNA in the blood of infected individuals (Alberti et al., 1979; Alter et
a!., 1976; Cappel et al., 1977; Imai et al., 1976; Weller et al., 1982; Hadziyannis et
al., 1983; Lieberman et al., 1983; Scotto etal., 1983; Karayiannis etal., 1985; Bonino
et al., 1986; Carloni et al., 1987; Cheng etal., 1989).
The application of PCR to HBV DNA detection in sera has verified this association,
demonstrating a 100% correlation of HBeAg with HBV DNA (Larzul et al., 1988,
1989; Kaneko et al., 1989a, 1989b; Liang et al., 1989; Okamoto et al., 1989b;
Sumazaki et al., 1989; Ulrich et al., 1989; Zeldis et al., 1989). While HBeAg is
associated with the presence of hepatitis B virions and infectivity, the absence of
detectable HBeAg does not exclude the presence of infectious viral particles. The
increased sensitivity offered by PCR has shown that viral DNA sequences are
present in the serum of patients with no detectable HBeAg (Kaneko et al., 1989a & b;
Liang et al., 1989; Okamoto et al., 1989b, 1990; Zeldis et al., 1989). Similar results
were obtained in this study using PCR to amplify a fragment of the S-gene. HBV
-DNA was detected in 100% of HBeAg positive sera, 10% of HBe negative sera and
32% of anti-HBe positive sera.
12.1 Determination of the potential infectivity of HBV DNA positive sera.
■Determining the infectious status of patients is not only of scientific interest, but also
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has implications in the control of transmission from infected individuals. The
infectivity of patients is particularly important in those requiring surgical procedures,
and in the management of HBsAg carriers. Hepatitis B carriers are not only an
important source of both vertical and horizontal transmission, but are also at a
greater risk of progressing to chronic liver disease and hepato-cellular carcinoma
(Chen et a/., 1986). It may, therefore, be of use to detect any HBV DNA in the
plasma, and in association with the patients HBe status determine the form of viral
DNA present in an attempt to correlate it with disease progression.
The detection of viral sequences is largely assumed to correlate with the presence of
whole virus in the patient's serum and, therefore, the detection of HBV DNA in HBe
negative and anti-HBe positive sera suggested that these samples were also
infectious. However, early data correlating the presence of HBeAg with HBV DNA
also included infectivity studies where HBeAg positive sera were found to be
approximately 108-fold more infectious than anti-HBe positive sera (Shikata et at.,
1977). Taking that information in conjunction with the data from this present study,
where HBe negative sera were less likely to contain HBV DNA than anti-HBe positive
sera, it was postulated that the viral sequences detected after seroconversion, from
HBeAg positive to negative, do not correlate to whole free virus and, therefore,
infectivity. In the absence of infectious free virus, the detection of viral sequences in
HBeAg negative sera may be attributed to immune complexed virus or free viral DNA
released from necrotic hepatocytes (Carman et a/., 1989; Liang et a!., 1989).
In this study, the forms of viral DNA present in clinical samples were determined by
selective separation of whole virus and IgG- and IgM-complexed virus prior to DNA
extraction. This was achieved by using polystyrene beads coated with anti-HBs, anti-
human IgG, and anti-human IgM specific antibodies respectively. All incubations
included DNase I to eliminate contamination by free viral DNA sequences. Due to the
lack of a suitable method for extracting free DNA, its detection was based on a
positive PCR result in the absence of all other forms of virus.
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Initial amplifications after selective extraction of 14 HBV DNA positive samples
showed that patients had a variety of viral forms in their sera (whole virus, and IgG &
IgM complexed virus). All HBe and HBs antigen positive samples were positive for
free and complexed virus. This was expected since the presence of both e and
surface antigens correlated to the early stages of infection where viral replication is
at its maximum (Figure 4). Seven samples had detectable levels of antibody to
HBeAg, and a variety of viral forms were detected, although only 2 samples were
positive for all 3 forms. Of the 4 samples with no detectable viral DNA by any of the
extraction methods, 2 were HBsAg positive (1 anti-HBe antibody positive and 1 HBe
negative) and 2 anti-HBs positive (both anti-HBe antibody positive). The viral DNA
detected in these samples was not associated with whole virus and may, therefore,
have been released from necrotic hepatocytes lysed after cessation of viral
replication.
Although HBV seronegative controls were utilised throughout, these were monitors of
the PCR method and did not control for the specificity of the antibody coating of the
beads. To control for this, HBV seropositive sera were incubated with blank beads
and beads coated with BSA and buffer. Samples which were positive for all 3 forms
were also HBV DNA positive after extraction with the 3 control beads, while samples
-positive for only 1 form were negative after these extractions. HBV DNA positive
samples incubated with blank and buffer coated beads were expected to result in
-non-specific detection of HBV DNA as the beads were designed to bind proteins
non-specifically. The lack of detection in some virus positive samples may be due to
a concentration effect. The non-specific binding of hepatitis B virions or immune
-complexes may have been restricted by an inappropriate pH (optimum binding
-pH9.2). Therefore, samples with fewer viral particles were less likely to bind non-
=specifically to the test beads. However, the results suggested that the coating
■process required further optimisation to eliminate the non-specific binding.
-Although false negative PCR results did not appear to be a problem in this study, the
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use of a single large diameter bead (6.5mm) offered a relatively small surface area
available for antibody binding and subsequent particle recognition. This could
present problems in samples with high HBsAg concentrations resulting from HBV
DNA negative filamentous and spherical particles. This was overcome by Liang et
at., (1989) by coating Sepharose beads with an IgM HBsAg-specific monoclonal
antibody. The antibody coated bead slurry was then incubated overnight with patient
serum, and DNA was heat extracted prior to amplification. The use of small beads
and a large antibody molecule (IgM) will also create a physical barrier against non¬
specific binding to the bead surface. This method proved highly sensitive, detecting
<10 copies per 200ul of serum (Liang et a!., 1989), however, the specificity of the
■binding step was not tested.
■In addition to non-specific binding of hepatitis B virus and immune complexes, beads
coated with antibodies specific for human IgG and IgM could be saturated with
-antibodies unrelated to HBV. HBV DNA positive extractions were obtained using
beads coated with anti-HBs, anti-human IgG and anti-human IgM specific antibodies.
The main concern was that some of these detections were due to non-specific
•binding of free and complexed virus. In defence of the results, samples which were
■repeatedly extracted by this method gave consistent data. When compared with the
ipatient HBV-specific antigen and antibody profile, the bead extraction and HBV
■specific PCR gave patterns of detection which correlated to the current
-understanding of HBV replication.
■In conclusion, the method requires further optimisation, primarily by changing from
large to smaller beads to enhance the specific binding of viral particles. The use of a
£>anel of non-HBV specific antibodies to block HBV binding may also assist in
optimising the coating process. Once operational, this method could be applied to a
■wide range of problems including the determination of patient infectivity by qualitative
=and quantitative analysis and detection of sequence variation in whole virus.
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12.2 Comparison of hepatitis B surface antigen subtyping by RIPA, PCR and
RD-PCR.
The subtyping of hepatitis B virus has conventionally been by characterization of the
HBsAg phenotype. The protein has a tertiary structure determined, in part, by
formation of disulphide cross-linking of cysteine residues in the region of the protein
associated with the d/y and w/r subtypes (Gerin et al., 1983; Takeshima et al., 1985).
These conformational differences were initially detected by agar gel diffusion
techniques, but are now more commonly characterized by antibody specific
immunoassays (Purcell et al., 1969; Holland et al., 1972; Hoofnagle et al., 1977;
Fang et al., 1978; Ukkonen & Koistinen, 1979; Wands & Zurawski Jr., 1981; Usuda
et al., 1985; Ren et al., 1988). Immunoassays are, however, highly dependent on the
specificity of the antibodies used and have often given rise to indeterminate results,
and/or compound subtypes expressing both d and y or w and r determinants
(Nordenfelt & Le Bouvier, 1973-1974; Mazzur et al., 1975; Courouce-Pauty et al.,
1979; Paul et al., 1986; Tachibana et al., 1989). The recent application of site-
directed mutagenesis has mapped the dand y determinants to codon 122 of the S-
gene (Okamoto et al., 1987a, 1989a).
The d and y subtypes differ at codon 122 of the S-gene (Okamoto et al., 1987a,
1989a), where subtype d specific samples have a lysine residue (AAA) and subtype
y samples an arginine residue (AGA, AGG or CGG). As a substantial number of the
serum samples included in the HBV DNA detection study had previously been
iphenotyped for the d and y determinants by RIPA, it was decided to develop a
comparative method of HBsAg subtyping using PCR.
The primary amplification product from the HBV DNA detection method was used as
«a source of viral DNA which spanned codon 122. To determine the subtype
-specificity of this product, primers were selected to hybridize to codon 122 at their 3'
■ends (Figure 9) on the basis that 3' primer-template mismatches would result in a
•loss of efficiency which could be exploited to amplify subtype d or y specific HBV
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DNA only (Newton et al., 1989; Kwok et al., 1990; Cassol et al., 1991; Larder et al.,
1991).
The results obtained in this way showed that different 3' mismatches amplified the d
and y specific sequences at different efficiencies. Two primers (029H & 394J) were
selected to hybridize to d and y specific subtypes respectively (Figure 9). Both
primers had a 3' T mismatch with the opposing subtype, however, both primers were
found to amplify both d and y specific sequences efficiently. This was in agreement
with a study by Kwok et al., (1990) which showed no reduction in amplification
■efficiency with 3' T:G and T:C mismatches. However, this was in direct contrast to a
study which utilised a T mismatch at the 3' end of both primers to detect d specific
sHBV DNA (Norder et al., 1990). Although the technique utilised in this study was
similar to that of Norder et al., (1990), the substantial difference in results may be
■attributable to variations in the methodologies. The main difference was that both
iprimers of the pair used by Norder et al., (1990) had 3' mismatches, whereas only 1
iprimer in the pair had a mismatch in this study. Since the differential amplification of
■sequences using primers with 3' end mismatches is dependent on a reduction in
■amplification efficiency and not to an absence of amplification, the use of 2
mismatched primers may have reduced the efficiency sufficiently to differentiate
between subtypes. Also, nested PCR, as used in this study, is the most sensitive
•technique for the detection of nucleic acids, and so it is possible that despite the
reduced efficiency, the amplification power was too great to discriminate between
.subtypes (Simmonds et al., 1990a). Norder et al., (1990) used a single PCR followed
by hybridization to determine the HBsAg subtype. The additional loss of amplification
power associated with the hybridization assay may also have contributed to the
ability to differentiate between the 2 subtypes.
In keeping with the data published by Kwok et al., (1989), it was decided to continue
to subtype samples using the y-specific primer with a 3' G:A mismatch, and to base
the d-specificity on HBV DNA positive samples which were amplification negative
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using the y-specific primer pair. Using this method, 38 HBV DNA positive samples,
which had previously been subtyped by RIPA, were further amplified with the y-
specific primer pair. The 2 subtyping assays were in agreement in 92% of samples,
with 3 giving conflicting PCR and RIPA results.
RIPA and PCR techniques differ considerably in their application and versatility in
HBsAg subtyping. The application of RIPA requires the presence of large quantities
of free circulating HBsAg protein in the blood of infected individuals, a characteristic
of acute and chronic hepatitis B. However, the assay is not definitive as it is based
on percentage blocking by both cf and / specific antibodies which are likely to carry a
degree of cross-reactivity due to the type common determinant a. Also, the assay
•requires the production of standard antibodies used to characterize the antigen, and
so it is a costly and time consuming method of HBsAg phenotyping.
■PCR subtyping is, in the first instance, dependent on the presence of viral DNA
which is generally only present during the acute phase of the infection and is cleared
■prior to complete resolution of the infection. However, the method is extremely
•sensitive requiring less than 10 template sequences for detection. Subtyping by PCR
is dependent on the comparative amplification efficiencies of template sequences
differing by as little as a single base. It, therefore, requires careful monitoring to
■maintain an adequate differentiation. However, PCR can detect all forms of viral DNA
-with an intact target sequence and can, therefore, be applied to the detection and
■subtyping of cell-associated viral DNA (both episomal and integrated); free virus;
immune-complexed virus; and viral sequences associated with hepato-cellular
oarcinoma. PCR is a more rapid, flexible and cheaper alternative to RIPA subtyping
of HBsAg.
■However, in view of the careful optimisation required for PCR subtyping using a y-
■specific oligonucleotide only, it was decided to develop an alternative method to
compare with both PCR and RIPA HBsAg subtyping.
■Alternative methods of HBV DNA subtyping have been published using a variety of
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techniques. Yotsumoto et at., (1990) used PCR to amplify the S-gene and
sequenced the product for adenine bases only. Sequence analysis was in agreement
with enzyme immunoassay data in 100% of samples despite the acknowledged risk
of PCR associated misincorporation (Saiki etal., 1988).
Other methods of typing by PCR have now been developed to compare viral
genotypes as opposed to phenotypes. This concept was first described for HBV by
Okamoto et at., (1988) and was used to categorise the virus into 4 groups showing
genetic relatedness. This analysis showed considerable variation in the pre-S region
which was exploited by Shih etal., (1991) and Norder et al., (1992) demonstrating
that some genotypes showed greater variation between 2 sequences of the same
subtype than between different subtypes. Since some of the existing methodologies
for HBsAg subtyping were found to be time consuming and in some cases
contradictory, it was decided to persist with the use of PCR to try and offer a simple
and rapid alternative.
This was achieved by amplifying the S-gene with the type-common primers used for
detection, and digesting the amplification product with the restriction enzyme Sau 3A
which distinguishes between band / subtypes (PCR-RD). From restriction maps of 5
'HBV subtypes (adw, adyw, ayw, adw2 and adrcg), it was predicted that d subtype
genomes would result in 3 bands (117, 204, 227bp) and / subtype 2 bands (227 and
321 bp). When analysed by agarose gel electrophoresis, it was found that d subtype
genomes resulted in 6 bands, and / subtype 3 bands. This was due to the
incomplete digestion of template DNA generated by PCR. The predicted bands for a
partial digest were 6 for d subtypes (117, 204, 227, 321, 431, and 548bp), and 3 for /
subtypes (227, 321, and 548bp, Figure 28). The resulting bands were easily
-distinguished on agarose gels giving a reliable and rapid method of genotyping HBV
=DNA for the dand / determinants (Figure 27).
To determine the efficacy of PCR-RD for HBsAg subtyping, the method was
■evaluated on 8 samples for which PCR and RIPA subtyping was in agreement. The
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PCR-RD results were in 100% agreement for the 4 d-specific and 4 y-specific
subtypes (Table 37). The method was also used to determine the subtype of the 3
samples with conflicting RIPA and PCR subtypes. The samples were all subtype d
by RIPA and y by PCR. The PCR results were most likely to be incorrect due to the
lack of a d-specific detection method. It was unlikely that the reaction would
incorrectly identify a y-specific sample, but conceivable that it could amplify a d-
specific sequence sufficiently for detection. It was, therefore, not surprising to find
that 2 of the 3 samples were subtyped d by the third method (Table 37). PCR-RD
was, therefore, thought to be the most appropriate method of HBsAg subtyping. It
offered a highly sensitive and flexible method which was also rapid and relatively
inexpensive. The only apparent disadvantage of this method was in the detection of
compound subtypes.
Although the d and y subtypes of HBsAg are generally mutually exclusive, mixed, or
compound subtypes have been described (Le Bouvier et at, 1972; Gordon et al.,
1972; Nordenfelt & Le Bouvier, 1973-74; Mazzur et al., 1975; Gibson, 1976).
Subtyping by PCR-RD will only detect d-specific sequences in a mixed population
due to the lack of a unique y-specific band in the digest product. Similarly, due to the
lack of a d-specific primer, the PCR method will fail to detect d-specific sequences in
a mixed population. Although RIPA is capable of detecting both d and y subtypes in
-compound samples, it is still a less sensitive, more costly and time consuming
-method.
■In view of these limitations, it is thought that PCR-RD is the method of choice for
■HBsAg subtyping, with the use of PCR subtyping as a back up for y-specific
confirmation. This will still offer a very rapid and flexible method of HBsAg subtyping,
-which will be applicable to a number of sources of virus including fresh and frozen
-serum and tissue samples, and fixed tissue, particularly those associated with
■hepatocellular carcinoma. PCR methods of HBsAg are, therefore, very rapid and
■flexible alternatives to RIPA, with multiple research and clinical applications.
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CONCLUSION
During this project, the polymerase chain reaction was successfully applied to the
detection of HIV and HBV nucleic acid in clinical samples. The technique was then
further applied to characterise the forms of nucleic acid present in these samples,
requiring modifications to the standard method.
PCR was an essential tool for the detection of HIV-1 DNA in clinical samples due to
the small number of infected cells present in the peripheral blood. Once detected,
HIV DNA was characterised into linear and 1 & 2LTR circular unintegrated viral DNA
forms (LUVD and CUVD). However, due to the non-specific integration of the proviral
sequence, an acceptable PCR method of detection was not devised. This would be
an immediate objective of any continuance of this project.
Whilst LUVD was not detected in clinical samples, the circular unintegrated forms
were found to be significantly associated with a more advanced disease stage
(0.02>P>0.01). It would, therefore, be of interest to expand this study, over time, to
evaluate these forms of HIV-1 DNA as prognostic markers. A longitudinal study like
this may also encompass the use of antiretroviral therapies and observe any effects
on UVD production. This would require the quantification of these forms to monitor
the load in relation to therapy.
The benefits of PCR to detect HBV DNA in sera of infected individuals was less
apparent due to the abundance of HBV DNA which can be readily detected by
hybridization assays. The increased sensitivity of PCR may, however, offer
advantages for the analysis of viral activity in hepatitis B carriers. This group of
patients are particularly at risk of developing liver disease including hepatocellular
carcinoma. Careful monitoring of viral activity in these patients may be beneficial in
understanding the mechanism of disease and also in determining the efficacy of
antiviral therapies. PCR may, therefore, be used for optimum HBV DNA detection in
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sera, and also to detect both viral DNA and RNA intermediates in infected
hepatocytes.
Further to this, the use of such a sensitive and rapid technique as PCR to subtype
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APPENDICES
Appendix I. HBV sample data.
Table 42: HBV results of radioimmunoassays (RIA) for HBs and HBe status,
HBV DNA detection by PCR, and HBsAg subtyping by
radioimmunoprecipitation assay (RIPA), nested PCR of HBsAg DNA, and Sau





DNA RIPA PCR PCR-RD
P35 Ag Ag + ay ay nd
P36 Ag Ag + ad ad ad
P37 Ag Ag + ad ad nd
P38 Ag Ag + ay ay ay
P39 Ag Ag + ay ay nd
P40 Ag Ag + ay ay nd
P41 Ag Ag + ay ay nd
P42 Ag Ag + ay ay nd
P43 Ag Ag + ad ad ad
P44 Ag Ag + ay ay ay
P45 Ag Ag + ay ay nd
P46 Ag Ag + ad ad ad
P47 Ag Ag + ay ay nd
P48 Ag Ag + ay ay nd
P49 Ag Ag + ay ay nd
P50 Ag Ag + ay ay nd
P51 Ag Ag + ay ay nd
P52 Ag Ag + ay ay nd
P53 Ag Ag + ad ad nd
P54 Ag Ag + ad ad nd
P55 Ag Ag + ay ay nd
P56 Ag Ag + ad ad nd
P57 Ag Ag + ad ad nd
P58 Ag Ag + ay ay ay
P59 Ag Ag + ay ay ay
P60 Ag Ag + ad ad ad
P61 Ag Ag + ad ad nd
P62 Ag Ag + ay ay nd
P63 Ag Ag + ad ad nd
P64 Ag Ab + ay ay nd
P65 Ag Ag + ad ay ay
P66 Ag + ad ad nd
P67 Ag Ab + ad ad nd
P68 Ag Ab + ad ay ad
P69 Ag Ab + ad ad nd
P70 Ag Ab + ad ad nd
P71 Ag Ab + ad ay ad
P72 Ag Ag + d/y ay nd
P73 Ag Ab + ay ay ay






DNA RIPA PCR PCR-RD
P75 Ag Ag + nd nd nd
P76 Ag Ag + nd nd nd
P77 Ag Ag + nd nd nd
P78 Ag Ag + nd nd nd
P79 Ag Ag + nd nd nd
P80 Ag Ag + nd nd nd
P81 Ag Ag + nd nd nd
P82 Ag Ag + nd nd nd
P83 Ag Ag + nd nd nd
P84 Ag Ag + nd nd nd
P85 Ag Ag + nd nd nd
P86 Ag Ag + nd nd nd
P87 Ag Ag + nd nd nd
P88 Ag Ag + nd nd nd
P89 Ag Ag + nd nd nd
P90 Ag Ag + nd nd nd
P91 Ag Ag + nd nd nd
P92 Ag Ag + nd nd nd
P93 Ag Ag + nd nd nd
P94 Ag Ag + nd nd nd
P95 Ag Ag + nd nd nd
P96 Ag Ag + nd nd nd
P97 Ag + nd nd nd
P98 Ag - - nd nd nd
P99 Ag - - nd nd nd
P100 Ag - - nd nd nd
P101 Ag - - nd nd nd
P102 Ab - - nd nd nd
P103 Ab - - nd nd nd
P104 Ab - - nd nd nd
P105 Ab - - nd nd nd
P106 Ab - - nd nd nd
P107 Ab - - nd nd nd
P108 - - - nd nd nd
P109 Ab - - nd nd nd
P110 Ab - - nd nd nd
P111 - - - nd nd nd
P112 Ab - - nd nd nd
P113 - - - nd nd nd
P114 Ab - - nd nd nd
P115 Ab - - nd nd nd
P116 Ab Ab + nd nd nd
P117 Ab Ab + nd nd nd
P118 Ag Ab + nd nd nd
P119 Ag Ab - nd nd nd
P120 Ag Ab - nd nd nd
P121 Ag Ab - nd nd nd
P122 Ag Ab - nd nd nd
P123 Ag Ab - nd nd nd






DNA RIPA PCR PCR-RD
P125 Ag Ab _ nd nd nd
P126 Ag Ab - nd nd nd
P127 Ag Ab - nd nd nd
P128 Ag Ab - nd nd nd
P129 Ag Ab - nd nd nd
P130 Ag Ab - nd nd nd
P131 Ag Ab - nd nd nd
P132 Ag Ab - nd nd nd
P133 Ag Ab - nd nd nd
P134 Ab - nd nd nd
P135 Ab Ab - nd nd nd
P136 Ab Ab - nd nd nd
P137 - Ab - nd nd nd
P138 Ab Ab - nd nd nd
P139 Ab Ab - nd nd nd
P140 Ab Ab - nd nd nd
P141 - Ab - nd nd nd
P142 Ab Ab - nd nd nd
P143 Ab Ab - nd nd nd
P144 Ag Ag + nd nd nd
P145 Ag Ag + nd nd nd
P146 Ag Ag + nd nd nd
P147 Ag Ag + nd nd nd
P148 Ag Ab + nd nd nd
P149 Ag Ab + nd nd nd
+, positive result; negative result; Ag, antigen positive; Ab, antibody positive;
ay, HBsAg subtype ay; ad, HBsAg subtype ad; d/y, sample ad and ay HBsAg
subtype on separate occassions; nd, not done. All PCR results represent
amplification results of 10ul aliquots of extracted DNA equating to 20ul of neat
serum.
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Appendix II. Medical Research Council AIDS Directed Program (MRC
ADP) reagents.
The repository reference number and source are given, with a description of








Hut78; human cutaneous T-cell
lymphoma






U937; human monocyte-1 ike cell from
a histiocytic lymphoma






C8166; human T-lymphoblastoid cell
line
Mr P. Chapman and Dr G. Farrar






LC5; HIV susceptible clone of human
embryonic lung fibroblasts
Dr V Erfle






U138MG; human glioblastoma cell
line
American Type Culture Collection





THP1; monocytic leukaemic line







Drs R. Gallo & M. Popovic









Chronically infected H9 cells


















HeLa T8+; Human epithelial-like










NIAID AIDS Research and
Reference Reagent Program











Recombinant HIV-1 gp160 from
yeast
Dr C. Thiriart and C. Bruck












































Antiserum to recombinant gp120
(CHO)




Appendix ill. Methods of analysis.
1. Calculation of the 50% tissue culture infective dose (TCID5q) by the
method of Reed and Muench (Johnson & Byington, 1990).
HIV-1 supernate was titrated in 5 replicates on C8166 susceptible cells and
data was analysed from the greatest dilution in which each replicate contained
no syncytia, to the greatest dilution in which each replicate contained syncytia.
For the example of C8166 cells infected with HIV-1 RF virus, this includes virus
dilutions of 1 in 105 to 1 in 107 (Table 43). The TCID5q lies between these
two dilutions, and so only data from that range of dilutions are included in the
calculations.
Table 43. Results of the syncytia assay in C8166 cells infected with HIV-
1 RF-
Total Total Mortality
Dilution CPE + CPE - infected uninfected ratio (%)
1 in 10§ 5 0 8 0 8/8 (100%)
1 in 10° 3 2 3 2 3/5 (60%)
1 in 107 0 5 0 7 0/7 (0%)
Key: CPE +, number of wells at each dilution in which syncytia were
observed; CPE -, wells at each dilution scored negative for syncytia formation.
The total infected and uninfected columns represent the cumulative values of
virus infected and uninfected wells respectively. The total infected column is
added from the highest to the lowest dilution, and the total uninfected from the
lowest to the highest dilution. The mortality ratio is calculated from the
cumulative infected total divided by the cumulative uninfected total for each
dilution.
From the calculated mortality ratio, the 50% endpoint dilution lies between 1 in
106 and 1 in 107 (60% & 0% respectively).
To obtain the interpolated value (x), the following formula was used:
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(% mortality at dilution next above 50%) - 50%
x =
(% mortality at dilution next above 50%) -
(% mortality at dilution next below 50%)
From the data in Table 43,
60%-50% 10%
x = = = 0.17
60%-0% 60%
The 50% endpoint dilution is 1 in 106-17, and so the 50% titre is estimated at
106-17. The TCID50 per millilitre of viral supernate is therefore 107•17 (1 OOul
of diluted supernate was used for each well).
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2. Method of calculating the molarity of oligonucleotides supplied by
Oswel DNA services (Department of Chemistry, The University of
Edinburgh).
Oligonucleotides were supplied in solution (1ml) with optical density readings
at 264nm. Their molarities were then calculated from their OD readings on the
basis of their molecular weight and extinction coefficient.
The molecular weight was calculated as follows:
M.Wt= [(251 xnA)+(242xnC)+(267xnG)+(227xnT)
+(62x(n-1 ))+(54xn)+(17x(n-1))]
and the micromolar extinction coefficient (at 264nm) is calculated as below;
MEC = [(8.8xnT)+(7.3xnC)+(11,7nG)+(15.4xnA)]x0.9
Where, nA = number of Adenines; nC = number of Cytosines; nG = number of
Guanines; nT = number of Thymines; and n = the total number of
bases; 62 x (n-1) is the molecular weight of the phosphate groups;
54 x n allows for hydration of the DNA; and 17 x (n-1) allows for the
cation on the phosphate groups (usually ammonium).
The extinction coefficient is multiplied by 0.9 as the base-base
interactions in single-stranded DNA suppresses the absorbance at
264nm.
Example: For the primer 160H, the calculations are as follows:
Primer 160H 5' CATGGGTACCAGCACACAAAGG 3'









To convert the OD units to milligrams
8.363g = 229.32 OD units
1mg = 229.31 8.363
= 27.42 OD units




The molarity = (218.8 x 10"®) 8363
= 26.2uM
The primer concentration is therefore 26.2uM.
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3. Statistical analysis of data by the Chi-square test.
Data was analysed by the Chi-square test, as described by Swinscow, (1991).
For each set of data, the null hypothesis was that the groups had similar
distributions. Two examples have been included, to demonstrate the methods
of calculating Chi-square, degrees of freedom, and the probability of the
results occurring in a 2 by 2 table (example 1) and a 3 by 2 table (example 2).
Due to the small sample size in 2 by 2 tables, the Yates correction for
continuity was applied.
Example 1. The null hypothesis is that the ability to isolate virus is similar in
samples with or without CUVD forms.
Table 44. Comparison of detection of CUVD with virus isolation (VI).
VI+ VI- Total
CUVD+ 14 7 21
CUVD- 7 7 14
Total 21 14 35
The table is in the basic format shown below:
VI+ VI- Total
CUVD+ a b a+b
CUVD- c d c+d




and, II indicates that the smaller of the 2 numbers enclosed should be
subtracted from the other.
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From the calculation, the Chi square = 0.402
Degree of freedom = (No. of columns-1)x(No. of rows-1)
= (2-1 )(2-1)
= 1
From the table of distribution of chi-square the result obtained at 1 degree of
freedom has the probability of P>0.50. The result, therefore, does not show a
significant correlation between the presence of CUVD and the ability to isolate
virus, and so the null hypothesis was confirmed.
Example 2. The null hypothesis is that the distribution of CUVD forms is
similar in CDC groups II, III, and IV.
Table 45. Detection of CUVD forms in samples categorised by CDC groups.
CDC group CUVD + CUVD - Total
II 6 6 12
III 10 10 20
IV 18 2 20
Total 34 18 52
Calculation of expected numbers and chi-square.
Where, E = expected number and O = observed number,
e.g. for CUVD positive samples in CDC group II,
E = (11 52) x 34
and for CUVD negative samples in CDC group III,
E = (10 52) x 18
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E 0-E (0-E) /E






















Total 34 18 0 0 3.012 5.694
Chi-square = the sum of the 2 columns of (O-E) /E
= 3.012 + 5.694 = 8.706
Degree of freedom
= (No. of columns - 1) x (No. of rows - 1)
= (2 - 1) x (3 - 1)
= 2
From the chi-square tables, the probability at 2 degrees of freedom is
0.02>P>0.01. The result is therefore significant, and so the null hypothesis is
disproved. The results show that CUVD is more likely to be detected in the
later stages of disease.
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Appendix IV. HIV sample data.
Each patient has been allocated a number, with letters (a, b, etc) indicating
multiple samples from any one patient. The date of sampling, current CDC
group, CD4+ cell count, and type of treatment, if any, has been detailed. The
PCR results are given with cell equivalents of the amplification aliquot used.



















env 1LTR 2LTR LUVD

































































pol & env 2 x 104; 1 & 2 LTR 4 x 104

































DNA PCR results pol env 1LTR 2LTR









DNA PCR results pol env 1LTR 2LTR

































































































































































































































































































































































env 1LTR 2LTR LUVD











































14a Date of Sample:
IV CD4+:
positive plasma p24 Ag:





















14b Date of Sample: 09.10.90.
IV CD4+: 260
positive plasma p24 Ag: positive
on AZT 03.05.90.; on Pentamidine 14.05.90.
8x10


































































































































































































































































































DNA PCR results pol env 1LTR 2LTR LUVD






21b Date of Sample: 08.01.91.
CD4+: 99
plasma p24 Ag: negative
on AZT 07.01.91.; on Pentamidine 15.12.90.
pol & env7 x 103; 1 & 2 LTR 2 x 104
positive










22a Date of Sample:
III CD4+:
positive plasma p24 Ag:
on AZT & Pentamidine 23.04.90.
8 x 104














22b Date of Sample:
III CD4+:
nd plasma p24 Ag:
on AZT & Pentamidine 23.04.90.
1 x 105


































































































































































































































on AZT 12.88 to 04.07.90.
pol & env 1 x 104; 1 & 2 LTR 3 x 104








































28c Date of Sample:
IV CD4+:
macrophage cells, isolated by adherence
none
3.5 x 104




pol env 1LTR 2LTR LUVD
+ + + + nd
25.03.91.
nd

















































pol & env 4x 104; 1 & 2 LTR 1.2 x 105






































































































pol & env 3.75 x 105; 1 & 2 LTR 4.5 x 105
pol
+






























































































































nq, not quantified; nd, not done; negative; +, positive; +h, band present but
heavier than expected; Pentamidine, pentamidine isethionate for treatment of
Pneumocystis carinir, AZT, Azidothymidine or Zidovudine, inhibitor of HIV-1
replication; CD4+ counts, CD4 surface antigen positive cells per millilitre of
blood; LUVD, linear unintegrated viral DNA; 1LTR and 2LTR, covalently
closed circular unintegrated viral DNA with 1 and 2 LTR sequences
respectively. Patients 2 & 9 were included as high risk seronegative controls.
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Appendix V. Sequences and coordinates of oligonucleotides.
Oligonucleotides were synthesized by Oswel DNA Service (Department of
Chemistry, The University of Edinburgh), and purified by high-performance
liquid chromatography.
HIV-1 specific oligonucleotides. The coordinates (51 to 3') of HIV-1 specific
sequences are based on the published sequence of HTLV-III by Ratner et at.,











from pot gene, position
3730 to 3751. (1)
Anti-sense primer 161H
from pot gene, position
3973 to 3951. (1)
Sense primer 002C
from pot gene, position
3756 to 3781. (1)
Anti-sense primer 003C
from pot gene, position
3883 to 3861. (1)
Sense primer 401C
from env gene, position
6117 to 6137. (1)
Anti-sense primer 404C
from env gene, position
6554 to 6532. (1)
Sense primer 402C
from env gene, position
6138 to 6157. (1)
Anti-sense primer 403C
from env gene, position
6454 to 6435. (1)
Anti-sense primer 077F
from gag gene, position


















position -340 to -363,
and 8776 to 8753. (2)
Anti-sense primer 780K
from U5 sequence,
position 126 to 102,
and 9241 to 9217. (3)
Sense primer 781K
from U3 sequence,
position -151 to -127,
and 8965 to 8989. (3)
Sense primer 782K
from envgene, position
8382 to 8406. (4)
Anti-sense primer 783K
from gag gene, position
257 to 234. (4)
Sense primer 556L
from po/gene, position
3771 to 3773. (1)
Sense primer 557L
from po/gene, position
3769 to 3773. (1)
Sense primer 558L
from po/gene, position
3767 to 3773. (1)
Sense primer 559L
from po/gene, position
3765 to 3773. (1)
Anti-sense primer 585N
from U3 sequence,














Sense primer 915R for
ligation sequence and
U3 termini (full length).
(3)




Sources of primer sequences.
(1) Based on those of Simmonds et al., (1990a).
(2) Adapted from the primer M844 used by Pang et al., (1990).
(3) Selected from the LTR sequences of Starcich et al., (1985) and
Hammarskjold & Rekosh, (1989).
(4) Modified from the nef and gag sequences used by Pauza, (1990).
HBV specific oligonucleotides. The coordinates (51 to 3") of HBV specific
sequences are based on the published sequence of an adr HBsAg subtype








057C, position 301 to
277.
Sense primer 058C,
position 42 to 63.
Anti-sense primer










specific, position 416 to
392.
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5' CTTGAGCAGTAGTCATGCAGGTCC 3' Anti-sense primer 394J,
subtype y specific,
position 416 to 393.
HBV specific oligonucleotides were derived from the analyses of 5 human
HBV DNA sequences of subtypes adrcg, adw, adyw, ayw, and abw2
(GenBank accession numbers: X01587; V00866 J02201; J02202; J02203
V01460; and X02763 respectively). Primers 057C, 058C, 869C, and 870C,
were selected from conserved regions of the S-gene. Primers 907E and 394J
were selected from the y specific sequence, and 029H from the d specific
sequence, hybridizing to codon 122 at their 3' ends (Figure 9).
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Appendix VI. Amino acid sequence of recombinant gp120 protein.
The amino acid sequence of the mature recombinant protein gp120 (residues
31 to 510 inclusively). Amino acids are supplied as 3 letter code, the key to
this code is supplied in Table 42. Variable amino acids are given in italics, and
tyrosine and histidine residues are in bold. The protein was produced using a
Baculovirus expression system in Chinese hamster ovary cells (Appendix II).
The protein sequence was kindly supplied by Dr Gary Clements from Celltech
Research (Slough).
31 40
Thr Glu Lys Leu Trp Val
r n
Thr Val Tyr Tyr Gly Val Pro Val
Trp Lys Glu Ala Thr
D u
Thr Thr Leu Phe Cys Ala Ser Asp Ala
60 70
Lys Ala Tyr Asp Thr Glu Val His
q n
Asn Val Trp Ala Thr His
Ala Cys Val Pro Thr Asp Pro
O u
Asn Pro Gin Glu Val Val Leu
90 100
Val Asn Val Thr Glu Asn Phe Asn Met Trp Lys Asn Asp Met
110
Val Glu Gin Met His Glu Asp lie lie Ser Leu Trp Asp Gin
120
Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Ser
130 140
Leu Lys Cys Thr Asp Leu Lys Asn Asp Thr Asn Thr Asn Ser
150
Ser Ser Gly Arg Met lie Met Glu Lys Gly Glu lie Lys Asn
160 Lys 170
Cys Ser Phe Asn lie Ser Thr Ser lie Arg Gly Lys Val Gin
180
Lys Glu Tyr Ala Phe Phe Tyr Lys Leu Asp lie lie Pro lie
190
Asp Asn Asp Thr Thr Ser Tyr Thr Leu Thr Ser Cys Asn Thr
200 210
Ser Val lie Thr Gin Ala Cys Pro Lys Val Ser Phe Glu Pro
220
He Pro lie His Tyr Cys Ala Pro Ala Gly Phe Ala lie Leu
230 240
Lys Cys Asn Asn Lys Thr Phe Asn Gly Thr Gly Pro Cys Thr
250
Asn Val Ser Thr Val Gin Cys Thr His Gly lie Arg Pro Val
260
Val Ser Thr Gin Leu Leu Leu Asn Gly Ser Leu Ala Glu Glu
270 Val 280
Glu Val Val lie Arg Ser Ala Asn Phe Thr Asp Asn Ala Lys
308
290/Thr
Thr He lie Val Gin Leu Asn Gin Ser Val Glu lie Asn Cys
300 Lys 310
Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser lie Arg lie Gin
320
Arg Gly Pro Gly Arg Ala
s s n
Phe Val Thr lie Gly Lys lie Gly
Asn Met Arg Gin Ala
J J U
His Cys Asn lie Ser Arg Ala Lys Trp
340/Ala Ala 350
Asn Asn Thr Leu Lys Gin lie Asp Ser Lys Leu Arg Glu Gin
360
Phe Gly Asn Asn Lys Thr lie lie Phe Lys Gin Ser Ser Gly
370 380
Gly Asp Pro Glu lie Val Thr His Ser Phe Asn Cys Gly Gly
390
Glu Phe Phe Tyr Cys Asn Ser Thr Gin Leu Phe Asn Ser Thr
400
Trp Phe Asn Ser Thr Trp Ser Thr Glu Gly Ser Asn Asn Thr
410 420
Glu Gly Ser Asp Thr lie Thr Leu Pro Cys Arg lie Lys Gin
Tie 430
Phe lie Asn Met Trp Gin Glu Val Gly Lys Ala Met Tyr Ala
440
Pro Pro lie Ser Gly Gin lie Arg Cys Ser Ser Asn lie Thr
460 Ser
Gly Leu Leu Leu Thr Arg Asp Gly Gly Asn Asn Asn Asn Glu
470
Ser Glu lie Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn
480 490
Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys lie Glu
500
Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Arg Arg Val Val
510
Gin Arg Glu Lys.
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Table 42. Three letter abreviations for amino acid residues.
Code Amino acid Code Amino acid
Ala Alanine lie Isoleucine
Arg Arginine Leu Leucine
Asn Asparagine Lys Lysine
Asp Aspartic acid Met Methionine
Cys Cysteine Phe Phenylalanine
Gin Glutamine Ser Serine
Glu Glutamic acid Thr Threonine
or glutamine Trp Tryptophan
Gly Glycine Tyr Tyrosine
His Histidine Val Valine
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Comparison of Hepatitis B Virus Subtyping of d/y
determinants by Radioimmunoprecipitation Assay
ind the Polymerase Chain Reaction
f.J. Nicholson, S.H. Black, P. Simmonds, C-W. Chung, D. Aw, and J.F. Peutherer
department ofMedical Microbiology, University ofEdinburgh, Edinburgh, Scotland
Using a double polymerase chain reaction a
method was devised for detecting and subtyping
hepatitis B virus DNA in serum samples. Primers
from the S-gene were selected from the se¬
quence analyses of five HBV HBsAg subtypes, to
amplify HBV DNA and subtype for / specific
DNA. Thirty-eight samples were subtyped for d
and / determinants by radioimmunoprecipita¬
tion assay (RIPA) and the polymerase chain
reaction (PCR). Subtyping by PCR and RIPA was
in agreement in 100% of subtype / samples and
83.3% of subtype d, giving an overall correlation
of 92.1%. As a third comparison, 12 amplified
samples were digested by the restriction enzyme
Sau 3A, which differentiates between subtypes /
and d. The digest results agreed with PCR in
83.3% of the samples. In addition, we compared
our standard phenol/chloroform extraction
against a rapid one step method. The phenol/
chloroform stage was found to be essential for
the removal of nucleases and polymerase inhib¬
itors present in sera.




It has been shown that HBeAg is a good indicator of
ral replication and is, therefore, related to the pres-
lce of HBV DNA in serum samples. Utilising the
ilymerase chain reaction [Saiki et ah, 1985], HBV
NA has been detected in 100% of HBeAg positive
sra, and in up to 75% ofHBeAg/anti-HBe negative and
iti-HBe positive sera [Bonino et ah, 1986; Chen et ah,
186; Okamoto et al., 1989], Hybridisation studies
itected HBV DNA in 4—21% of similar HBeAg nega-
ve samples [Weller et ah, 1982; Karayiannis et ah,
185; Carloni et ah, 1987; Cheng et ah, 1989], demon-
rating the improved sensitivity offered by PCR.
The surface antigen of hepatitis B virus (HBsAg) has
an immunodominant determinant a, and two further
sets of determinants d/y [Le Bouvier, 1971] and wlr
[Bancroft et ah, 1972] that are generally believed to be
mutually exclusive. This gives four major subtypes of
HBsAg, adw, adr, ayw, and ayr, which are determined
by conventional serology. At the molecular level, the
dly and w/r determinants were shown to be coded for by
amino acid residues 110 to 160 of the HBsAg gene
[Gerin et ah, 1983; Takeshima et ah, 1985], From
site-directed mutagenesis, Okamoto et ah [1987b] dem¬
onstrated that a base change of G to A resulted in
amino acid 122 changing from arginine to lysine, and
the subtype from ay to ad. Similarly, a G to A point
mutation at amino acid 160 resulted in a change from
aw to ar [Okamoto et ah, 1987a],
We compared the detection of HBV DNA by PCR
with HBsAg, anti-HBs, anti-HBc, and HBe status, and
developed a method of subtyping for the d/y determi¬
nants of the HBsAg, using a subtype specific primer
from the S-gene.
MATERIALS AND METHODS
Source of HBsAg and Anti-HBs Positive Sera
Sera submitted to the Hepatitis Reference Labora¬
tory' (University of Edinburgh, Medical School) were
tested by standard radioimmunoassays for HBsAg
(Blood Products Laboratory, Elstree), anti-HBs and
anti-HBc (Hepatitis Reference Laboratory, Edin¬
burgh), and HBeAg/anti-HBe (Middlesex Hospital).
The 109 samples studied were selected to include a
range of HBV serological markers: 54 HBsAg/HBeAg
positive; 6 HBsAg positive, HBeAg/anti-HBe negative;
23 HBsAg/anti-HBe positive; 11 HBsAg negative, anti-
HBs positive, HBeAg/anti-HBe negative; 9 HBsAg
negative, anti-HBs/anti-HBe positive; 3 HBsAg nega¬
tive, anti-HBc positive, HBeAg/anti-HBe negative; and
3 HBsAg negative, anti-HBc/anti-HBe positive. These
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were tested for HBV DNA by PCR. Thirty-eight of the
HBsAg positive/HBV DNA positive samples (32
HBeAg positive, 7 anti-HBe positive, and 1 HBeAg/
anti-HBe negative) were subtyped by RIPA and PCR.
Samples from 10 low-risk seronegative individuals
were used as negative controls. Reference HBsAg prep¬
arations and antisera were supplied by the Research
Resources Branch, National Institutes of Health (Be-
thesda, MD). The panel of HBsAg subtypes [Courouce
et al., 1976], as described at the first HBsAg Subtype
Workshop, Paris 1975, was kindly supplied by Dr. A.M.
Courouce, Centre National de Transfusion Sanguine (6
Rue Alexandre-Cabanel, Paris, France).
HBsAg for purification and the subtyping RIPA was
prepared from HBsAg-positive blood donations sup¬
plied by the Glasgow and West of Scotland Blood
Transfusion Service, Law Hospital (Carluke, Lanark¬
shire).
Purification of HBsAg
HBsAg was purified from separate samples of anti¬
gen-positive plasma as described by Burrell [1975].
Preparation of Rabbit Anti-HBs
Antisera were prepared in rabbits by immunisation
with purified HBsAg emulsified in Freund's incomplete
adjuvant.
HBsAg Absorption of Rabbit Anti-HBs Sera
To produce monospecific antisera, aliquots of rabbit
sera were cross-absorbed with appropriate subtype
antigens. After absorption the samples were centri-
fuged at 37,000^ for 2 hr and the supernate stored at
4°C.
Radiolabelling Purified HBsAg
Samples of purified HBsAg were radiolabelled with
iodine (125I) by the modified chloramine-T method as
described by Burrell et al. [1973],
Analyses of Rabbit Anti-HBs After Absorption
With HBsAg
Standard titration curves of the absorbed antisera
with radio-labelled antigen were used to determine the
working dilution of the antiserum in RIP subtype
assays. Fourfold dilutions from 1:100 (in 1:160 carrier
rabbit serum diluted in RIP buffer) of absorbed rabbit
anti-HBs serum were incubated with 125I-HBsAg and
neat HBsAg-negative human serum for 16 hr at 4°C.
The rabbit antibody was precipitated by adding anti-
rabbit IgG serum (donated by Scottish Antibody Pro¬
duction Unit) in RIP buffer, and incubated for a further
16 hr at 4°C. The percentage of 125I-HBsAg bound to
rabbit anti-HBs was determined as described by Bur¬
rell et al. [1973]. The dilution of absorbed anti-HBs
serum, giving 40-70% binding of labelled antigen, was
used as the working dilution of antiserum in the assays
of antigen subtypes. The anti-HBs activity of each
absorbed rabbit antiserum was characterised by RIP
assay with eight known-subtypes (Paris Panel ofAnti¬
gen Subtypes). After precipitation with anti-rabbit IgG
serum the percentages of 1ZjI-HBsAg bound in the
precipitates of the control and the test samples were
calculated as before.
RIP Assay for Subtyping
HBsAg samples from positive patients were tested
for subtype determinants by RIP assays using the
absorbed rabbit anti-HBs sera of "defined-subtype"
activity. One in ten and 1:100 dilutions of the samples
were assayed in parallel with samples of the neat
diluent. Also included in each subtype assay were 100
p.1 samples of the "determinant-negative" control at
1:10 dilution, i.e., the subtype antigen used in the
absorption of the rabbit antiserum. The technique was
described by Burrell et al. [1978], for HBsAg detection.
DNA Extractions
Sera (200 p.1) were incubated for 45 min on ice with
proteinase K (Sigma) at 100 pg/ml in an equal volume
of Lysis buffer (200 mM NaCl, 100 mM EDTA, 100 mM
Tris, pH 8.0). N-lauroylsarcosine was added to a final
concentration of 1% (w/v), and samples were incubated
at 65°C for 3 hr. After phenol/chloroform extraction, the
aqueous phase was precipitated with ethanol (2 x vol¬
ume) and 4M potassium acetate (0.1 volume). DNA
pellets were resuspended in 100 pi of 0.1 x STE
(10 x STE: 10 mM Tris, 100 mM NaCl, 1 mM EDTA,
pH8.0).
Rapid DNA Extractions
Patient sera (100 pi) were incubated with proteinase
K (100 pg/ml) and N-lauroylsarcosine (1% w/v) at 60°C
for 60 min, then boiled for 10 min. The samples were
centrifuged at 9,800g for 10 min, and the supernates
used directly for PCR.
DNA Amplification
Resuspended DNA was amplified essentially as de¬
scribed by Simmonds et al. [1990], excluding dimeth-
ylsulphoxide and EDTA from the reaction. To reduce
the risk of contamination and monitor performance,
samples were amplified in batches of ten, each batch
consisting of five samples and five controls numbered
randomly. The three negative controls were obtained
from low risk, seronegative individuals. The two posi¬
tive controls, a d and y subtype, were patient samples
found to subtype consistently by RIPA and PCR. To
avoid the possibility of gross contamination, no cloned
HBV genomes were used. Patient samples, although
not standardised, offered a more appropriate control
than cloned material as they included possible serum
contaminants, known to inhibit Taq polymerase [Zeldis
et al., 1989],
To ensure that the initial amplification of viral DNA
was specific, the secondary and subtype-specific ampli¬
fications used nested inner primers to amplify an
aliquot of primary amplified material [Mullis et al.,
1986],
Each batch was amplified and analysed by gel elec¬
trophoresis. False positive or negative results obtained
in any control resulted in the batch being discarded and
ubtyping of HBV
iplification repeated. Each sample was subtyped
and samples found to differ were then subtyped
ler five times.
Oligonucleotide PCR Primers
onucleotide primers were synthesised by Oswel
Service, Department of Chemistry, University of
lrgh, and purified by high-performance liquid
itography. Their sequences were derived from
talyses of 5 human HBV DNA sequences of
es adrcg, adw, adyw, ayw, and adw2. Primers
058C, 869C, and 870C, were selected from con-
regions of the S-gene. Primers 907E and 394J
elected from the y-specific sequence, and 029H
le d-specific sequence, hybridising to codon 122 at








uots (10 fxl) of the amplification products were
ed by gel electrophoresis, against ladders of
digested by Hae III (Gibco BRL) and DNA
dar-weight marker VI (Boehringer Mannheim),
•s 058C and 869C were used for primary ampli-
i, yielding a band of 548 bp. The nested primers
and 870C) gave a band of 235 bp, and the
e-speciflc primers used in conjunction with
resulted in bands of 350 bp.
Sau 3A Digest of PCR Products for
Confirmatory Subtyping
;enerate sufficient HBV DNA to visualise the
tion digest products on an agarose gel, an aliquot
of primary amplified product was re-amplified
le outside primer pair 058C/869C. The amplifi-
product was restricted with 2.5 units of Sau 3A
inger Mannheim) at 37°C for 1.5 hr. The restric-
igest (15 fil) was electrophoresed on a 1.5%
e gel, against DNA molecular-weight marker VI
inger Mannheim), at 150 V.
RESULTS
Comparison of Rapid and Full DNA
Extraction Methods
teen samples were extracted by both methods,
lplified as described. When analysed by agarose
ictrophoresis, 13 (100%) of the samples were
e for HBV DNA after the full extraction method,
44%) after the rapid extraction. The difference in
vity observed was probably due to the presence of
srase inhibitors in the rapid extracts. In addition
, rapid extracts stored at — 20°C for a period of
onths, often gave negative results when re-
ied. This may be accounted for by the presence of
ses not removed during extraction. All subse-
DNA for HBV detection and subtyping, was
;ed by the full phenol/chloroform method.
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TABLE I. Comparison of HBV DNA Detection in Sera
Against Markers of Infection (HBsAg, Anti-HBs,









54 6 23 83
(54) (2) (8) (64)
0 11 9 20
(0) (0) (2) (2)
0 3 3 6
(0) (0) (0) (0)
* Nos. in parentheses are total No. of HBVDNA positive samples by
PCR.
Detection of HBV DNA by PCR
The HBsAg, anti-HBs, anti-HBc, and HBe status of
109 samples were determined by radioimmunoassays.
Eighty-three were HBsAg positive; 20, anti-HBs/anti-
HBc positive; and 6, HBsAg/anti-HBs negative, anti-
HBc positive. DNA was extracted and an aliquot used
for the specific amplification of HBV DNA by a double
PCR, using primer pairs 058C/869C and 057C/870C
(Fig. 2). HBV DNA was detected in 64 (77%) of HBsAg
positive samples (54 HBeAg positive, 2 HBeAg/anti-
HBe negative, and 8 anti-HBe positive), and 2 (10%) of
the anti-HBs positive samples (both anti-HBe positive).
The results are summarised in Table I.
Subtyping of HBV
Thirty-eight HBV DNA positive samples were sub-
typed by RIP assay. Eighteen samples were subtyped d,
20 subtyped y. These samples were also subtyped by
PCR, using the y-specific primer (907E), and 870C as a
nested primer pair.
Subtyping by PCR is based on the theory that a 3'
mismatch of a primer with the template DNA results in
a decrease in amplification efficiency [Newton et al.,
1989]. Utilising this theory, two subtype-specific prim¬
ers (029H and 907E) were selected to subtype samples
d andy, respectively. These primers were selected from
our sequence analysis which showed the three bases of
codon 122 to be involved in d/y subtyping (Fig. 1). In
contrast, only the central base of this codon is published
as being essential for dly subtyping [Okamoto et al.,
1987b]. To correlate with published data a third primer
394J was selected, identical to 907E except for the loss
of the 3' terminal guanine residue. When tested, it was
found that primers 209H and 394J acted like subtype
common primers, amplifying both d and y subtype
DNA. The primers 029H and 394J had a T:C and C:A
3' mismatch, respectively. These mismatches were
shown to allow significant amplification by Kwok et al.
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adr g t
adw t
adyw t c g
adw2 t
ayw egg t a
Consensus AGCACGGGAC CATGCAAAAC CTGCACGACT CCTGCTCAAG
Primer 907E GCCTG GACGTACTGA TGACGAGTTC
029H TTTTG GACGTGCTGA GGACGAGTTC
394J CCTG GACGTACTGA TGACGAGTTC
Fig. 1. Sequence analysis ofS-gene from codon 117 to 130. The consensus sequence of the above 5 HBV
subtypes is given in uppercase, and their subtypic variation in lowercase. The primers selected to












Fig. 2. Ethidium bromide stained agarose gel ofHBV DNA detection and subtyping by PCR, and Sau
3A digest results. Lane 1: 0X174/77ae III digest ladder. Lane 3: Sau 3A digest of sample 11 (subtype y).
Lane 5: Sau 3A digest of sample 2 (subtype cD. Lane 7: Subtype-specific amplification of sample 2. Lane
9: Subtype-specific amplification (870C/907E) of sample 11. Lane 11: Secondary amplification (057C/
870C). Lane 13: Primary amplification (058C/869C). Lane 14: DNA molecular-weight marker VI. Lanes
2,4,6,8,10,12 were negative controls.
etween subtypes. The y-specific primer (907E) was
ilected with a 3' G:A mismatch, shown to reduce the
CR product yield 100-fold. In addition to this, the
econd and third base mismatches enhanced the effect
{wok et al., 1990], Primer 907E, therefore, distin-
uished between subtypes d and y by not amplifying d
ubtype samples sufficiently for ethidium bromide vi-
ualisation on agarose gels. Due to the lack of a d
pecific primer, d subtyping was based on a negative
esult with the y-specific primer pair. To account for
this, negative samples with the y-specific primers were
only accepted as true subtype d, if the primary ampli¬
fication band was visible, indicating the presence of
amplified viral DNA (Fig. 2). Due to these preliminary
studies all PCR subtyping used the nested primer pair
870C/907E.
PCR and RIPA subtyping agreed in 20 (100%) of
subtype y samples, and 15 (83.3%) ofsubtype d samples,
giving an overall correlation of 92.1% for the 38 sam¬
ples tested (Table II).
Subtyping of HBV
TABLE II . Comparison of RIPA and PCR
Subtyping of HBsAg
. subtype d y
No. 18 20
subtype d 15 0
subtype y 3 20
e to the three samples with conflicting RIPA and
results, a third method of subtyping was used,
restriction maps of five HBV subtypes (adw,
, ayw, adw2, and adrcg), it was observed that a
3A digest of the S-gene would discriminate be-
1 d and y subtype genomes. These maps predicted
d subtype genomes would result in three bands
204, 227bp) andy subtype two bands (227 and 321
Vhen analysed by agarose gel electrophoresis, it
hund that d subtype genomes resulted in five
;, and y subtype three bands (Fig. 2). Due to the
s of template DNA generated by PCR, neither
t was complete. The predicted bands for a partial
t were six for d subtypes (117, 204, 227, 321, 431,
48 bp), and three for y subtypes (227, 321, and 548
Due to the limitation of agarose gels, 2 of the d
ic bands (204 and 227 bp) migrated together,
:ing in five bands for d subtype samples. Twelve
les were tested, nine ofwhich confirmed PCR and
results. Of the three remaining samples, one
ile 32) confirmed PCR, and two (samples 35 and
IPA (Table III).
DISCUSSION
; polymerase chain reaction is the most sensitive
od for the detection of specific DNA sequences, and
insequently improved the rate ofdetection ofHBV
in patient samples with serological markers of
ion [Larzul et al., 1988,1989,1990; Kaneko et al.,
Liang et al., 1989; Zeldis et al., 1989; Lin et al.,
. The main disadvantage of this increased sensi-
is the possibility of false-positive results from
mination of samples by template DNA [Lo et al.,
. To avoid contamination, we developed a rapid
3d of extraction which minimised handling of
les. This proved to be less sensitive when com-
with the full extraction, and so it was concluded
the phenol/chloroform step of the extraction
3d was essential to remove inhibitors which re-
the efficiency of PCR, and nucleases which can
de DNA in stored samples.
V has previously been subtyped by serology on the
of three-dimensional epitopes. The region of the
e involved in subtyping (amino acids 110-160)
ertiary structure due to the formation of disul-
bridges by cross linking of cysteine residues,
I a conformational determinant for antibody rec-
on [Gerin et al., 1983; Takeshima et al., 1985]. In
irison, our method of subtyping by PCR is re-
jd to a linear epitope, or sequential determinant,
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consisting of three bases coding for amino acid 122.
Like RIPA, subtyping by Sau 3A digest is based on
multiple sites of the S-gene. Due to this similarity in
subtyping, RIPA and Sau 3A restriction digest results
were expected to correlate more closely than with PCR.
However, codon 122, although involved in antibody:an-
tigen recognition, is not part of a restriction site for Sau
3A. It is, therefore, possible for codon 122 to code for one
determinant and for the other sequences involved in
restriction sites and antibody binding to be the other
determinant. This phenomenon could explain the re¬
sults obtained with samples 35 and 38.
Alternatively, PCR subtyping relies upon a 3' mis¬
match to differentially amplify viral DNA. By reducing
the overall efficiency of PCR for amplification with the
subtype specific primer pair, it may be possible to
further optimise the reaction for HBV DNA subtyping,
and obtain a better correlation with standard methods
of subtyping. To support this theory, Norder et al.
[1990] were able to use a primer similar to 029H (which
we found to be indiscriminant) to detect d subtype
samples. Their detection was based on a 3' T:C mis¬
match of both nested inner primers, used in a single
PCR, and detected by hybridisation with a 32P-labelled
probe. Their use of two subtype-specific primers for a
single PCR followed by hybridisation, has overcome the
reported amplification efficiency of T:C mismatches,
and allowed discrimination between subtypes d and y.
The third sample (32) with aberrant PCR and RIPA
results when digested by Sau 3A confirmed the PCR
result. Although the digest and RIPA subtyping meth¬
ods involve different sites of the S-gene, their conflict¬
ing results highlight problems associated with RIP
assays. RIPA subtyping involves a number of antibody
purifications from polyclonal sera, whose subtypic de¬
terminants are characterised by blocking by HBsAg of
known subtype. As with PCR, subtyping by RIPA is not
absolute and, therefore, requires similar careful opti¬
misation.
Two HBsAg negative samples gave HBV DNA posi¬
tive results on repeated extractions. Although no clin¬
ical information was available, both had antibodies to
core and surface antigen indicating exposure to infec¬
tion. HBV DNA detected in HBsAg negative samples
could be due to the presence of immune complexes of
hepatitis B virions in the blood [Liang et al., 1989], or
to the release of HBV DNA from necrotic hepatocytes
[Carman et al., 1989]. These samples demonstrate the
sensitivity of PCR in detecting HBV DNA in patient
sera with serological markers indicative of recovery.
Since PCR can detect one molecule of template DNA
from patient samples [Simmonds et al., 1990], it is
therefore advantageous over RIP assays, which are
dependent on high HBsAg concentrations which de¬
cline with anti-HBs production.
In conclusion, the polymerase chain reaction offers a
rapid method of subtyping hepatitis B virus from sera
of patients at various stages of infection. In contrast to
RIPA, increased sensitivity is achieved by PCR with
the ability to detect a single molecule of HBV DNA.
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TABLE III. Comparison of RIPA, PCR, and Sau 3A Restriction Digest
Subtyping of HBsAg
Sample HBsAg HBeAg/Ab PCR RIPA PCR DIGEST
No. result positive result subtype subtype subtype
11 + Ag + y y y
2 + Ag + d d d
5 + Ag + y y y
13 + Ag + d d d
26 + Ag + y y y
27 + Ag + d d d
32 + Ag + d y y
25 + Ag + y y y
10 + Ag + d d d
35 + Ab + d y d
38 + Ab + d y d
4 + Ab + y y y
Since PCR detects HBV directly, it can be used in the
detection and subtyping ofHBV in blood, liver biopsies,
frozen or fixed tissue, and for studies on hepatoma
tissues. The sensitivity and flexibility of PCR will
hopefully help advance the study of the molecular
epidemiology of the hepatitis B virus.
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